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Abstract 
 
Introduction 
Traditional, complementary and alternative medicines have been used to treat various 
health conditions. The use of such medicines among HIV/AIDS and TB patients in sub-
Saharan Africa has increased considerably, and within this context, questions have been 
raised about the medical use of herbs or extracts as treatment alternatives without 
adequate clinical testing and without monitoring of adverse effects once on the market. 
Furthermore, potential herb-drug interactions (HDI) have been predicted based on the 
pharmacological and pharmacokinetic properties of prescription medications and the 
phytoconstituents within the herbs. 
 
This study investigated the potential of six popular African herbs consumed by 
HIV/AIDS and TB patients, viz., Withania somnifera, Glycyrrhiza glabra, Astragalus 
membranaceus, Inula helenium, Althaea officinalis and Ocimum basilicum, to inhibit the 
cytochrome P450 enzyme CYP2B6 and the esterase-mediated metabolism pathway of 
rifampicin and their ability to induce CYP3A4 and CYP2B6. The study was undertaken 
in four phases: (1) qualitative assessment of various classes of phytocompounds present 
in each herbal extract by biochemical phytoprofiling, (2) study of the potential inhibitory 
effects of the extracts on cytochrome CYP2B6 and on the metabolism pathway of 
rifampicin to 25-O-desacetyl rifampicin by in vitro assays using human liver microsomes 
(HLM), (3) analysis of the potential inducing effects of the herbal extracts on mRNA 
expression of CYP2B6 and CYP3A4 in HepG2 cell lines, using reverse transcription 
polymerase chain reaction (RT-PCR) and agarose gel electrophoresis (AGE), and (4) 
fingerprint analysis, identification and relative quantification of the major 
phytoconstituents present in each extract and prediction of compounds which may cause 
HDI by liquid chromatography-mass spectrometry coupled with photo diode array 
detection (LC-MS/PDA). 
 
Methods 
Dried roots of Withania somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula 
helenium, Althaea officinalis and dried leaves and inflorescence of Ocimum basilicum 
were obtained from Pharma Germania, South Africa. Aqueous, methanol, ethanol and 
ethyl acetate extracts were prepared and analysed using biochemical tests to identify the 
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presence of various classes of phytocompounds. HLM assays were conducted to evaluate 
the inhibitory potential of each extract on the CYP2B6-mediated metabolism of efavirenz 
to 8-Hydroxy efavirenz, and the biotransformation of rifampicin to 25-O-desacetyl 
rifampicin. The protocol included the incubation of the herbal extract, HLM, co-factors 
and substrates in phosphate buffer for 30 min at 37 
o
C, termination of reaction and HPLC 
analysis of the supernatant from the centrifuged assay sample (at 245 nm for efavirenz 
and its metabolite, and 254 nm for rifampicin and its metabolite). The half-maximal 
inhibitory concentrations (IC50) for the active extracts were calculated based on the 
percentage of remaining activity relative to the control. Time-dependent inhibition (TDI) 
IC50 fold-shift was evaluated using 30 min pre-incubation with NADPH, followed by 
incubation with substrate in buffer for another 30 min, using six concentrations (1-200 
𝜇g/mL) of the herbal extract. CYP2B6 and CYP3A4 mRNA expression assays were 
conducted for measuring the induction potential of the extracts, where the 50% cytotoxic 
concentration (CTC50) of all herbal extracts was determined by screening them (1000.00-
31.25 𝜇g/mL) against HepG2 cells. The HepG2 cells were incubated for 24 h with the 
CTC50 concentration, for each herb. This was followed by extraction and purification of 
total mRNA and its expression through RT-PCR, followed by AGE. Relative sample 
expression levels were calculated and represented as fold-response levels of induction 
relative to a cell control (using rifampicin and dexamethasone as positive controls). 
LC-MS/PDA was used to identify and relatively quantify the potential phytochemical 
constituents in each extract. 
 
Results 
O.basilicum, G.glabra I.helenium and A.membranaceus contained most of the relevant 
groups of phytocompounds such as flavonoids, phenols, alkaloids, glycosides and 
terpenoids based on the biochemical qualitative analysis. The aqueous and methanolic 
extracts of O.basilicum showed reversible and time-dependent inhibition of CYP2B6 
(TDI IC50s 33.35 𝜇g/mL, 4.93 𝜇g/mL, IC50 shift-fold >1.5 for both extracts), while the 
methanolic and ethanolic extracts inhibited the formation of 25-O-desacetyl rifampicin 
(IC50s 31 𝜇g/mL, 8.94 𝜇g/mL). The methanolic extract of O.basilicum showed the highest 
TDI with a 7.4-fold increase in the IC50. All extracts of I.helenium inhibited CYP2B6 
(IC50s 63 𝜇g/mL, 89.43 𝜇g/mL) and rifampicin metabolism (IC50s 42.79 𝜇g/mL, 18.58 
𝜇g/mL, 62.10 𝜇g/mL); the aqueous extract showed the highest TDI with a 3-fold increase 
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in the IC50. Only the methanolic and ethyl acetate extracts of W.somnifera inhibited 
CYP2B6 (IC50 79.16 𝜇g/mL, 57.96 𝜇g/mL). TDI was mainly observed between the herbal 
extracts and CYP2B6. 
The ethanolic and methanolic extracts of A.officinalis induced CYP3A4, with 48%-fold-
response shift compared to the cell control (no inducer). The ethanolic extract of 
O.basilicum and G.glabra caused moderate induction of CYP3A4 and CYP2B6. The 
aqueous extract of A.membranaceus showed moderate and equal induction of CYP3A4 
and CYP2B6 (36% fold-response increase). 
All extracts exhibited less than 2-fold induction (200%) response, in contrast to the 
positive controls, rifampicin and dexamethasone. 
Major phytocompounds detected in the LC-MS/PDA analysis of the extracts included 
flavonoids, phenols, glycosides, saponins and terpenoids. Relative amounts of the 
identified compounds were determined by comparison to standard calibrators, quercetin 
and gallic acid (expressed in mg/L equivalent units). Phenols such as rosmarinic acid 
(approximately 2298 mg/L in the aqueous extract) and caftaric acid were found in 
O.basilicum extracts along with the flavonoids salvigenin, rutin and isoquercetin and 
other compounds such as linalool, hydroxyjasmonic acid and eucommiol. The aqueous 
extract of I.helenium contained mostly polyphenols such as chlorogenic and 
caffeoylquinic acids, whereas other solvent extracts contained the sesquiterpenoid 
tanacetol A, helenin (isoalantolactone) and macrophyllilactone B. The methanolic and 
ethyl acetate extracts of W.somnifera comprised of withaperuvin, isopelletierine, 
salvigenin, withanolides and withaferin A (approximately 1117 mg/L in the ethyl acetate 
extract), and the extracts of A.membranaceus contained mainly calycosin, formononetin, 
astragalosides I and IV.  
The extracts of A.officinalis mainly comprised of quinic acid and altheahexacosanyl 
lactone derivatives (approximately 3874 mg/L in the methanol extract), d-galacturonic 
acid monohydrate, phloretin along with the fatty acid trihydroxy-octadecenoic acid, and 
the G.glabra extract mainly consisted of glabridin, liquiritin apioside, liquiritigenin and 
licochalcones. 
 
Conclusion 
A.membranaceus, I.helenium, O.basilicum and W.somnifera have been shown to contain 
astragalosides, alantolactones, phenolic acids and withanolides that may inhibit drug 
metabolising enzymes such as CYP2B6, CYP3A4 and the enzymes responsible for 
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metabolism of rifampicin (including B-esterases). A.officinalis and G.glabra can cause 
moderate induction of CYP3A4 due to the higher concentration of lactones and chalcones 
present in their extracts. 
These in vitro findings may be relevant for clinical use of these herbs together with 
conventional medicines metabolised by these enzymes, if sufficient hepatic 
concentrations are attained in humans. 
The results of this study will help to guide planning and designing of clinical trials to 
confirm the potential relevance of HDI in patients.  
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Abstrak 
Inleiding  
Tradisionele, aanvullende en alternatiewe medisyne word gebruik om verskeie 
gesondheidstoestande te behandel. Die gebruik van sodanige medisyne vir MIV/vigs- en 
TB-pasiënte in Afrika suid van die Sahara het aanmerklik toegeneem, en in hierdie 
konteks word vrae gevra oor die medisinale gebruik van kruie of ekstrakte as 
behandelingalternatiewe sonder voldoende kliniese toetsing en sonder monitering van 
negatiewe gevolge nadat dit op die mark verskyn het. Moontlike kruiemedikasie-
interaksies (KMIs) word voorts voorspel op grond van die farmakologiese en 
farmakokinetiese eienskappe van voorskrifmedikasie en die fitobestanddele in die kruie. 
 
Hierdie studie was ŉ ondersoek na die potensiaal van ses gewilde Afrika-kruie wat deur 
MIV/vigs- en TB-pasiënte gebruik word, naamlik Withania somnifera, Glycyrrhiza 
glabra, Astragalus membranaceus, Inula helenium, Althaea officinalis en Ocimum 
basilicum, om die sitochroom P450-ensiem CYP2B6 en die esterase-bemiddelde 
metabolismebaan van rifampisien en hul vermoë om CYP3A4 en CYP2B6 te induseer, te 
inhibeer. Die studie is in vier fases onderneem: (1) kwalitatiewe assessering van 
verskillende klasse van fitoverbindings teenwoordig in elke kruie-ekstrak deur 
biochemiese fitoprofilering, (2) bestudering van die potensiële inhiberende gevolge van 
die ekstrakte op sitochroom CYP2B6 en op die metabolismebaan van rifampisien tot 25-
O-desasetiel-rifampisien deur in vitro-ontledings met gebruik van menslewermikrosome 
(MLM), (3) ontleding van die potensiële induserende uitwerkings van die kruie-ekstrakte 
op mRNA-uitdrukking van CYP2B6 en CYP3A4 in HepG2-sellyne met gebruik van 
omgekeerde transkripsie polimerasiekettingreaksie (RT-PCR) en agarose-jel-
elektroforese (AGE), en (4) vingerafdrukontleding, -identifisering en relatiewe 
versyfering van die vernaamste fitobestanddele teenwoordig in elke ekstrak en 
voorspelling van verbindings wat KMI‟s kan veroorsaak deur vloeibare chromatografie-
massa-spektrometrie gepaard met fotodiode-rangskikkingwaarneming (LC-MS/PDA). 
 
Metodes 
Droë wortels van Withania somnifera, Glycyrrhiza glabra, Astragalus membranaceus, 
Inula helenium en Althaea officinalis en droë blare en infloressensie van Ocimum 
basilicum is van Pharma Germania, Suid-Afrika, verkry. Water-, metanol-, etanol- en 
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etielasetaat-ekstrakte is voorberei en ontleed met behulp van biochemiese toetse om die 
teenwoordigheid van verskillende klasse fitoverbindings te identifiseer. MLM-ontledings 
is uitgevoer om die inhiberende potensiaal van elke ekstrak op die CYP2B6-bemidelde 
metabolisme van efavirenz tot 8-hidroksie-efavirenz en die biotransformasie van 
rifampisien tot 25-O-desasetiel-rifampisien te evalueer. Die protokol het die inkubasie 
van die kruie-ekstrak, MLM, kofaktore en substrate in fosfaatbuffer vir 30 minute teen 37 
o
C, beëindiging van reaksie en hoëdruk- vloeibare chromatografie-ontleding van die 
bodrywende stof van die gesentrifugeerde toetsmonster (teen 245 nm vir efavirenz en sy 
metaboliet, en 254 nm vir rifampisien en sy metaboliet) ingesluit. Die half-maksimale 
inhiberende konsentrasies (IC50) vir die aktiewe ekstrakte is bereken op grond van die 
persentasie oorblywende aktiwiteit in verhouding tot die kontrole. Tydafhanklike 
inhibisie (TAI) IC50-verskuiwingsvou is geëvalueer deur 30 minute pre-inkubasie met 
NADPH, gevolg deur inkubasie met substraat in buffer vir ŉ verdere 30 minute met die 
gebruik van ses konsentrasies (1-200 𝜇g/mL) van die kruie-ekstrak. CYP2B6- en 
CYP3A4 mRNA-uitdrukkingontledings is uitgevoer om die induksiepotensiaal van die 
ekstrakte te meet, waar die 50% sitotoksiese konsentrasie (CTC50) van alle kruie-
ekstrakte bepaal is deur hulle teen HepG2-selle te toets (1000.00-31.25 𝜇g/mL). Die 
HepG2-selle is vir 24 uur met die CTC50-konsentrasie vir elke krui geïnkubeer. Dit is 
gevolg deur ekstraksie en suiwering van totale mRNA en sy uitdrukking deur RT-PCR, 
gevolg deur AGE. Relatiewe monsteruitdrukkingvlakke is bereken en as 
vouresponsvlakke van induksie in verhouding tot ŉ selkontrole voorgestel (met gebruik 
van rifampisien en deksametasoon as positiewe kontroles). LC-MS/PDA is gebruik om 
die potensiële fitochemiese bestanddele in elke ekstrak te identifiseer en te relatief 
kwantifiseer. 
 
Resultate 
O.basilicum, G.glabra, I.helenium en A.membranaceus het die meeste van die toepaslike 
groepe fitobestanddele soos flavonoïde, fenole, alkaloïde, glikosides en terpenoïede op 
grond van die biochemiese kwalitatiewe ontleding bevat. Die water- en metanoliese 
ekstrakte van O.basilicum het omkeerbare en tydafhanklike inhibisie van CYP2B6 getoon 
(TAI IC50s 33.35 𝜇g/mL, 4.93 𝜇g/mL, IC50-verskuiwingsvou 1.5 vir albei ekstrakte), 
terwyl die metanoliese en etanoliese ekstrakte die vorming van 25-O-desasetiel-
rifampisien geïnhibeer het (IC50s 31 𝜇g/mL, 8.94 𝜇g/mL). Die metanoliese ekstrak van 
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O.basilicum het die hoogste TAI getoon met ŉ 7.4-voudige toename in die IC50. Alle 
ekstrakte van I.helenium het CYP2B6 (IC50s 63 𝜇g/mL, 89.43 𝜇g/mL) en rifampisien-
metabolisme (IC50s 42.79 𝜇g/mL, 18.58 𝜇g/mL, 62.10 𝜇g/mL) geïnhibeer; die 
waterekstrak het die hoogste TAI getoon met ŉ drievoudige toename in die IC50. Slegs 
die metanoliese en etielasetaatekstrakte van W.somnifera het CYP2B6 (IC50 79.16 𝜇g/mL, 
57.96 𝜇g/mL) geïnhibeer. TAI is hoofsaaklik tussen die kruie-ekstrakte en CYP2B6 
waargeneem. 
 
Die etanoliese en metanoliese ekstrakte van A.officinalis het CYP3A4 geïnduseer, met 
48%- vouresponsverskuiwing in vergelyking met die selkontrole (geen induseerder nie). 
Die etanoliese ekstrak van O.basilicum en G.glabra het matige induksie van CYP3A4 en 
CYP2B6 veroorsaak. Die waterekstrak van A.membranaceus het matige en gelyke 
induksie van CYP3A4 en CYP2B6 (36%-vouresponstoename) getoon. Alle ekstrakte het 
minder as tweevoudige induksierespons (200%) getoon in vergelyking met die positiewe 
kontroles, rifampisien en deksametasoon. 
 
Vername fitobestanddele waargeneem in die LC-MS/PDA-ontleding van die ekstrakte het 
flavonoïde, fenole, glikosides, saponiene en terpenoïede ingesluit. Relatiewe hoeveelhede 
van die geïdentifiseerde verbindings is bepaal in vergelyking met standaard kalibreerders, 
kwersetien en galliensuur (uitgedruk in mg/L ekwivalente eenhede). Fenole soos 
rosmariensuur (ongeveer 2298 mg/L in die waterekstrak) en kaftariensuur is gevind in 
O.basilicum-ekstrakte tesame met die flavonoïde salvigenien, rutien en isokwersetrien en 
ander verbindings soos linaloöl, hidroksiejasmoniese suur en eukommiol. Die 
waterekstrak van I.helenium het meestal polifenole soos chlorogeniese en 
kaffeoïelkiniensure bevat, terwyl die ander oplosmiddelekstrakte die seskwiterpenoïed 
tanasetol A, helenien (isoalantolaktoon) en makrofillielaktoon B bevat het. Die 
metanoliese en etielasetaat-ekstrakte van W.somnifera het bestaan uit witaperuvien, 
isopelletiërien, salvigenien, witanolides en witaferien A (ongeveer 1117 mg/L in die 
etielasetaatekstrak), en die ekstrakte van A.membranaceus het hoofsaaklik kalikosien, 
formononetien en astragalosiede I en IV bevat.  
 
Die ekstrakte van A.officinalis het hoofsaaklik bestaan uit kiniensuur en 
alteaheksakosaniel-laktoon-derivate (ongeveer 3874 mg/L in die metanolekstrak), d-
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galakturonsuur-monohidraat en floretien tesame met die vetsuur trihidroksie-
oktadesenoësuur, en die G.glabra-ekstrak het hoofsaaklik bestaan uit glabridien, 
liwiritinapiosiede, likwiritigenien en likochalkone. 
 
Gevolgtrekking  
Daar is gevind dat A.membranaceus, I.helenium, O.basilicum en W.somnifera 
astragalosiede, alantolaktone, fenoliese sure en witanolides bevat wat 
middelmetaboliserende ensieme soos CYP2B6, CYP3A4 en die ensieme verantwoordelik 
vir metabolisme van rifampisien (insluitende B-esterases) kan inhibeer. A.officinalis en 
G.glabra kan matige induksie van CYP3A4 veroorsaak weens die hoër konsentrasie 
laktone en chalkone teenwoordig in hul ekstrakte. Hierdie in vitro-bevindinge kan 
relevant wees vir kliniese gebruik van hierdie kruie tesame met konvensionele medikasie 
wat deur hierdie ensieme gemetaboliseer is indien voldoende hepatiese konsentrasies in 
mense verkry word. 
 
Die resultate van hierdie studie sal help om die beplanning en ontwerp van kliniese toetse 
te rig om die potensiële relevansie van KMI‟s onder pasiënte te bevestig. 
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Chapter 1 
INTRODUCTION 
 
 
1.1 Overview of drug metabolism 
The human liver is the principal site of drug metabolism, where a drug is chemically converted 
to a metabolite through oxidation, reduction, conjugation and hydrolysis, prior to its elimination 
from the body. The study of this biotransformation is critical to understand the clinical profile of 
a drug, the pharmacokinetics and toxicology of its metabolites, determination of the dosage 
regimens and its potential to cause interactions in combination with other drugs. The human 
body is constantly exposed to „xenobiotics‟ or foreign substances such as chemicals from the 
food, air, water as well as drugs or herbal supplements for treating diseases, and has various 
enzymes to eliminate these substances. 
 
The xenobiotic metabolism occurs in two phases. Phase I involves oxidation, reduction and 
hydrolysis of the lipid-soluble drug. Phase II involves reactions that are synthetic in nature, and 
the conjugation with an endogenous substance such as glucuronic acid, sulfate or glycine; 
whereby polar metabolites are formed which are excreted by the kidney (urine) and liver (bile) 
(White, 2012). Cytochrome P450 (CYP), a microsomal group of isoenzymes catalyse the 
oxidation of xenobiotics in phase I. These enzymes form the basis of this study. 
 
1.2 Cytochrome P450 enzymes 
CYPs are the major enzymes involved in drug metabolism, accounting for about 75% of the 
total metabolism of the drugs within the human body (Guengerich, 2008; Williams et al., 2005). 
Most drugs undergo deactivation by CYPs, either directly or by facilitated excretion from the 
body, although some substances are bioactivated by CYPs by formation of active metabolites. 
Human CYPs are primarily located either in the mitochondrial inner membrane or the 
endoplasmic reticulum of cells. Many endogenous and exogenous chemical substances are 
primarily metabolised by these CYPs. Some CYPs such as CYP19 (aromatase) metabolize only 
one substrate (or very few), while others may metabolize multiple substrates. These 
characteristics give the CYPs a very important role in the metabolism of medicine. CYPs play 
critical roles in the synthesis and breakdown of hormones, including estrogen and testosterone 
synthesis and metabolism as well as cholesterol synthesis, and the metabolism of vitamin D 
(Salphati and Benet, 1998; Guengerich, 2008; Bjorkman, 2005). 
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Potentially toxic compounds including products of endogenous metabolism (such as bilirubin) 
and drugs are also metabolised by the CYPs, primarily in the liver. Drugs are predominantly 
biotransformed by a limited subset of CYPs, namely CYP1A2, CYP2A6, CYP2B6, CYP2Cs 
(principally CYP2C8, CYP2C9 and 
CYP2C19), CYP2D6, CYP2E1 and 
CYP3A4 (Gomez-Lechon et al., 
2004; DiPiro, 1999; Cupp and 
Tracy, 1998). These CYPs are 
responsible for more than 50% of 
the total drug metabolism 
(Wilkinson, 2005). Recent studies 
revised the CYP distribution „pie‟ 
chart to include CYP4F enzymes to 
the total contribution of all the 
hepatic P450 enzymes, as 
illustrated in Fig. 1 (Michaels and 
Wang, 2014). 
 
Inhibition or induction of these enzymes can result in altered clearance and pharmacokinetics 
(PK) of drugs leading to very high or low concentrations and therefore to adverse effects or lack 
of efficacy. This is particularly important considering that the aging population is often on 
multiple drugs (polypharmacy) for various ailments. Therefore, evaluation of drug interactions 
is part of the assessment of drug efficacy and safety. 
 
                                                                                                                 ** GI – gastrointestinal, CL – clearance  
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The screening of absorption, distribution, metabolism, excretion and toxicity (ADMET) drug 
properties during a drug discovery and development process, as well as understanding drug 
interactions with the CYPs is critical (Fig. 2), and has the potential to increase the chances for 
identification of a new drug candidate within a shorter time frame (Zhang and Surapaneni, 
2012). 
 
CYP3A4 is the most prevalent in humans, and the most important enzyme in terms of drug 
biotransformation. CYP3A4 isoenzyme is involved in many clinically significant drug-drug 
interactions (DDI). Studies involving CYP3A4 and DDI/HDI are becoming an integral part of 
drug research (Ogu and Maxa, 2000). Many studies have recorded the interaction of herbal 
medicines prominently with CYP3A4, along with other CYPs, whereby the CYP3A4-herb 
interaction analysis is an evaluation model of high importance (Wanwimolruk et al., 2014). 
 
CYP2B6 is involved in the metabolism of clinically important drugs. The discovery of 
extensive variations of the CYP2B6 gene (the most common being CYP2B6*6), the potential 
effects of ethnic variations on its expression as well as the emerging evidence for its clinical 
relevance, have demonstrated the important role of this enzyme (Desta and Flockhart, 2017). 
Most of the HDI evaluations have been performed using CYP2D6, CYP1A2, CYP2C19, 
CYP2C9, CYP3A4, and CYP2E1, but very little information is available on how herbal 
medicines affect the expression of CYP2B6. Considering the high prevalence of HIV/AIDS 
across Africa, the wide-spread use of efavirenz in treatment, and the variation of CYP2B6 
expression on efavirenz metabolism, one of the main objectives of this study was to assess the 
influence of selected herbal medicines on the activity of CYP2B6, including its functional 
characterization. 
 
1.1.1 Cytochrome P450 2B6 
The cytochrome P450 (CYP) enzyme CYP2B6 is one among 12 human CYPs, primarily 
involved in the metabolism of drugs and other xenobiotics and constitutes less than 1% of the 
total hepatic CYP content (Zanger et al., 2007). This highly polymorphic enzyme has upto 38 
reported allelic variants (PharmVar, 2017). Therapeutically important drugs metabolized 
primarily by CYP2B6 include the non-nucleoside reverse transcriptase inhibitor (NNRTI), 
efavirenz (Ward et al., 2003; Desta et al., 2007). Besides efavirenz, drugs such as artemisinin, 
bupropion, ketamine, methadone and cyclophosphamide (∼8% of those on the market) undergo 
metabolism via the CYP2B6 pathway.  
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CYP2B6 genotype is the most important genetic factor influencing plasma efavirenz 
concentrations. Human CYP2B6 is strongly inducible by several drugs including phenytoin and 
phenobarbital. Enzyme induction involves phenobarbital-responsive enhancer module 
(PBREM,-1.7 kb) and a distal xenobiotics-responsive enhancer module (XREM, -8.5 kb). The 
pregnane X receptor (PXR, NR1I2) and/or constitutive androstane receptor (CAR, NR1I3) bind 
to this module to mediate an increase in transcription (Sueyoshi et al., 1999; Wang et al., 2003; 
Faucette et al., 2004). The variants of CYP2B6 can affect transcriptional regulation, splicing, 
mRNA and protein expression, and catalytic activity. These polymorphisms are clinically 
relevant for HIV-infected patients treated with the reverse transcriptase inhibitor efavirenz, 
along with other drug substrates of CYP2B6 (Zanger and Klein, 2013). Previous studies have 
shown the induction of CYP2B6 by herbal medicine (Fan et al., 2009) as well as the inhibitory 
effect of African herbal medicines on CYP2B6 (Thomford et al., 2016).This study focuses on 
CYP2B6 because of its primary involvement in the metabolism of efavirenz, and the impact of 
herbal medicines that are co-administered with efavirenz in HIV patients. 
 
1.1.1.1 Efavirenz metabolism 
Efavirenz containing combined antiretroviral therapy (ART) is the first line treatment 
(Manosuthi et al., 2016) in Sub-Saharan Africa. Efavirenz is primarily metabolized to 8-
Hydroxy efavirenz mainly by CYP2B6 and to a lesser extent by CYP3A and, to 7-Hydroxy 
efavirenz by CYP2A6. 8-Hydroxyefavirenz is metabolized to 8,14-dihydroxy efavirenz by 
CYP2B6 (Ward et al., 2003). Ethnicity, CYP2B6*6 and ABCB1 c.4036A/G have been shown 
to be significant predictors of efavirenz pharmacokinetics in HIV/AIDS patients in Africa 
(Ngaimisi et al., 2013). 
 
1.1.2 Cytochrome P450 3A 
Fifty–60% of all CYP drug metabolism is mediated by the CYP3A subfamily of enzymes 
(Slaughter and Edwards, 1995), which comprises of CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43 (Daly, 2006). Among these, CYP3A4 forms the major portion of 
CYP3A protein present in the human liver and up to 90-fold variations may be observed in its 
catalytic activity. Subjects carrying defective alleles of CYP3A4 may be predisposed to health 
conditions such as prostate cancer, type 2 diabetes mellitus and estrogen receptor negative 
breast cancer (Lamba et al., 2002). CYP3A5 is polymorphically expressed in about 10-30% 
human livers, and represents upto 50%of the total hepatic CYP3A in such scenarios (Roy et al., 
2005; Daly, 2006; Lamba et al., 2002). Its amino acid sequence (85%) is identical to CYP3A4; 
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however it varies in its catalytic activity and regioselectivity towards substrates (Daly, 2006). 
The CYP3A5 gene contributes to inter-individual and inter-racial variation of CYP3A mediated 
metabolism of drugs, including anticancer drugs (irinotecan, docetaxel, vincristine), antimalarial 
(mefloquine, artemether), antipsychotics (olanzapine), antiestrogen (tamoxifen), 
immunomodulators (tacrolimus, cyclosporine), antibiotics (clarithromycin), antihistamines 
(chlorpheniramine, terfenadine, astemizole), antihypertensives (verapamil, nifedipine, 
amlodipine, felodipine), antivirals (indinavir, nelfinavir, ritonavir, saquinavir), steroids 
(testosterone, estradiol, progesterone and androstenedione) (Shimada & Guengerich, 1989; 
Flockhart, 2007) and carcinogens (Gene: cytochrome P450, 2017). 
 
Cytochromes belonging to the CYP3A subfamily have large active sites that bind to multiple 
substrates that are structurally different. Kinetic models have been designed on the assumption 
that CYP3A4 contains two distinct and independent substrate binding domains within the active 
site, resulting in the metabolism of two different substrates coexisting at the active site. The 
resultant velocity equations were used to derive kinetic parameters involved in the substrate-
enzyme reactions and the nature of metabolic interaction between the two substrates was 
described using the kinetic constants (Shou et al., 2001). 
 
CYP3A4 can be induced more than the other CYPs (Dogra et al., 1998; Denison and Whitlock, 
1995; Waxman and Azaroff, 1992). CYP3A4 is induced by rifampicin, HIV antiretroviral drugs 
such as efavirenz and nevirapine, carbamazepine, dexamethasone, glucocorticoids, 
phenobarbital, phenytoin, sulfadimidine and St. John‟s wort (Flockhart, 2007). Inhibitors of 
CYP3A4 include nelfinavir, ketoconazole, grapefruit juice, quinine, erythromycin, itraconazole, 
valproic acid, telithromycin, and verapamil (Flockhart, 2007). The metabolism pathway 
catalysed by CYP3A4 forms a major route for elimination of many drugs, and the induction of 
its expression is often implicated in clinically relevant drug-drug interactions. Rifampicin, a 
potent inducer of CYP3A4 activity (Hellum et al., 2007; Gurley et al., 2006; Erickson et al., 
1999), is commonly used as a positive control to investigate and evaluate the induction potential 
of test compounds on CYP3A4. CYP3A4 is a key enzyme related to DDIs occurring in TB 
treatment, particularly drug-resistant TB, and co-infection with TB/HIV (Kwara et al., 2010). 
 
1.1.3 Rifampicin metabolism and esterases 
Rifampicin is part of the major regimen for the treatment of active TB disease, including HIV-
infected patients (Department of Health and Human Services, 2016; British HIV Association, 
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2011). Rifampicin induces CYP3A4 mRNA in liver HepG2 and blood mononuclear cells 
(Glaeser et al., 2005; Gashaw et al., 2003). Rifampicin induced gut and liver (hepatic) CYP3A4, 
and autoinduces its own metabolism (Kliewer and Willson, 2002). Rifampicin is metabolized to 
25-O-desacetyl rifampicin, via deacetylation by esterases or by enzymes present in microsomal 
cells (Jamis-Dow et al., 1997). The des-acetyl derivative is eliminated in bile. Some of its other 
metabolites include 3-formyl rifamycin, rifampicin N-oxide, and rifampicin quinone (Mohan et 
al., 2003). P-glycoprotein (P-gp) transporter induction along with B-esterases, are involved in 
disposition of rifampicin (Staudinger et al., 2010).  
 
B-esterases are enzymes that hydrolyse carboxyl esters and exhibit very broad substrate 
specificity. Acetylcholinesterase, human carboxylesterase (CES), and butyrylcholinesterase 
belong to the B-esterase family, CES2 being the most important enzyme with the broadest 
substrate specificity. Variations in the promoter region of CES2 affect the gene expression, and 
alter the metabolism of rifampicin (Song et al., 2013). 
 
Another study demonstrated that decreased expression of CYP3A4 contributed to increased oral 
absorption of rifampicin, indicating the possible involvement of CYP3A4 in pre-systemic 
metabolism of rifampicin (Prakash et al., 2003; Venkatesan, 1989). 
 
Rifampicin-induced CYP3A4 activation and expression models have been used for predicting 
the pharmacokinetics of CYP3A4 substrate drugs as well as clinically relevant DDI (Yamashita 
et al., 2013). Most of the in vitro HDI studies investigate the role of rifampicin as an inducer of 
CYP3A4 along with other drugs and herbal extracts; less information is available on the effect 
of herbal medicines on the metabolism pathway of rifampicin to 25-O-desacetyl rifampicin. In 
vitro studies have not explored the use of rifampicin as a substrate for HLM assays, to analyse 
the effect of herbal medicines on its pathway by measuring the enzyme kinetics of 25-O-
desacetyl rifampicin. 
 
In this study the effects of the selected herbs on the rifampicin metabolism pathway was 
investigated to understand the changes in its pharmacokinetics associated with 25-O-desacetyl 
rifampicin. The potential of the herbs tested to inhibit this pathway was ranked based on their 
IC50 values. 
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1.3  HIV/AIDS and tuberculosis 
Drug interactions pose an increasingly complex challenge for clinicians treating HIV infected 
patients. Current treatment guidelines recommend the use of a combination of at least three anti-
retroviral drugs for the treatment of HIV-infected patients (Combination Antiretroviral Therapy, 
cART). In addition to medications to treat HIV infection, patients often receive therapy for 
concomitant conditions or for prophylaxis of opportunistic infections. Due to the amount of 
drugs received by an HIV-infected patient, clinicians are often forced to rely on clinical 
judgment and predict drug interactions without having supporting data (HIV Clinical Resource, 
2010). 
 
Drug interactions involving metabolism are the most common, and their clinical relevance is 
often difficult to predict. Most drugs used in cART, especially NNRTIs and protease inhibitors, 
are metabolized via the CYP system. NNRTI-based cART remains a first-line regimen for the 
treatment of HIV-infected patients with TB in resource-limited settings. Efavirenz is a preferred 
NNRTI with favourable treatment outcomes (Meintjes et al., 2017; Manosuthi et al., 2016). 
 
TB is an opportunistic infection with a higher prevalence in immune compromised patients, 
such as HIV‐infected individuals. Medications used to treat TB can have significant interactions 
with other drugs. The interaction that is clinically most relevant is that of the enzyme induction 
associated with rifampicin, a first-line agent used in combination with isoniazid for the 
treatment of TB infection (Kerantzas et al., 2017; Kreek et al., 1976). The standard treatment of 
drug-susceptible TB comprises of a 2-month initial intensive phase comprising of rifampicin, 
pyrazinamide, isoniazid and ethambutol, followed by 4 months of continuation phase of 
rifampicin and isoniazid. cART should be initiated in all HIV-infected patients with TB, within 
the first 8 weeks of starting antituberculous treatment and within the first 2 weeks for patients 
with CD4 cell counts <50 cells/mm3 (WHO TB guidelines, 2017; Manosuthi et al., 2016). 
Isoniazid, a CYP3A4 inhibitor (Wen et al., 2002) when used along with rifampicin may also 
induce various CYP isoenzymes leading to the formation of acetyl-isoniazid from isoniazid. 
The latter is further converted to monoacetyl hydrazine and catalysed by CYPs to form other 
hepato-toxic compounds, thereby increasing isoniazid toxicity (Chen and Raymond, 2006). 
 
Selection of the appropriate drugs prescribed for HIV/AIDS and TB, is critical. The treatment 
guidelines take into account the effect of each drug on the CYP system as shown in Table [1] 
below. 
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Table [1] Drugs and CYP Interactions (Lee et al., 2014; FDA Clinical Pharmacology Guidelines, 2012; HIV 
Clinical Resource, 2010; Arbex et al., 2010; Kivisto et al., 1995) 
DRUG EFFECT ON THE CYP SYSTEM 
HIV/AIDS TREATMENTS 
Non-Nucleoside Reverse Transcriptase Inhibitors  
Delavirdine (DLV)  CYP3A4 inhibitor  
Efavirenz (EFV)  CYP3A4 inducer (inhibitor in vitro)  
Etravirine (ETR)  CYP3A4 Inducer, CYP2C9 and CYP2C19 inhibitor  
Nevirapine (NVP)  CYP3A4 inducer  
Protease Inhibitors  
Amprenavir (APV),  
 Fosamprenavir (FPV)  
CYP3A4 inhibitor/inducer  
Atazanavir (ATZ)  CYP3A4 inhibitor, CYP1A2, CYP2C9 inhibitor  
Darunavir/r (DRV/r)  CYP3A4 inhibitor  
Indinavir (IDV)  CYP3A4 inhibitor  
Lopinavir/ritonavir (LPV/r)  CYP3A4 inhibitor CYP2D6 inhibitor (CYP3A4 inhibition > CYP2D6) CYP3A4 
and CYP1A2 inducer  
Protease Inhibitors  
Amprenavir (APV),      
 Fosamprenavir (FPV)  
CYP3A4 inhibitor/inducer  
Atazanavir (ATZ)  CYP3A4, CYP1A2, CYP2C9 inhibitor  
Darunavir/r (DRV/r)  CYP3A4 inhibitor  
Indinavir (IDV)  CYP3A4 inhibitor  
Lopinavir/ritonavir (LPV/r)  CYP3A4, CYP2D6 inhibitor; (CYP3A4 inhibition > CYP2D6); CYP3A4 and 
CYP1A2 inducer  
 Nelfinavir (NFV)  CYP3A4 inhibitor/inducer  
Ritonavir (RTV)  CYP3A4, CYP2D6 inhibitor; (3A4 inhibition >CYP2D6); CYP3A4 and CYP1A2 
inducer  
Saquinavir (SQV)  Weak CYP3A4 inhibitor  
Tipranavir/ritonavir  
 (TPV/r)  
CYP3A4 inhibitor  
Potent P-gp inducer  
TUBERCULOSIS TREATMENTS 
 Pyrazinamide No significant CYP interactions 
 Rifampicin CYP3A4 and CYP2C9 Inducer 
 Isoniazid Inhibitor on CYP2C9, CYP2C19, and CYP2E1, but its effect on the CYP3A family 
is minimal. 
 Ethambutol Strong inhibitory potential against CYP1A2 and CYP2E1, moderate against 
CYP2C19 and CYP2D6 and weak against CYP2A6, CYP2C9 and CYP3A4 
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1.4  Inhibition of CYP enzyme Activity 
Clinical DDI or HDI involving inhibition or time-dependent inactivation of the CYP enzymes 
can result in clinically relevant side effects resulting from reduced clearance/increased exposure 
of the drug being affected, and diminished clinical efficacy with increased dosage requirements.  
Enzyme inhibition is classified as reversible or irreversible. In the case of reversible inhibition, 
the inhibitor binds non-covalently; irreversible inhibitors commonly bind with the enzyme 
through the formation of covalent bonds or react with residues/ by-products involved in the 
catalysis and alter them chemically. Since reversible inhibitors do not react with the enzyme and 
form any chemical bonds, they are formed rapidly and can be easily separated, thus the enzyme-
inhibitor complex gets dissociated quickly in contrast to irreversible inhibition (Alsanosi et al., 
2014). 
 
1.4.1 Reversible inhibition 
In reversible inhibition (further subdivided into competitive, non-competitive, uncompetitive, 
and mixed types) the enzyme activity is fully restored when the inhibitor is removed from the 
system in which the enzyme functions. In reversible inhibition, there exists equilibrium between 
the inhibitor, I, and the enzyme, E [equation (1.4.1)]: 
E+I⇌EI      (1.4.1) 
The equilibrium constant (Ki, the inhibitor constant) for the dissociation of the enzyme–
inhibitor complex, is given by equation (1.4.2). 
Ki=[E][I][EI]      (1.4.2) 
Thus, Ki is a measure of the affinity of the inhibitor for an enzyme, similar to the constant Ks, 
which is a measure of the affinity of a substrate for an enzyme (Ochs, 2000). 
 
1.4.1.1  Competitive inhibition 
In competitive inhibition, the inhibitor is commonly a structural analogue of the substrate S and 
competes with it to bind at the active site thereby forming the product of the reaction P (Ochs, 
2000).  
Thus, two reactions are possible: 
E+S⇌ES→E+P     (1.4.3) 
E+I⇌EI      (1.4.4) 
The metabolic rate of the reaction (v) can be expressed as: 
v = Vmax [S]/ Km(1+[I]/Ki) + [S]    (1.4.5) 
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Where, Vmax is the maximum velocity of the reaction, and Km is the Michaelis-Menten constant-
the substrate concentration at which the reaction rate is half of Vmax (Nelson and Cox, 2008). 
 
1.4.1.2  Non-competitive inhibition 
In non-competitive inhibition, the inhibitor binds to the enzyme at a site different from the 
substrate binding site, and has no structural resemblance to the substrate. There is no 
competition between the inhibitor and the substrate, and increasing substrate concentration 
cannot overcome the inhibition (Ochs, 2000). The inhibitor binds either to the enzyme–substrate 
complex or a free enzyme; in both cases, the complex formed is catalytically inactive. Non-
competitive reactions are shown in equations (1.4.6) and (1.4.7).  
E+I↔EI (inactive)     (1.4.6) 
ES+I↔ESI (inactive)     (1.4.7) 
The value of Vmax is reduced by the inhibitor because the concentration of active enzyme is 
reduced; Km is unaffected.  
The metabolic rate of the reaction can be expressed as: 
v = {Vmax/ (1+[I]/Ki)} [S]/Km + [S]    (1.4.8) 
 
1.4.1.3 Uncompetitive inhibition 
In uncompetitive inhibition, the inhibitor binds to the enzyme once the substrate binding is 
complete, and not alone. Consequently, the likelihood of uncompetitive inhibition occurs in 
conditions where the concentrations of both substrate and enzyme are high.  
The metabolic rate of the reaction can be expressed as: 
v = {Vmax/ (1+[I]/Ki)} [S]/Km/(1+[I]/Ki) + [S] (1.4.9) 
A special case of uncompetitive inhibition is substrate inhibition, where the substrate itself 
binds to the enzyme at high concentrations, and blocks its activity. 
 
1.4.1.4  Mixed inhibition 
Mixed inhibition is considered a „mixture‟ of competitive inhibition and uncompetitive 
inhibition. The inhibitor can bind to the enzyme alone, before the substrate binds (such as in 
competitive inhibition), or can bind to the enzyme substrate complex formed (such as in 
uncompetitive inhibition) (Ramsay and Tipton, 2017; Ochs, 2000). However, the inhibitor has a 
greater affinity for one of the two states, and not both. 
The metabolic rate of the reaction can be expressed as: 
v = Vmax/ (1+[I]/Ki) + (1 + Ks /[S]) × (1 + [I]/Ki)   (1.4.10) 
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1.4.2 Irreversible inhibition 
In irreversible inhibition, also referred to as mechanism-based inhibition (MBI) or time-
dependent inhibition (TDI), the rate of metabolic recovery is similar to reversible inhibition, and 
dependent upon the production of new enzyme, rather than the dissociation of the enzyme-
inhibitor complex, and elimination of the inhibitor. 
 
In TDI, the potency of the inhibitor increases upon prolonged exposure to the enzyme during 
the pre-incubation period, thereby reducing the enzyme activity. Metabolites that possess 
stronger inhibitory activity than the parent molecule are formed during such reactions, which 
bind irreversibly to the enzyme and inactivate it.  
 
MBI can further be divided into quasi-irreversible and true irreversible inhibition. In quasi-
irreversible inhibition, the metabolite of the reaction interacts with the ferrous structure of the 
CYP heme, and forms a metabolic intermediate complex that makes the enzyme inactive. In 
true irreversible inhibition, the substrate forms strong covalent bonds with the enzyme and 
cannot be dissociated (Tihanyi and Vastag, 2011). 
 
1.5  Traditional medicines 
Traditional medicines which include herbal remedies, homeopathy, oriental medicine and 
acupuncture, and spiritual therapies have been used for millennia to treat acute and chronic 
diseases. At least 28,000 plant species are currently recorded as being of medicinal use, 
although less than 16% of the species used in plant-based medicines are cited in a medicinal 
regulatory publication (SOTWP, 2017). In many regions of the world, people rely on traditional 
herbal medicines (THMs) for their primary healthcare (Tapsell et al., 2006). In Germany, it is 
estimated that 90% of the population use herbal medicines (WHO TMS, 2014; Payyappallimana 
and Subramanian, 2015; Ong et al., 2005). Herbal medications have been used in India, African 
countries, China, Central and South America, and Europe for centuries. The Indian traditional 
medical system called Ayurveda (Sanskrit: Ayur means „longevity‟ or „life‟ and Veda means 
„science‟) dates back to over 5000 years and the practices that are derived from Ayurvedic 
medicine are regarded as part of complementary and alternative medicines (CAM) (NCCAM-
NIH, 2006), and along with Siddha Medicine and Traditional Chinese medicine (TCM), forms 
the basis for systems medicine. In December 2016, the Chinese government recognised 
improved scientific understanding of the TCM and its value in treating chronic conditions by 
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announcing their aim to integrate the same into their healthcare system by 2020 (Xinhuanet, 
2016). 
 
Traditional African medicine is a holistic discipline involving indigenous herbs and African 
spirituality, typically involving herbalists, spiritual healers, diviners and midwives. Practitioners 
of traditional African medicine claim to be able to cure diverse health conditions such as HIV-
AIDS, TB, cancers, psychiatric disorders, high blood pressure and cholera (Helwig, 2005). In 
recent years, the herbal remedies and treatment methods used in traditional African medicine 
have gained more appreciation from researchers in medicine and technology. Developing 
countries have started assessing the high costs involved in the establishment of modern health 
care systems with new and advanced technologies (Mahomoodally, 2013). Due to this reason, 
many African countries have recently expressed interest in the integration of traditional African 
medicine into the continent's national health care systems (Ubani, 2011). Organizations like the 
National Research Foundation of South Africa, have allocated funds for research on promoting 
indigenous knowledge systems in the country. 
 
The traditional health practitioners (THPs) use a wide variety of treatments ranging from 
„magic‟ and spiritual healing, to biomedical methods such as fasting and dieting, herbal 
therapies, bathing, massage, and other surgical procedures (Conserve Africa, 2002). Conditions 
such as migraine, abscesses, pleurisy and cough are often cured using the method of "bleed-
cupping" and the application of herbal ointments followed by herbal drugs (Mehta and Dhapte, 
2015). In some African cultures, hot herbal ointment is rubbed across the patient's eyelids to 
cure migraines and headaches. Herbal mixtures are often used as cures for malaria, which 
involves steam inhalations of herbal concoctions (Onwuanibe, 1979).  
 
In tropical Africa, over 4000 plants are popularly used as medicinal plants (Ubani, 2011; 
Stanley, 2004). Medicinal plants are used to treat many diseases, illnesses and other health 
conditions, the uses and effects of which are of growing interest to Western societies and the 
pharmaceutical researchers. Plants such as Siphonochilus aethiopicus (African ginger), 
Lessertia frutescens (Cancer bush), Aloe ferox, Hypoxis hemerocallidea (African potato), 
Harpagophytum procumbens (Devil‟s claw), Tulbaghia violacea (Wild garlic), etc., are some of 
the plants classified as medicinal in Southern Africa (Directorate Plant Pr., 2013). Certain 
pharmacological and toxicological effects of plants such as Lessertia and Hypoxis have been 
identified when used for patients with HIV/AIDS (Mills et al., 2005). 
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Some of the commonly used medicinal plants in Cameroon, Tanzania, Madagascar and Malawi 
include Prunus africana (Pygeum), Securidaca longipedunculata, Justicia flava, Lessertia 
frutescens, Agaura salicifolia, Turraea holstii, Jatropha multifida, Sterculia africana, 
Spirostachys africana, Turraeanthus africanus, Antiaris africana and Albizia adianthifolia 
(Ntie-Kang et al., 2013; van den Bout-van den Beukel et al., 2008). Acacia senegal (Senegal 
gum), Artemisia herba-alba, Aspalathus linearis (rooibos), Centella asiatica, Catharanthus 
roseus, Momordica charantia (bitter melon), Cyclopia genistoides, Momordica charantia 
and Pelargonium sidoides are among the other commonly used medicinal plants that form part 
of African herbal pharmacopeia with commercial importance (Mahomoodally, 2013). 
 
1.6  Herb-drug interactions 
Today herbs are widely used in teas, vitamins and natural supplements. Besides the potential 
benefits of herbal medicine, it is important to recognize possible HDI, which might have 
pharmacological or toxicological effects. Overdose of certain herbs or conventional drugs can 
be toxic. Synergistic therapeutic effects may lead to adverse complications in the dosing of 
long-term medications – e.g., herbs traditionally used to decrease glucose concentrations in 
diabetes (Bailey and Day, 1989) could theoretically precipitate hypoglycaemia if taken in 
combination with conventional drugs (Bailey et al., 1989). Herbal medicines are complex 
mixtures of more than one active ingredient (phytocompounds). The multitude of such 
phytocompounds which are pharmacologically active increases the likelihood of interactions 
with other conventional drugs. Hence, the chances of HDI are theoretically higher than drug–
drug interactions, because synthetic drugs usually comprise of a single molecule or a few 
chemical entities.  
 
Various classes of chemical compounds are present in plants, which include flavonoids, 
phenols, saponins, glycosides, alkaloids, terpenoids, and coumarins. Some of these compounds 
are potentially capable of interacting with the CYPs, and altering their expression and activity. 
Previous research has reported particular class of phytocompounds including the structure of 
some of the molecules (Fig. 3) responsible for causing HDI. This model connects the 
phytochemical constituents of the herb to its effect (previously reported) on the CYPs. 
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As illustrated in Fig. 3, flavonoids have the potential to modulate the activity of cytochromes 
P450, mainly the CYP1A subfamily, significantly. The administration of rutin and quercetin 
enhances all measured specific activities of certain CYPs, but to a lesser extent compared to 
significantly high induction effect of isoquercitrin (Křížková et al., 2009). Many indole 
alkaloids have previously been reported as inhibitors of CYP2E1 and CYP2A6 (Wang et al., 
2015). Coumarins are competitive inhibitors of CYP1B1 (Mammen et al., 2005), CYP1A1 and 
CYP1A2 (Cai et al., 1996). Phytophenols such as tannic acid and trans-resveratrol have been 
proven to have an inhibitory effect on the enzymatic marker of CYP2E1, while gallic acid also 
had a time-dependant inhibitory effect on CYP3A4 (Pu et al., 2015).  
 
The inhibition and mechanism-based inactivation potential of phenethyl isothiocyanate (PEITC) 
on CYP activities have been investigated using microsomes expressing specific human CYP 
isoforms, extracted from baculovirus-infected insect cells (Nakajima et al., 2001; Thapliyal and 
Maru, 2001). Saponins such as deglycosylated ginsenosides can moderately inhibit CYP 
activities in vitro with IC50 values 10-50 μM (Yu et al., 2012), while cycloastragenol inhibits 
CYP3A4 activity in rat liver microsomes (Wei et al., 2014). 5,7-dimethoxyflavanone 
constituent present in a pacific beverage kava inhibits CYP1A2, CYP2C9, CYP2C19, CYP2D6 
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and CYP3A4 (Showman et al., 2015), and the triterpene astragaloside IV from Astragalus has 
an inhibitory effect on CYP2C9 and CYP3A4 (Shan et al., 2012). 
 
1.6.1 Herb - drug interactions of African herbal medicines 
Usage of herbal medicines, such as Hypoxis hemerocallidea, Lessertia frutescens, 
Harpagophytum procumbensis, Spirostachys africana and Hoodia gordonii, remains popular as 
an alternative or complementary form of treatment, especially in Africa (Pereira et al., 2010; 
Mills et al., 2005; Prevoo et al., 2004; van Wyk, 1997). L.frutescens and H.hemerocallidea were 
recommended by the South African Ministry of Health in the treatment of HIV/AIDS (Giraldo, 
2002), including phase II trials conducted by the South African Herbal Science and Medicine 
Institute (SAHSMI) on L.frutescens (Aboyade et al., 2014). 
 
The misconception that herbal remedies are completely safe due to their “natural” origins 
imperils human safety. In addition to potential inherent toxicity, different types of adverse 
interactions can occur with concomitant use of herbal medicines with conventional 
pharmaceuticals. Previous in vitro studies showed the inhibition of CYP3A4 and pregnane X 
receptor (PXR) by L.frutescens (Mills et al., 2005; Fasinu et al., 2013), CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9 and CYP3A4/5 by H.hemerocallidea (Fasinu et al., 2013; Mills et 
al., 2005), CYP1A2, CYP2D6 and P-gp transporters by H.procumbensis (Cordier and 
Steenkamp, 2004) and CYP3A4 by hoodigogenin A, extracted from H.gordonii (Madgula et al., 
2010); while S.africana significantly induced CYP3A4 mRNA levels (van den Bout-van den 
Beukel et al., 2008). 
 
Some of the CYPs being highly polymorphic pose a problem for pharmaceutical drug tailoring 
and design, to meet an individual‟s specific metabolic activity characteristics (The Royal 
Society, 2005). This is further complicated by the influence of herbal remedies. Unlike the more 
popular herbal medicines used in developed countries, very few data exists on the potential of 
African herbal medicines to cause HDI. Therefore, further research in the specific field of HDI 
for African herbal medicines is needed. 
 
1.7  Herbal medicines selected for this research project 
The herbs selected for this study viz., Withania somnifera, Glycyrrhiza glabra, Astragalus 
membranaceus, Inula helenium, Althaea officinalis and Ocimum basilicum are commonly used 
in Africa by THPs as CAM for HIV/AIDS and TB. These herbs are available in the pharmacies 
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as health supplements, essential oils and tea extracts. O.basilicum is a common culinary spice, 
while G.glabra and A.officinalis extracts are used in confectionaries also. However further 
research is required on the effect of these herbs on the metabolism of HIV/TB medication. 
 
1.7.1 Withania somnifera 
Withania somnifera (L.) Dunal, known commonly as ashwagandha or the Indian ginseng 
(winter cherry (Eng.); koorshout (Afr.); ubuvuma 
(Xhosa); ubuvimbha (Zulu)) is a popular herb in 
Ayurvedic medicine, as well as African herbal 
medicine (fig. 4). 
In southern Africa this plant grows at altitudes of 
15 - 2300 m. The berries and leaves are applied 
externally to tumours, tubercular glands, 
carbuncles, and ulcers (Mirjalili et al., 2009).The 
roots are used to prepare the herbal 
remedy ashwagandha, which has been 
traditionally used to treat various symptoms and 
conditions, having antioxidant properties 
(Scartezzini and Speroni, 2000) and constituents 
such as steroidal lactones (Mirjalili et al., 2009). 
Studies have also been done on ashwagandha 
being used in the treatment of neurodegenerative 
disorders (ven Murthy et al., 2010) and even a 
stress reliever (Cooley et al., 2009). In India and many parts of Africa, the root extract of 
Withania is used as a cure for diseases such as candidiasis and HIV/AIDS (Masevhe et al., 
2015). Recent studies have even shown ashwagandha to neutralize the toxic effects induced by 
β-amyloid-induced toxicity and HIV-1Ba-L (clade B) infection using a human neuronal SK-N-
MC cell line (Kurapati et al., 2013). In vitro studies have also been conducted on the root 
extracts of ashwagandha to understand the anti-HIV activity of these extracts (Rege et al., 
2010). 
 
HDI data: A research study in 2013 showed the lack of any significant CYP3A interactions of 
Withaferin A, Withanolide A and Withanoside IV from Withania using rat and human liver 
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microsomes (Savai et al., 2013). Other studies showed no in vitro CYP1A, CYP3A4 and 
CYP2D6 inhibition of Withania in human and rat liver microsomes (Savai et al., 2014). 
 
1.7.2 Glycyrrhiza glabra 
Historical sources for the use of Glycyrrhiza species as medicine, for symptoms of viral 
respiratory tract infections and hepatitis, include ancient manuscripts from China, India and 
Greece (Fiore et al., 2008). Popularly known as „liquorice‟, Glycyrrhiza glabra L. is common to 
northern parts of Africa (irksos (African/ Arabic)) (fig. 5). 
 
Studies have been done on antiviral effects of the extracts. Reduction of membrane fluidity lead 
to inhibition of fusion of the 
viral membrane of HIV-1 with 
the cell, induction of interferon 
gamma in T-cells, inhibition of 
phosphorylating enzymes in 
vesicular stomatitis virus 
infection and reduction of viral 
latency (Fiore et al., 2008). The 
phytocompound glycyrrhizin (or 
glycyrrhizic acid), found in 
liquorice, has been proposed as 
being useful for liver protection 
in tuberculosis therapy (Gupta et al., 2008). Glycyrrhizin has demonstrated hepatoprotective, 
antimicrobial, antiviral and anti-inflammatory properties, and increasing effects on blood-
pressure in vitro and in vivo, as is supported by the finding that intravenous glycyrrhizin (based 
on the theory that oral delivery of the compound has limited entry into the circulation) slows the 
progression of viral and autoimmune hepatitis (Sato et al., 1996; van Rossum et al., 1998; Chien 
et al., 2011; Yasui et al., 2011). Liquorice extract has demonstrated activity in a clinical trial, 
when applied topically, against atopic dermatitis (Reuter et al., 2010). Additionally, liquorice 
has lipid-lowering effects in patients with hyperlipidaemia (Hasani-Ranjbar, 2010). Liquorice 
has demonstrated efficacy in treating inflammation-induced skin hyperpigmentation (Leyden et 
al., 2011). Liquorice extracts may be useful in preventing bacterial plaques in the oral cavities 
and neurodegenerative disorders (Messier et al., 2012). Anti-ulcer, laxative, anti-diabetic, anti-
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inflammatory, immunomodulatory, antitumor and expectorant properties of liquorice have also 
been noted (Mazumdar et al., 2012; Ming and Yin, 2013; Fiore et al., 2008). 
 
HDI data: G.glabra and its principle bioactive compound, glycyrrhizin, showed a weak 
interaction potential with CYP3A4 and CYP2D6 isoenzymes (Pandit et al., 2011). In other 
studies, liquorice compounds especially isoprenylated flavonoids and aryl coumarins, affected 
the activities of CYP isozymes in vitro. Glabridin inhibited CYP3A4, CYP2B6, and CYP2C9 
(Kent et al., 2002) and glycyrrhetinic acid inhibited CYP2C9, CYP2C19 and CYP3A4 (Zhao et 
al., 2012) while glycyrrhizin induced human CYP3A4 (Tu et al., 2010). 
 
1.7.3 Astragalus membranaceus 
Astragalus membranaceus 
(Fisch.) Bunge (Milk Vetch 
Root and Huang Qi 
(Chinese)) is one of the 50 
fundamental herbs used 
in TCM (Duke and Ayensu, 
1985) (fig. 6). It has been 
asserted as a medicinal 
tonic in improving the 
functioning of the adrenal 
glands, lungs and the GIT, increase metabolism and sweating, promote healing and immunity, 
and reduce fatigue (Balch, 2006).  
 
Biotechnology firms are working on deriving a telomerase activator from Astragalus (de Jesus 
et al., 2011). The chemical constituent cycloastragenol (also called TAT2) is being studied to 
help combat HIV based on its telomerase activation properties, as well as infections associated 
with chronic diseases or aging (United Press Int., 2009). Astragalus roots are being sold as 
supplementary medicine for HIV and other chronic diseases, in pharmacies in South Africa. It 
has gained more popularity in Africa as a health supplement for supporting the immune system, 
preventing colds and upper respiratory infections, and is available in the form of capsules, 
tablets, tinctures and powder (NCCAM-NIH, 2010). 
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HDI data: In an in vitro study using HLMs, A.membranaceus inhibited CYP3A4-mediated 
metabolism of testosterone and increased the Cmax and AUC of midazolam (Pao et al., 2012). 
The pure molecules astragaloside IV and cycloastragenol are inhibitors of CYP3A4, and 
CYP2C9 (Wei et al., 2014; Shan et al., 2012). 
 
1.7.4 Inula helenium 
Inula helenium L. (Elecampane) also called scabwort (horseheal, elf dock (Eng.); rasan 
(African/ Arabic)) is a perennial composite plant common in many parts Africa, Great Britain, 
and can be found throughout central and Southern Europe and in Asia. The roots of this plant 
are used as folk medicine in many countries in Europe and Asia (fig. 7). The phytoconstituents 
include flavonoids, phenols, inulin (Afemei et al., 2012), alantolactones and helenin (Bruneton, 
1995). It is used by herbalists for respiratory conditions; it loosens phlegm and is good in cases 
of colds, bronchitis and emphysema. It is also useful during the menopause to help reduce night 
sweats (Bartram, 1998). Some herbalists 
prescribe Inula as medicine for a wide range of 
other diseases including TB. A bioassay guided 
research-based analysis on the constituents of 
Elecampane such as eudesmanolides, 
alantolactone, isoalantolactone, and 11-alpha 
H,13-dihydroisoalantolactone, exhibited 
significant activity against Mycobacterium 
tuberculosis with minimum inhibitory 
concentrations of 32-128 μg/mL (Cantrell et al., 
1999). 
 
HDI data: Alantolactone showed a potent inhibitory effect on CYP3A4 activity with IC50 values 
of 3.56 μM (HLMs) and 3.90 μM (recombinant CYP3A4) (Qin et al., 2015), while 
isoalantolactone showed potent inhibition of CYP2C19 (Kong et al., 2014).  
 
1.7.5 Althaea officinalis 
Althaea officinalis L., commonly known as „marshmallow‟ (Baer-ul-Khtmk (African/ Arabic); 
Gulkhairo (Pers.)) is a perennial species indigenous to Africa, which is used as a medicinal 
plant and ornamental plant (fig. 8). A confection made from the root since ancient Egyptian 
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time evolved into today's marshmallow treat. The generic name, Althaea, is derived from the 
Greek word ‘althein’ which means „to cure‟, from its healing properties (Simonetti, 1990).  
 
Marshmallow is traditionally used 
in the treatment of irritations in the 
mucous membranes, including use 
as a gargle tonic for mouth and 
throat ulcers, as well as gastric 
ulcers (Williamson and Wyandt, 
1997). A study on rats concluded 
that an extract from the flowers has 
potential benefits for health 
conditions such as hyperlipidemia, 
gastric ulcers and platelet aggregation (Hage-Sleiman et al., 2011). The root has been used since 
the middle ages in the treatment of sore throat (Rachel, 2006). Extracts for marshmallow are 
claimed to cure tuberculosis, pertussis, pneumonia, dry cough, night sweats, five heart heats, 
small rapid pulse and other wide range of diseases and body conditions (Cravotto et al., 2010; 
Sutovska et al., 2007; Basch et al., 2003). A phytochemical study on the constituents of the 
plant led to the isolation of three phytocompounds, altheahexacosanyl lactone (n-hexacos-2-
enyl-1,5-olide), 2β-hydroxycalamene (altheacalamene) and altheacoumarin (Rani et al., 2010). 
 
HDI data: No relevant research data on potential interactions of A.officinalis with CYPs have 
been published. 
 
1.7.6 Ocimum basilicum 
Ocimum basilicum L. or sweet basil 
(Basilikum, Soet balsam (Afr.); 
Mrihani (Swahili)) is a common 
culinary herb, native to India, China, 
Southeast Asia, New Guinea and many 
parts of Africa. It was originally 
domesticated in India, having been 
cultivated there for more than 5,000 
years (Soule, 2011). 
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Its leaves are mostly used in Italian and Southeast Asian cuisines (fig. 9). Basil is used for its 
medicinal properties in Ayurveda and Siddha medicine (a traditional Tamil system of 
medicine). The volatile oil of basil comprises of eugenol (Akgül, 1989) which is used in 
medicine as a local antiseptic and anaesthetic (Jadhav et al., 2004). The anti-TB activity of the 
crude methanolic extract from the aerial parts (leaves, fruits and flowers) of the plant has been 
reported (Siddiqui et al., 2012). In vitro studies have shown that compounds in basil oil have 
antioxidant, antiviral, and antimicrobial properties (Bozin et al., 2006; Chiang et al., 2005; de 
Almeida et al., 2007; Manosroi et al., 2006). O.basilicum is traditionally used for supplementary 
treatment of stress, asthma and diabetes in India (Duke, 2008). 
 
HDI data: A methanol-dibutyl ether extract of basil showed inhibitory activity on CYP1A2 
(Jeurissen et al., 2007). Another study showed that the methanolic extract of basil inhibits 
CYP2D6, CYP3A4, CYP3A5, and CYP3A7 (Nguyen et al., 2014). 
 
1.8 Experimental in vitro assays to assess CYP enzyme activities 
As the liver is the major drug-metabolizing organ, liver-derived systems are most effective and 
suitable for metabolic studies. Liver microsomes, recombinant enzymes, liver slices and 
primary hepatocytes are most recommended for in vitro metabolism data. In this study, HLM 
was used and analyses of the samples were carried out using an HPLC-PDA system. 
 
1.8.1 CYP inhibition - liver microsome assays 
During drug development and HDI studies, liver microsomes are often the first hepatic model 
used in metabolic studies. Microsomes are easily prepared from homogenized liver tissue, 
separated by differential centrifugation into microsomal, S9, cytosolic and mitochondrial 
fractions. 
 
Selecting the most appropriate substrate specific to a particular CYP is critical for measuring its 
activity in in vitro studies (Frye, 2004). In recent years, the scientific literature has detailed 
information on the substrates metabolized by the major human CYPs (Walsky and Obach, 2004; 
Donato and Castell, 2003; Yao et al., 2007) and the U.S. Food and Drug Administration (FDA 
Clinical Pharmacology Guidelines, 2012) also outlines the in vitro and in vivo CYP specific 
substrates, inducers and inhibitors.  
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Classical inhibition assays involve the co-incubation of HLM and co-factors (glucose-6-
phosphate, glucose-6-phosphate dehydrogenase, magnesium chloride, NADPH) at 37 
o
C with 
several concentrations of the tested plant extract and selective substrates (such as efavirenz for 
CYP2B6) in phosphate buffer for individual CYP enzymes (Masimirembwa et al., 2003; 
Bjornsson et al., 2003; Walsky and Obach, 2004). The assay is terminated after the incubation 
time, using chilled acetonitrile, centrifuged and the supernatant is analysed using HPLC-PDA 
(Polasek et al., 2006). Inhibition potency of the extracts can be ranked in order of IC50 or Ki. To 
a standardized comparison of the results obtained from different incubations, a typical CYP 
inhibitor (positive control, recommended as per FDA guidelines) must be included in each assay 
and compared to reference values. Before performing CYP inhibition assays, characterization 
and optimization of the kinetic parameters of the CYP substrate in the microsomal system is 
necessary (Bu et al., 2001).  
 
 
 
The Cytochrome P450 TDI IC50 shift assay is used to identify both reversible and time-
dependent inhibitors. The IC50 shift assay determines the IC50 value of a test compound based 
on three different experimental conditions; 0 min pre-incubation, 30 min pre-incubation with 
NADPH and no pre-incubation with NADPH. The TDI shift is a comparison of the IC50s for the 
preincubation with NADPH to the one with no preincubation. 
 
HLMs contain a wide variety of drug metabolizing enzymes and are commonly used to support 
in vitro ADME studies. The CYP activities in the HLM are determined using validated LC-
MS/MS methods and provided in the datasheet. HLMs have long-term stability and can be 
cryopreserved. Relevant animal models for pharmacokinetic and toxicological studies can be 
identified by comparing the CYP metabolic profiles (liver microsomes) from different species 
with those of the human liver microsomes (Jia and Liu, 2009). 
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A major limitation of this in vitro model is that microsomes lack drug metabolizing cytosolic 
enzymes (glutathione S-transferases, sulfotransferases, xanthine oxidase, soluble epoxide 
hydrolases, alcohol dehydrogenase etc.). 
 
1.8.1.1 Analysis of HLM assay samples: 
Most in vitro assays involve HPLC separations, MS analysis or the use of radiometric probes 
for metabolite detection (Lahoz et al., 2006). Selective fluorescence activity assays are applied 
to biological models expressing single CYPs. 
 
1.8.1.1.1 HPLC (photo diode array/ variable wavelength detection) 
The HPLC-PDA platform uses full wavelength detection range from 190 nm to 800 nm and 
provides superior separation for analytes (drug and its metabolites, internal standard) which 
have UV-Vis absorption. The PDA passes a wide spectrum of light through the sample, after 
which it is separated into individual wavelengths and passed onto an array of photosensitive 
diodes. Each diode is specifically sensitive to one wavelength (Müllertz et al; 2016). 
 
The VWD uses a deuterium or similar lamp which produces a broad spectrum of wavelengths 
separated by a diffraction grating. The instrument is adjusted so that only a particular 
wavelength of interest passes through the sample. The concentration of the sample is measured 
equivalent to the light that wasn‟t absorbed by the sample. 
 
The HLM assay samples are run through specific columns and the separation of the drug, its 
metabolite and the internal standard is analysed using the peak retention times and areas for 
each, and quantification of the metabolite (ratio of the peak areas of the metabolite to the 
internal standard. 
 
The HPLC method provides good sensitivity and stability for measuring light-absorbing 
compounds (~pg level), and is easy to operate. The advantage of using HPLC methodology for 
analysis of in vitro assay samples is that it is fast, sensitive and cheaper compared to many other 
techniques (Müllertz et al; 2016). 
 
1.8.1.1.2 LC-MS analysis 
HPLC coupled with electrospray ionization quadrupole time-of-flight (Q-TOF) tandem mass 
spectrometry has been demonstrated to be a powerful tool for analysis of biological samples 
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including the characterization of structural features and fragmentation behavior patterns (Li et 
al., 2011). LC–MS/MS (Triple quadrupole QqQ, Q-TOF), with its high sensitivity and 
speciﬁcity, has become a preferred analytical method for P450-involved HDI studies. The 
principle of an LC-MS is to convert the specific analyte to a gas-phase ion using electrical 
charge, which converts the resultant flux of the charged ions into a proportional electric current. 
This is converted into digital information by the system which displays it as a mass spectrum. 
The drug, its metabolite and the internal standard have specific masses which can be detected 
and quantified. Single or multiple reaction monitoring allows mass transitions that form the 
fingerprint of a specific analyte. There are several modes of MS detections including 
electrospray ionization (ESI) and atmospheric pressure chemical ionization ion trap mass 
spectrometry (APCI-IT-MS). Electrospray ionisation and tandem MS (ESCI-LC-MS) combines 
high speed switching between ESI and APCI within the ion source, enabling the use of MS 
methods with differing combinations and durations of both, within the same analysis. A QqQ 
MS has two quadrupole mass analysers in series with a non-mass analysing quadrupole in 
between which causes the fragmentation of the analyte (drug/ metabolite) through interaction 
with the collision gas (radiofrequency-only quadrupole). In Q-TOF MS, the analytes are 
converted to charged ions and accelerated by an electric field. The time taken by each ion to 
reach the detector is based on velocity which depends on its mass-to-charge ratio. The ion can 
be identified using this ratio and other known experimental parameters. 
 
Advantages of LC-MS analyses are high sensitivity, broad quantitative range and the possibility 
to analyse fluorescent and non-fluorescent probes. Being more suitable for increased throughput 
drug screening (Turpeinen et al., 2006; Fung et al., 2003; Chu et al., 2000), the samples are 
analysed by using fast gradients and short columns, thereby reducing the HPLC run time 
significantly. 
 
1.8.2 S9 fractions and hepatocytes 
S9 fractions are obtained by the differential centrifugation of liver homogenates in isotonic 
potassium chloride. These subcellular fractions contain both phase I and II enzymes and 
therefore provide an ideal in vitro system for studying CYP activity as well as better 
representation of in vivo drug metabolism. S9 fractions provide a simple, convenient cost-
effective and efficient alternative to other complex liver models and can be used to determine 
whether a drug undergoes oxidative metabolism and analyse its kinetic parameters, based on 
metabolite formation (Kawaguchi et al., 2018). However, the enzyme activity in S9 fractions is 
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substantially lower when compared to human liver microsomes (Brandon et al., 2003), which 
may result in undetected metabolite formation (Hakura et al., 1999). 
 
In vitro hepatocyte models are reliable and readily available for inhibition studies. 
Cryopreserved hepatocytes are used to study inhibitory effect of herbal medications on 
cytochromes (Fasinu et al., 2013; Thelingwani et al., 2012). 
 
1.8.3 Recombinant CYP systems 
Human CYP enzymes heterologously expressed in different host systems show catalytic 
properties comparable to those of HLMs (Gonzalez and Korzekwa, 1995; Tang et al., 2005; 
Wang et al., 2000). Recombinant human CYPs are isolated in microsomal forms and are 
commercially available for CYP phenotyping, metabolic stability screening and inhibitory 
potential evaluation; moreover, they can be used for metabolism or toxicity studies including 
HDI assays (Naritomi et al., 2004; Bort et al., 2004). 
 
A major advantage of recombinant CYPs in relation to HLM is the use of non-selective 
fluorimetric probes for high-throughput activity assays. 
 
1.8.4 CYP induction 
Induction of a drug metabolism enzyme refers to a process where the enzyme activity increases 
upon administration of a particular compound (inducer) through increased expression or 
synthesis, or by stabilization of the enzyme (Barry and Feely, 1990). Most drug transporters and 
oxidative and conjugative enzymes are inducible to a varying degree. However, the induction of 
CYP enzymes is of most concern, due to their prominent role in the drug metabolism. The 
induction of CYP enzymes are regulated by three principle nuclear receptors, namely, the 
pregnane X receptor (PXR), the constitutive androstane receptor (CAR), and the aryl 
hydrocarbon receptor (AhR) (Lin, 2006).  
 
The investigation of the induction of CYPs by herbal extracts is equally important as the 
inhibition assays. The key recommendations for CYP induction assays as per the US FDA, are 
to use human hepatocytes, mRNA level evaluation (recommended as endpoint) and initial study 
on CYP1A2, CYP2B6 and CYP3A4 (FDA Clinical Pharmacology Guidelines, 2012; Zhao, 
2012). Induction of CYPs occurs when a drug or herbal extract triggers increased gene 
transcription thereby generating a higher amount of active protein compared to the normal 
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biological baseline. This may results in increased hepatic drug clearance. In the presence of an 
inducer of a particular CYP, the AUC of the co-administered drug metabolised by this CYP, is 
often reduced. St John‟s wort is an example of a CYP3A4 inducer which reduces the AUC of 
midazolam, a CYP3A4 substrate often used as marker drug for in vivo interaction studies, by 
79% on co-administration (Mueller et al., 2006).  
 
In this study induction of CYP was measured using mRNA expression in HepG2 (human liver 
carcinoma) cells (Fig. 11 a, b, c), through RT-PCR, followed by AGE. 
 
 
Fig. 11 A Clusters of HepG2 cells (stock culture), B & C Individual HepG2 cells in normal and neon view. 
 
1.8.4.1 mRNA quantification – Cell-based assays 
The mRNA quantification assays provide an invaluable tool in the assessment of induction in 
drug discovery programs of both in vitro and in vivo test samples, as well as in HDI studies. The 
quantification includes methods that use agarose gel electrophoresis (AGE) and radiolabeled 
probes as well as high-throughput methods based on polymerase chain reaction (PCR) using 
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complementary DNA (cDNA) technology or other advanced hybridization/amplification 
techniques, such as, branched DNA (bDNA) technology. 
 
In the cDNA technology, the stock cells (such as HepG2) cells are cultured in 96-well microtiter 
plates and incubated, with the test sample (herbal extract) for 24 h at various concentrations. 
The cells are then treated with MTT dye and the absorbance is measured at 540 nm. The 
percentage of cell growth inhibition is calculated using the absorbance values obtained for each 
concentration of the extract and the extract concentration required to cause 50% cytotoxicity 
within the HepG2 cells (CTC50) is generated from the dose-response curve.  
The CTC50 concentration of each extract is used for subsequent 24 h incubations with the cells, 
and the total cellular RNA is isolated from these cells post incubation. cDNA is synthesized 
from the RNA using RT-PCR procedure and primers specifically designed for the CYPs. The 
amplified samples are then subjected to AGE and relative fold-expression levels are quantified 
(Reddy et al., 2015) (Fig. 11 d). 
 
Analysis equipment availability and cost are often the deciding factor in the final choice of the 
analysis technique. The cDNA – RT-PCR method is highly efficient in assessing the fold-level 
induction of CYPs by herbs. However the cost involved in procuring CYP-specific primers can 
be high, and the method optimization can be time-consuming and tedious.  
 
The bDNA technology is a hybridization-based method similar to an enzyme-linked 
immunosorbent (ELISA) assay (Urdea et al., 1991; Collins et al., 1997), where cell lysates are 
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applied to a plate coated with oligonucleotides with a specific sequence not related to the target 
mRNA, the capture probe. Two additional oligonucleotide probe sets are added, one that 
hybridizes with the capture probe and mRNA of interest (the capture extender probe), and the 
other that hybridizes with the mRNA of interest and has a sequence that can hybridize with a 
label probe (the bDNA). The label probe is coupled with an enzyme that allows for 
quantification of the mRNA, commonly alkaline phosphatase (AP).  
 
This methodology is commonly used in clinical applications for the detection of HIV (Zhang 
and Surapaneni, 2012; Patel et al., 2009). Disadvantages of bDNA assays are the requirement of 
specialized reagents and technical know-how, and high cost involved. 
 
1.8.4.2 Reporter gene assays 
The reporter gene assay is an invaluable tool for analysing the molecular mechanisms of mRNA 
transcription for many genes. Additionally, it has become an effective methodology to help 
researchers define the mechanism by which enhancer elements in DNA interact with receptors 
that are responsible for the inducible nature of many drug metabolizing enzymes, such as 
CYP3A4, CYP2B6 and CYP1A2 (Garrison et al., 1996; Moore et al., 2000; Dickins, 2004). A 
reporter construct has two essential constituents within the regulatory region, namely, the 
enhancer element and the promoter element. These elements can vary widely. The promoter 
element can be derived from a general promoter, commonly thymidine kinase (TK) or 
cytomegalovirus (CMV) or even from a CYP of interest such as CYP3A4, CYP2C9, CYP1A2, 
CYP2B6, etc. The enhancer element, which is the element to which the receptor of interest will 
bind, is of critical importance in this methodology. 
 
Well characterized PXR-based reporter gene assays have been developed. Reporter assays 
require the transfection of PXR, since PXR is not expressed in most if not all transformed cell 
lines. These assays are based on higher - density plate formats (384 -or 1536 - well) and provide 
a convenient high – throughput assay to screen molecules for PXR transactivation. A reasonable 
correlation of PXR activity in reporter gene assays with enzymatic activity and mRNA in 
primary human hepatocytes validates this assay for CYP induction studies (Luo et al., 2002). 
Several PXR ligand binding assays have been developed to help in the screening of various 
molecules in drug discovery programs (Jones et al., 2000; Moore et al., 2000; Zhu et al., 2004; 
Shukla et al., 2009). 
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1.8.4.3 Protein quantification 
The most popular techniques for protein quantification include Western blot, ELISA, 
multiplexed immunoassay with beads, and quantitative proteomics. 
 
The ELISA assay to measure protein levels, was first described in 1971 for immunoglobulin G 
(Engvall and Perlmann, 1971). The general procedure for this assay involves the following 
steps: The test sample (hepatocytes incubated with plant extract) containing an unknown 
amount of antigen (or target protein) is coated/fixed on to a microtiter plate through surface 
binding and left overnight at 4 
o
C. Then the blocking of the proteins is done using 3% BSA in 
PBS. The primary CYP antibody is then added, which binds to the antigen followed by the 
secondary detection antibody which is most often linked to a reporter enzyme such as AP or 
HRP. In the final step, a substrate is added (3,3‟,5,5‟-Tetramethylbenzidine (TMB) or 
phosphatase), which is acted upon by the reporter enzyme to generate a quantifiable signal, for 
example, fluorescence or luminescence. The specific pure CYP isoenzymes are coated in 
various dilutions and blocked using the same procedure, and the optical density at a particular 
wavelength is measured, to prepare a calibration curve and the concentrations of the 
proteins/antigens in the unknown samples can be extrapolated using the standard curve. 
 
The advantages of this method are its high sensitivity to provide high-throughput assays. Using 
a small amount of sample, it provides accurate protein quantification within a short turnaround 
time. Multiple samples can be analysed within a single plate, and comparative analysis of levels 
of induction by each sample in duplicates is achieved with better accuracy (less coefficient of 
variation (CV)). Being highly adaptable, this method has been applied to study drug - induced 
changes in expression levels of CYP isozymes, GSTs, and drug transporters (Nilsen et al., 1998; 
Kyokawa et al., 2001; Devi and Devaraj, 2006). However the cost involved in procuring CYP-
specific antibodies is high. Also the CYPs induced by herbs are relative to the total content of 
the P450 enzyme system within the liver fraction or hepatocytes used in the assays; ELISA only 
quantifies the proteins from the assay. 
 
Other methods used for protein quantification are as follows.  
Mass spectrometry has been used for both absolute and relative quantitation of proteins and 
peptides, in enzyme induction research. Matrix-assisted laser desorption/ionization – Time of 
flight (MALDI – TOF) has been used to quantifyP450 isozymes in various rat and rabbit liver 
microsomes (Galeva et al., 2003) and highly homologous P450s such as CYP2B1 and CYP2B2 
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were easily differentiated. In this ionization technique, a laser energy absorbing matrix is used 
to create ions from large molecules with minimal fragmentation (Hillenkamp et al., 1991), and 
involves three steps: 1. the test sample with a suitable matrix material is applied on to a metal 
plate, 2. a pulsed laser is passed through the sample and the matrix material causing their 
ablation and desorption, and 3. finally, the resultant molecules are ionized and accelerated into a 
mass spectrometer for further analysis (Karas and Kruger, 2003). 
 
In the LC-MS analysis the analyte and internal standard peptides co-elute, with the exception of 
mass difference whereby the concentration of the corresponding peptide analyte can be 
quantified relative to the internal standard. To aid in the design and optimization of proteomic 
experiments, several software packages are available to predict MRM transitions and peptides 
for a given protein based on unique peptide sequences (Mallick et al., 2007; Kohl et al., 2008). 
Recently, a detailed comparison between immunoassays and a nano-LC-MS assay was 
conducted for quantitation of CYP2D6.1 and CYP2D6.2 allelic isozymes (Yu et al., 2009). 
 
Western blots are performed with chemiluminescence detection (Kricka, 2003). A general 
procedure of Western blot starts with gel electrophoresis of a protein sample followed by 
transfer to a nitrocellulose membrane. The membrane is then probed for the antigen of interest 
with a primary antibody, and subsequently, a secondary detection antibody is applied to 
recognize the primary antibody, using a reporter enzyme such as horseradish peroxidase (HRP). 
Some of the other common techniques include reporter gene assays, and hepatocyte-cell based 
assays. 
 
1.8.4.4 Hepatocyte cell - based assays 
Several in vitro hepatocyte models have been characterized for their ability to accurately assess 
new chemical entities for their induction liabilities. Primary human hepatocytes are the best 
characterized system to assess induction, and accepted by the regulatory agencies. Several 
reports have demonstrated the usefulness of such cells to assess the induction potential of these 
chemical entities (Hewitt, et al. 2007; LeCluyse et al., 2000). Cryopreserved human hepatocytes 
have been used for several induction studies including herbal medicines, to understand the 
effect on the cytochromes (Jackson et al., 2017; Cho et al., 2014; Klieber et al., 2010; Garcia et 
al., 2003). 
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Hepatocyte-like cell-based assays are also being used currently. The guidelines issued by the 
FDA (FDA Clinical Pharmacology Guidelines, 2012) allows for P450 induction data generated 
in immortalized cells. Fa2N–4 is a nontumorigenic immortalized cell line that has been 
evaluated extensively for its potential use as a reliable in vitro model system to assess CYP 
enzyme induction. The induction of various important genes such as CYP1A1/2, CYP3A4, 
CYP2C9, CYP2B6, UGT1A, and MDR1 as measured by mRNA expression levels 
(Nagarajappa et al., 2016) and CYP metabolism-activity has been demonstrated (Mills et al., 
2004). 
 
1.9   Phytochemical extraction, separation and analysis 
Phytochemicals are non-nutritive, biologically active compounds found in plants. Some of these 
phytochemicals have potential disease preventing properties and used as medicine. The 
common phytochemical classes include flavonoids, catechins, anthocyanidins, polyphenols, 
coumarins, isothiocyanates, alkaloids, terpenoids, glycosides and saponins. One or more active 
molecules of these classes are present in the plants, some of which have the potential to 
interfere with the activity of the CYP system. 
 
1.9.1 Extraction 
The general techniques of plant extractions include maceration, infusion, percolation, digestion, 
decoction, hot continuous extraction (Soxhlet), aqueous-alcoholic extraction by fermentation, 
and ultrasound extraction (sonication). For aromatic plants, hydrodistillation techniques (water 
and steam distillation), hydrolytic maceration followed by distillation are employed (ICS-
UNIDO, 2008).  
 
In this study four solvents were used for extraction namely, water, methanol, ethanol and ethyl 
acetate. Hot water decoctions and exhaustive extractions were used for preparing various 
extracts (Pandey and Tripathi, 2014). 
 
The basic parameters influencing the quality of an extract are: 
1. Plant part used as starting material (dried roots, leaves, bark and inflorescence). 
2. Choice of solvent used for extraction (water, ethanol, methanol, ethyl acetate, chloroform, 
hexane, DMSO). 
3. Extraction procedure (maceration, hot water decoction, infusion and exhaustive extraction). 
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1.9.2 Qualitative analysis 
The qualitative biochemical analysis is of critical importance in HDI studies whereby the 
intensity of the various classes of phytocompounds present in the herb can actually be linked to 
a prediction model based on known research data (illustrated in fig. 3), as to indicate if the herb 
has the potential groups of phytocompounds (such as flavonoids, phenols, glycosides, 
terpenoids etc.) capable of causing clinically relevant interactions with the CYPs. This would be 
the precursor step to analysing the activity of the herbal extracts further using in vitro assays 
and detailed phytochemical fingerprinting using HPLC/MS where various reference standards 
can be used for the particular class of phytocompounds present in each herb (for e.g. rutin and 
quercetin for flavonoids and gallic acid for phenols), predominantly (Raaman, 2006). 
 
Qualitative analysis of the extracted plant sample is performed by various biochemical tests 
(Raaman, 2006; Harborne, 1973) such as: 
1. Formation of white precipitate in the presence of Mayer‟s reagent or brown coloration on 
addition of Wagner‟s reagent, indicating the presence of alkaloids. 
2. Formation of green coloration in the presence of ferric chloride solution, indicating the 
presence of phenols. 
3. Keller-Kiliani test, where addition of glacial acetic acid followed by ferric chloride and 
sulphuric acid to form prominent brown ring coloration indicates the presence of glycosides. 
4. Formation of reddish-brown precipitate on the addition of vanillin reagent, indicating the 
presence flavonoids. 
5. Leibermann-Burchard test, where the addition of chloroform followed by acetic anhydride 
and concentrated sulphuric acid results in the formation of dark bluish precipitate, indicating the 
presence of phytosteroids in the sample. 
6. Salkowski Test, where the addition of chloroform followed by concentrated sulphuric acid, 
results in the formation of reddish-brown layer in the sample, indicating the presence of 
terpenoids. 
 
1.9.3 Separation and purification 
Methods of separation and purification of compound include: 
1. Paper chromatography  
2. Thin-layer chromatography  
3. Gas-liquid chromatography  
4. HPLC (PDA/VWD), HPLC-MS 
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5. Gel permeation chromatography 
 
1.9.3.1 LC-MS/PDA analysis 
The standard procedure of analysis using both HPLC and LC-MS analysis includes 
identification of a compound by comparison of specific data obtained from HPLC and MS 
analyses with those of reference compounds (Yang et al., 2010). LC-MS methodology, merging 
the separation of phyto-components with quantitative analysis or qualitative identification, 
provides an effective means of analysing complex samples, being the most popular and 
advanced chromatographic technique in analysing plant samples and herbal mixtures.  
 
Full mass scan analysis of the sample in both positive and negative ionisation modes, allows the 
extraction all possible masses which can then be interpreted and linked to known compounds, 
using high quality mass spectral databases and online repositories. A full scan mode will 
monitor a range of masses know as mass to charge ratio (abbreviated m/z). A typical mass scan 
range can be set in the MS and will detect compound fragments within that range over a set time 
period. The various solvent extracts of each herb are analysed by LC-MS coupled with PDA as 
well as MS/MS fragmentation, and the resultant chromatograms are compared with the 
reference compounds for identification and relative quantification (Fig. 12).  
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The tentative identification of possible compounds depends on various factors such as match of 
the PDA retention times at a particular wavelength, m/z transitions matching known compounds 
and the derived molecular formula for the positive or the negative scans, based on literature 
reviews as well as online mass spectral databases (Stander et al., 2017; Bolleddula et al., 2012). 
Tentatively identified compounds are compounds that can be detected by the analytical testing 
methods developed using LC-MS, but the exact identity and concentration cannot be confirmed 
without further analytical investigation, such as isolation and purification. These compounds are 
detected and classified using LC-MS but the analysis is not target-specific (Murphy et al., 
2003). 
 
Phytochemical fingerprinting is a major step in understanding the natural composition of any 
herb. Fingerprint approach using LC-MS chromatography is one of the most effective tools in 
assessing the quality of herbal medicines. In many industries, such techniques are mandatory for 
quality assurance of various synthetized chemicals. 
 
1.9.3.2 Limitations 
Since the fragment information of MS is easily affected by ionization modes and HPLC 
conditions, it is necessary to establish universal database with the help of the reference 
substances development, for the HPLC-MS like the GC-MS. Another limitation of HPLC/MS is 
that the peak capacity of an HPLC column is limited. In LC-MS analysis, chemical 
identification and structural elucidation of a particular compound based on mass spectral 
database can be tedious since various compounds have the same m/z ratio. Also in LC-MS 
analysis, some of the extracts might have peaks within the same transitions of the reference 
standards, which could indicate the possibility of another compound (plant metabolite) 
matching the same transition such as an isomeric form or an isobar (Bjarnholt et al., 2014). 
 
1.10 Motivation and rationale of this study 
The South African healthcare system is under considerable pressure because of the high 
prevalence of tuberculosis and HIV/AIDS, along with non-communicable diseases such as 
cardiovascular diseases, diabetes, cancers, chronic respiratory diseases and mental illness (Wyk 
et al., 2013). These diseases affect the overall quality of life of an individual and have resulted 
in increased healthcare expenses. The challenges associated with such health conditions and the 
sociocultural outlook and family history of many patients especially in Africa have increased 
the use of THMs for many diseases (Hughes et al., 2015). Herbal medicines are easily available 
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in the form of supplement tablets, teas, extracts, and essential oils, in most of pharmacies, health 
stores, or local market. 
 
Although often herbal medicines are presumed safe by consumers, considering they are natural, 
there are serious risks associated with their inappropriate use. Therefore, there is a need to 
develop standards to assure the safety of herbal medicines, especially in Africa (Kuete, 2017). 
One of the concerns is the possibility of HDIs when herbal medicines are co-administered with 
conventional drugs, as discussed above. 
 
The objective of the present research study is to understand and critically evaluate how the 
following herbs: Withania somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula 
helenium, Althaea officinalis and Ocimum basilicum, can interact with drug pharmacokinetics, 
especially with the CYP enzymes responsible for most of drug metabolism. These herbs have 
been used as medicines by THPs for centuries in Africa, for various medical conditions such as 
HIV and TB. No adequate research has been performed on the appropriate dosage regimens for 
these herbs and their potential to interact with the CYPs involved in drug metabolism. The 
THPs involved in this study, had shown their interest in understanding the possibilities of HDI, 
whereby they could also ensure safer use of herbs and make their customers aware of the 
potential interactions. 
 
One of the greatest challenges faced by many countries in Africa, especially South Africa is the 
control of concomitant HIV and tuberculosis epidemics. Drug-resistant tuberculosis (DR-TB) is 
a major threat to the efforts to end TB in South Africa (Cox et al., 2017) and the mortality rate is 
high for this epidemic. The increasing DR-TB cases, HIV-TB co-infection and TB mortality 
constitutes a situation crisis in Africa which needs urgent attention. The two drugs used in this 
research, efavirenz and rifampicin are part of first line regimens for treatment of HIV and TB in 
South Africa. The pharmacokinetic profile of these drugs can be affected if the enzymes that 
metabolize them undergo inhibition or induction. This can ultimately affect the effective dose 
regimens of the drugs or even have toxic effects. 
 
CYP2B6 is predominantly involved in the metabolism of efavirenz, whereas esterases are 
involved in the metabolism of rifampicin. However, not much research has been done on the 
effect of HDI on the metabolism pathway of rifampicin to 25-O-desacetyl rifampicin. This 
study focuses on this pathway, to understand the inhibition potential of the selected herbs, 
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which are typical and relevant examples of herbal medicines used by THPs for the treatment of 
TB and HIV. Introducing rifampicin as a substrate with HLMs, to assess its metabolism profile 
and analyse if these herbs have the potential to induce or inhibit the formation of 25-O-
desacetyl rifampicin is critical, because if the pharmacokinetics of this metabolism pathway is 
affected, it may lead to incomplete metabolism of rifampicin, which may result in toxicity, 
including mortality (Sridhar et al., 2012; Cheng et al., 1988). 
 
The research presented in this thesis can be divided into four parts: (1) biochemical qualitative 
phytoprofiling of the various groups of phytocompounds present in the extracts, (2) inhibition 
assays using HLM to assess if these herbs can inhibit CYP2B6 and the metabolism pathway of 
rifampicin to 25-O-desacetyl rifampicin, (3) induction assays using HepG2 cells to study the 
possibility of induction of mRNA expression for CYP2B6 and CYP3A4 by the herbs, and (4) 
LC-MS/PDA phytochemical analyses of the chosen herbal extracts to identify and relatively 
quantify the major phytoconstituents present in each extract and predict the compounds capable 
of causing clinically relevant HDI.  
 
1.11 Potential benefits of this study  
Metabolism studies are required to understand the interactions between herbal medicines and 
synthetic drugs, before conclusions are derived on the appropriate use of such herbal medicines, 
especially when consumed with conventional drugs. This research is beneficial in providing 
new information on the possibility of HDI of the traditional African herbal medicines Withania 
somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula helenium, Althaea officinalis 
and Ocimum basilicum.  
 
It forms a critical step in the evaluation of these herbal medicines and their constituents for 
inhibitory or inducing effect on drug metabolising enzymes, to develop appropriate, 
scientifically based product information of such supplements. The results of this research will 
important for planning and designing future clinical pharmacokinetic interaction studies. 
Together, the new information gained by these research investigations will be important in 
formulation of health and safety policy recommendations for the use of herbal supplements, 
including the risk of HDI, and to provide advice to health care practitioners and patients on the 
risk of HDI when co-administering conventional medicines together with herbal medicines.  
  
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
37 
 
1.12 Hypothesis 
The hypothesis of this study was that Withania somnifera, Glycyrrhiza glabra, Astragalus 
membranaceus, Inula helenium, Althaea officinalis and Ocimum basilicum, which are 
consumed as THM for many diseases including HIV and TB, will interact with the CYP2B6–
mediated metabolism of conventional drugs such as efavirenz and/or with the B-esterases-
mediated rifampicin metabolism pathway, in the human liver.  
 
1.13 Research: Aim and objective 
The primary aim of this research was to analyse selected African herb varieties used as 
traditional medicines for various diseases including HIV/AIDS and TB, namely Withania 
somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula helenium, Althaea officinalis 
and Ocimum basilicum, and investigate their potential interactions on CYP2B6 mediated 
metabolism of efavirenz (to 8-Hydroxy efavirenz), esterase-mediated rifampicin (to 25-O-
desacetyl rifampicin) metabolism pathway, and inducing effect on CYP2B6/CYP3A4 mRNA 
expression. This was achieved through in vitro assays using HLM and HepG2 cells. The active 
extracts were subjected to detailed phytochemical analysis using LC-MS/PDA, to link the 
potential phytoconstituents to the activity on CYPs. Statistical analysis of the IC50 and TDI fold-
shift, as well as fold-response of each extract on CYP2B6/CYP3A4 mRNA expression in 
HepG2 cells, was performed to compare the possible inhibition and induction effects of the 
investigated herbal extracts.  
 
1.14 Ethical consideration 
This study was approved by the University of Stellenbosch Health Research Ethics Committee 
(Reference number X15/04/002, Appendix 2). 
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Chapter 2 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals and reagents 
Pure 8-Hydroxy efavirenz (E8H), 25-O-desacetyl rifampicin (25ODESRIF) and neostigmine 
methyl sulphate (NEO) were obtained from Clearsynth Labs Ltd. (Mumbai, India) while 
efavirenz (EFV), rifampicin (RIF), ticlopidine (TICL) and nelfinavir mesylate hydrate (NELF) 
were obtained from Sigma-Aldrich (Steinheim, Germany). 
 
Purified water (Adrona B30 purification systems, Adrona SIA, Latvia), HPLC-grade methanol 
(Sigma-Aldrich, Germany), ethanol (Merck KGaA, Darmstadt, Germany) and ethyl acetate 
(BDH Chemicals, England) were used for the extractions. 
 
The following reagents were used to conduct the biochemical tests for detecting classes of 
phytochemicals: 
 Vanillin reagent: 1% Vanillin in 70% concentrated sulphuric acid (BDH chemicals, 
England) – to test for flavonoids.  
 Wagner‟s reagent: 2 g of iodine (BDH chemicals, England) and 6 g of potassium iodide 
(Merck, Germany) in 100 mL of water – to test for alkaloids. 
 Dilute Ammonia Solution (Hopkin and Williams, England) – to test for alkaloids. 
 0.1% ferric chloride solution, neutral ferric chloride solution (Sigma-Aldrich, Germany) – to 
test for tannins and phenols. 
 10% sodium hydroxide solution (BDH chemicals, England) – to test for coumarins. 
 Magnesium solution (Hopkin and Williams, England) – to test for tannins. 
 Glacial acetic acid, concentrated sulphuric acid (BDH chemicals, England), ferric chloride 
(Sigma-Aldrich, Germany) – to test for glycosides. 
 Chloroform, acetic anhydride (BDH chemicals, England) – to test for steroids. 
 
For the HPLC/MS analysis, LC grade acetonitrile and methanol was purchased from Sigma-
Aldrich (Steinheim, Germany) and Merck KGaA (Darmstadt, Germany), and purified filtered 
water was prepared using Millipore purification systems (Billerica, MA, USA). Leucine 
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enkaphalin (lock mass reference standard) for LC-MS analysis was purchased from Sigma-
Aldrich (Steinheim, Germany). 
 
2.1.2 Human liver microsomes and HepG2 cell lines 
The HLM screening was performed using pooled human liver microsomes (mixed gender - 
H0630) from Xenotech LLC (Kansas, USA). HepG2 (human hepatocellular carcinoma cells) 
cell line was procured from National Centre for Cell Sciences (NCCS), Cell Repository, Pune, 
India. 
 
2.1.3 Reagents and apparatus for inhibition/ induction assays 
For the inhibition assays, glucose-6-phosphate sodium salt, glucose-6-phosphate 
dehydrogenase, magnesium chloride, phosphate buffer solution 1 M, and β-nicotinamide 
adenine dinucleotide phosphate hydrate (NADPH) were purchased from Sigma-Aldrich 
(Steinheim, Germany). 
 
For the induction assays, microtiter 96–well U–bottom plates from Tarsons Products Pvt. Ltd., 
Kolkata, India were used for the induction assays. 25 cm
2
 cell culture flasks were purchased 
from Corning® Inc. (New York, US). 
 
MTT (thiazolyl blue tetrazolium bromide), phosphate buffered saline pH 7.4 (PBS), nutrient 
mixture F-12 Ham, EDTA, Dulbecco's modified Eagle‟s medium – high glucose (DMEM), 
trypsin, and the antibiotics for cell culture were purchased from HiMedia Laboratories 
(Mumbai, India). Dimethyl sulfoxide (DMSO) was purchased from Finar Ltd. (Gujarat, India). 
Gibco™ Fetal bovine serum (FBS) was purchased from Thermofisher Scientific (MA, USA). 
Tri-Xtract™ for the isolation of RNA was purchased from G-Biosciences Ltd. (MO, US).  
 
Esco class II biosafety cabinet (Esco Technologies, PA, USA) was used for cell culturing. CO2 
Incubator manufactured by Nuaire (MN, USA) was used for all incubations. AE-series inverted 
microscope (Motic Asia, Hong Kong) was used for tissue culture inspection. BioTek Epoch 
automated microplate reader with Gen5 2005 software v1.10.8 (BioTek Instruments, Inc. USA) 
was used for plate incubations and readings. Polymerase chain reactions were done using the 
MJ mini thermocycler (Bio Rad, Hercules, CA, USA). 
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2.1.4 Data analysis 
For the statistical data plots, including the non-linear regression graph plots for determining the 
IC50, GraphPad Software Inc. (San Diego, CA; www.graphpad.com) Prism version 5.00 for 
Windows, was used.  
Digital imaging and relative sample expression levels for gel electrophoresis was done using 
inGenius - gel documentation system comprising of GeneTools analysis software (Syngene, 
MD, USA). 
 
2.1.5 Herbs 
The dried roots of Withania somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula 
helenium, Althaea officinalis and leaves, seeds and inflorescence of Ocimum basilicum were 
obtained in packed form, from Pharma Germania, Benoni, Gauteng; the contents being pure, 
and certified (Table 2). A voucher specimen could not be submitted, because the dried herb 
parts were in semi-powdered form. 
 
Table [2] Herbs, CoA# and Code names 
 
Plant Species 
 
Part 
Certificate of 
Analysis (CoA #) 
Code for Sample Preparation/ 
Reference 
Aqueous Methanol Ethanol Ethyl acetate 
Withania somnifera (Ws) Dried roots 137202 WsA1 WsM2 WsE3 WsEtA4 
Glycyrrhiza glabra (Gg) Dried roots 4243500 GgA1 GgM2 GgE3 GgEtA4 
Astragalus 
membranaceus (Am) 
Dried roots B311400/FP136095 AmA1 AmM2 AmE3 AmEtA4 
Inula helenium (Ih) Dried roots 462563 IhA1 IhM2 IhE3 IhEtA4 
Althaea officinalis (Ao) Dried roots 471255 AoA1 AoM2 AoE3 AoEtA4 
Ocimum basilicum (Ob) Dried leaves and 
inflorescence 
PFI-2645 ObA1 ObM2 ObE3 ObEtA4 
 
Note: The code name for each extract was derived using the initials of the scientific name, the 
type of solvent in serial order (1
st
: aqueous – A1, 2nd: methanol – M2, 3rd: ethanol – E3, 4th: 
ethyl acetate – EtA4). 
 
2.2 Methods 
The methods are divided into four phases of study: 
1. Biochemical analysis of each extract using various chemical reagents that are reactive-
specific for certain groups of phytocompounds (based on precipitate formation and reaction 
color intensity). 
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
41 
 
2. In vitro assays with HLM and the analysis of samples using HPLC.  
3. Induction assays for mRNA expression of CYP2B6 and CYP3A4 in HepG2 cells. 
4. Phytochemical fingerprinting of the active herbal extracts using LC-MS/PDA analysis, 
which includes tentative identification of major compounds based on the peak intensity, 
mass transitions and UV-maxima. 
 
PHASE – I: EXTRACTION AND BIOCHEMICAL PHYOPROFILING 
2.2.1 Extraction of herbal supplements for bioassays 
2.2.1.1 Exhaustive extraction 
Water decoction extract (A1): The dried roots of W.somnifera, G.glabra, A.membranaceus, 
I.helenium, A.officinalis and dried leaves of O.basilicum were powdered, weighed (4 g) and 
extracted exhaustively with water (Adrona B30, upto 500 mL for 9 days) using mechanical 
agitation. The extracts obtained were filtered and concentrated/ evaporated at 50 °C using a 
centrifugal vacuum concentrator (miVac, England) to complete dryness and marked as WsA1, 
GgA1, AmA1, IhA1, AoA1 and ObA1, and stored in a desiccator at 2-4 °C. 
 
Methanol extract (M2): The dried roots of W.somnifera, G.glabra, A.membranaceus, 
I.helenium, A.officinalis and dried leaves of O.basilicum were powdered, weighed (4 g) and 
extracted exhaustively with methanol (HPLC grade, upto 500 mL for 9 days) using mechanical 
agitation. The extracts obtained were filtered and concentrated/ evaporated at 45 °C using a 
centrifugal vacuum concentrator (miVac, England) to complete dryness and marked as WsM2, 
GgM2, AmM2, IhM2, AoM2 and ObM2, and stored in a desiccator at 2-4 °C. 
 
Ethanol extract (E3): The dried roots of W.somnifera, G.glabra, A.membranaceus, I.helenium, 
A.officinalis and dried leaves of O.basilicum were powdered, weighed (4 g) and extracted 
exhaustively with ethanol (HPLC grade, upto 500 mL for 9 days) using mechanical agitation. 
The extracts obtained were filtered and concentrated/ evaporated at 45 °C using a centrifugal 
vacuum concentrator (miVac, England) to complete dryness and marked as WsE3, GgE3, 
AmE3, IhE3, AoE3 and ObE3, and stored in a desiccator at 2-4 °C. 
 
Ethyl acetate extract (EtA4): The dried roots of W.somnifera, G.glabra, A.membranaceus, 
I.helenium, A.officinalis and dried leaves of O.basilicum were powdered, weighed (4 g) and 
extracted exhaustively with ethyl acetate (HPLC grade, upto 500 mL for 9 days) using 
mechanical agitation. The extracts obtained were filtered and concentrated/ evaporated at 45 °C 
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
42 
 
using a centrifugal vacuum concentrator (miVac, England) to complete dryness and marked as 
WsEtA4, GgEtA4, AmEtA4, IhEtA4, AoEtA4 and ObEtA4, and stored in a desiccator at 2-4 
°C. 
 
Percentage of yield was calculated as per equation (2.2.1): 
Extract %yield = (W1/W2)×100       Eq. (2.2.1) 
Where, W1 is net weight of residue extract in grams after extraction and W2 is total weight of 
dried herb in grams taken for extraction. 
 
2.2.2 Biochemical phyto-profiling 
A series of standard biochemical tests were performed to assess and evaluate the 
phytochemistry of the herbs, and rank them based on the intensity of the compounds present in 
each extract, as outlined below (Raaman, 2006; Harborne, 1973). The analysis was mainly done 
to assess the presence of nine specific classes of phytocompounds, viz., alkaloids, saponins, 
phenols, tannins, glycosides, terpenoids, flavonoids, steroids and coumarins. These compounds 
had previously been reported of causing HDI for many popular herbs. The objective of this 
analysis was to evaluate the content of each extract based on the precipitate formation, color and 
intensity, for each extract depending on the biochemical reactions (as below) for identifying the 
specific class of phytocompound and rank each herb for its potential to interfere with CYP 
activity.  
 
For all the biochemical analyses, the test solution was prepared for each extract by dissolving it 
in its respective solvent, at a final concentration of 1 mg/mL. 
 
2.2.2.1 Test for alkaloids  
a. Wagner‟s test 
To 150 μL of test solution, equal amount of Wagner‟s reagent was added. Formation of reddish-
brown coloration indicated the presence of alkaloids. 
 
b. Harborne test 
120 μL of dilute ammonia solution was added to 150 μL of test solution of each plant extract 
followed by addition of concentrated sulphuric acid (Harborne, 1973). Formation of yellow 
coloration indicated the presence of alkaloids. 
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2.2.2.2 Test for saponins 
About 150 μL of the test solution was mixed with 120 μL of distilled water and shaken 
vigorously for a stable persistent froth, which indicated the presence of saponins. 
 
2.2.2.3 Test for glycosides (Keller-Kiliani test) 
To 150 μL of the test solution, 100 μL of glacial acetic acid was added. To the resultant, a pinch 
of ferric chloride was added. Finally, 50 μL of sulphuric acid was added to the resultant 
solution. Formation of a prominent brown ring indicated the presence of glycosides. 
 
2.2.2.4 Test for tannins  
To 150 μL of test solution, 100 μL of 0.1% ferric chloride was added and observed for 
formation of blue-black precipitate, which indicated the presence of tannins. 
  
2.2.2.5 Test for flavonoids  
To 150 μL of the test solution, equal amount of Vanillin reagent was added. Formation of 
reddish-brown colour precipitate indicated the presence of flavonoids. 
 
2.2.2.6 Test for phenols  
To 150 μL of the test solution, 100 μL of neutral ferric chloride solution was added. Formation 
of greenish colour indicated the presence of phenols. 
  
2.2.2.7 Test for steroids (Leibermann-Burchard test) 
To 150 μL of the test solution, 100 μL of chloroform was added. Then 3-4 drops of acetic 
anhydride and 3 drops of concentrated sulphuric acid were added. Dark bluish precipitate was 
formed if phytosteroids were present. 
  
2.2.2.8 Test for terpenoids (Salkowski test) 
200 μL of the plant extract solution was mixed with 75 μL of chloroform, and 125 μL of 
concentrated sulphuric acid was carefully added from the sides of the test-tube. The gradual 
formation of a reddish-brown layer indicated the presence of terpenoids in the plant extract. 
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2.2.2.9 Test for coumarins 
To 150 μL plant sample extract solution, equal quantity of 10% sodium hydroxide solution was 
added and heated at 100 
o
C for 5 min. Formation of yellow color indicated the presence of 
coumarins in the plant extract. 
 
PHASE – II: CYP INHIBTION STUDY 
2.2.3 HLM assay validation 
The HLM assay was validated, by incubating EFV and RIF as substrates and NEO as internal 
standard. Briefly, a standard 200 μL incubation mixture containing liver microsomes (ranging 
from 0.25 – 1.00 mg/mL protein concentration), EFV/ RIF (100 𝜇M) in 0.2 M phosphate buffer 
pH 7.4 at 37 °C was incubated in duplicate. The reactions were initiated with NADPH (final 
concentration 1.3 mM) along with the co-factors MgCl2 (final concentration 3.3 mM), glucose-
6-phosphate (final concentration 1.3 mM) and glucose-6-phosphate dehydrogenase (1 U/mL), 
and then terminated with 200 μL of chilled acetonitrile spiked with the internal standard NEO 
(20 𝜇M). The samples were centrifuged using 0.22 μm polypropylene centrifuge tube filters 
(Spine-X
®
 Costar, USA) at 13000 rpm for 5 min and 15 μL of the supernatants were subjected 
to HPLC analysis. 
 
1. HPLC–EFV method: The HPLC gradient method was slightly modified from a previous 
study on CYP1A interaction (Varghese et al., 2014). The HLM-EFV assay incubates for 
determination of CYP2B6 activity, were run on a C-18 Phenomenex-Evo column (150 x 2.6 
mm, 3.5 μm) by gradient elution using mobile phase comprising of water (A): acetonitrile (B) at 
a flow rate of 0.7 mL min
−1
 for clear separation EFV, its major metabolite E8H and the internal 
standard. The detection wavelength was 245 nm. 
 
2.HPLC–RIF method: For determination of CYP3A4 activity, the RIF incubates were run on a 
C-18 Phenomenex Luna column (150 x 4.6 mm, 5 μm) by gradient elution using mobile phase 
comprising of water (A): methanol (B) at a flow rate of 0.8 mL min
−1
 for separating rifampicin, 
its metabolite 25ODESRIF and the internal standard NEO. The detection wavelength was 254 
nm. The gradient solvents program was set as (𝑇𝑇min/% solution B) and 0/10, 5/80, 10/95, 
9/80, and 11.5/10 for both methods. 
 
Both the HPLC methods for EFV and RIF were validated for consistency, linearity and 
precision. A linear response was obtained in the concentration range 0 – 200 𝜇M for both EFV 
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and RIF, and their metabolites (R
2
 = 0.9930 and 0.9950 respectively). This concentration range 
was selected based on the literature search of the maximum concentration used in in vitro 
incubation assays for both drugs (100-150 𝜇M). LLOD and LLOQ were determined for EFV 
(7.57 𝜇M, 22.95 𝜇M), E8H (7.99 𝜇M, 24.24 𝜇M), RIF (5.86 𝜇M, 17.75 𝜇M) and 25ODESRIF 
(7.78 𝜇M, 23.57 𝜇M), based on the International Council for Harmonisation (ICH) guidelines. 
Based on the rate of metabolite formation the optimum protein concentration was determined 
(0.5 mg/mL for EFV and 0.25 mg/mL for RIF), and the same assays were repeated for various 
incubation time slots – 15, 30, 45 and 60 min with fixed protein concentration, in duplicate. 
Based on the rate of metabolite formation, the optimum time of incubation was selected. The 
optimum protein concentration and time of incubation for both EFV and RIF assays, were used 
further to determine the kinetics of both drugs (Table 3). 
 
Table [3] HLM assay constituents and HPLC parameters/ conditions for sample analysis. 
Substrate EFV (CYP2B6) RIF (esterases) 
Concentration (Km) 15 μM 48 μM 
Structure 
 
 
Metabolite E8H 25ODESRIF 
 
Structure 
 
  
Internal Standard NEO 
Concentration 20 μM 
 
Structure 
 
 
Enzyme concentration 0.5 mg/mL 0.25 mg/mL 
NADPH 
concentration 
1.3 mM 1.3 mM 
Phosphate buffer 0.2 M 0.2 M 
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HPLC 
Column 
C-18 Phenomenex-Evo column (150 x 2.6 
mm, 3.5 μm) 
C-18 Phenomenex Luna column (150 x 4.6 
mm, 5 μm) 
Flow rate 0.7 mL min
−1
 0.8 mL min
−1
 
Run Time 10.5 min 11.5 min 
Injection 15 𝜇L 15 𝜇L 
Mobile Phase 
(Gradient) 
Water: Acetonitrile  
 90:10 (0 min)  20:80 (5 min)  5:95 (10 
min)  90:10 (11.5 - 12.5 min) 
Water: Methanol  
 90:10 (0 min)  20:80 (5 min)  5:95 (10 
min)  90:10 (11.5 - 12.5 min) 
Column Temperature 20 
o
C 27 
o
C 
Wavelength 245 nm 254 nm 
 
3. Rate of metabolite formation: The rate of metabolite formed per sample analysed in the 
HPLC was based on the ratio of area under the curve for E8H and 25ODESRIF to that of the 
internal standard NEO, in each chromatogram. The standard calibration curve was derived for 
pure E8H and 25ODESRIF in concentrations ranging from 0-150 μM (spiked with 20 μM 
NEO) based on the ratio of the peak areas for E8H and 25ODESRIF to that of the internal 
standard NEO plotted against the concentration of E8H and 25ODESRIF. This was further used 
to calculate the reaction rate (pmol/mg protein/min) and the kinetics constants (Km and Vmax). 
 
2.2.4 Determination of kinetics of EFV and RIF 
For determining the kinetics of EFV, various concentrations in the range of 0-125 𝜇M were 
incubated with HLM for 30 min using the same procedure as in section 2.2.5, and the reactions 
were terminated using 200 μL of chilled acetonitrile spiked with the internal standard, 
centrifuged and the top layer of the supernatant was subjected to HPLC analysis. The optimal 
incubation time (30 min) and the concentration of HLM (0.5 mg/mL protein) for the kinetics 
study was selected based on the rate of metabolite formation from the time/protein-variant 
incubations.  
 
For determining the kinetics of RIF, various concentrations in the range of 0-150 𝜇M were 
incubated with HLM, buffer and the co-factors for 30 min, and the reactions were terminated 
using 200 μL of chilled acetonitrile spiked with NEO, centrifuged and the top layer of the 
supernatant was subjected to HPLC analysis. The optimal incubation time was maintained at 30 
min and the concentration of HLM at 0.25 mg/mL protein. 
 
Apparent kinetic constants (Km and Vmax) were estimated by fitting formation rates of metabolite 
versus substrate concentrations to appropriate kinetic equations by nonlinear regression analysis 
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using GraphPad Software. The in vitro intrinsic clearance, CLint was calculated as below (eq. 
2.2.2) (Ogburn et al., 2010): 
 
CLint= Vmax/Km         Eq. (2.2.2) 
 
2.2.5 Inhibition assays – HLM and plant extracts 
2.2.5.1 Two-point screening 
The inhibitory potential of each extract was assessed using a two-point screening with HLM, 
maintaining the final concentrations of each extract at 20 and 200 μg/mL. The activity potential 
of each extract was compared with the control incubation of HLM. Based on the Km values 
determined, 15 μM EFV and 48 μM RIF were used as substrates for CYP2B6 and the formation 
of 25ODESRIF (B-esterases), respectively, with 20 μM NEO as the internal standard (Ward et 
al., 2003). This basic screening was done to analyse if the extracts showed any inhibitory 
activity. Briefly, a standard 200 μL incubation mixture containing liver microsomes and 
substrate (0.5 mg/mL protein concentration for 15 μM efavirenz and 0.25 mg/mL protein 
concentration for 48 μM rifampicin) in 0.2 M phosphate buffer (pH 7.4) and the plant extract 
(final concentration 20, 200 μg/mL, dissolved in < 1% solvent) at 37 °C was incubated for 30 
min, in duplicates. The reactions were initiated with the mix comprising of NADPH (final 
concentration 1.3 mM) along with the co-factors magnesium chloride (final concentration 3.3 
mM), glucose-6-phosphate (final concentration 1.3 mM) and glucose-6-phosphate 
dehydrogenase (1 U/mL – dissolved in 5 mM sodium citrate buffer), and terminated with the 
addition of 200 μL of chilled acetonitrile spiked with NEO. The samples were centrifuged using 
0.22 μm polypropylene centrifuge tube filtersat 13,000 rpm for 10 min and the supernatants 
were subjected to HPLC analysis, using same methodology as described in section 2.2.5. TICL 
(10 and 75 μM) was used as the standard inhibitor control for CYP2B6 (Flockhart, 2007). 
NELF (10 and 75 μM) was used to in the rifampicin metabolism assays to evaluate if any 
inhibition could be observed on its metabolism pathway (Polsky-Fisher et al., 2006). 
 
Enzyme activity in the control incubate (no inhibitor), as well as solvent vehicle controls were 
also measured, in duplicate assays. 
The amount of metabolite formed relative to the control was expressed in percentage remaining 
activity and calculated as in equation (2.2.3): 
 
% residual activity = (Test – test control)/ (Control – control blank) × 100% Eq. (2.2.3) 
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2.2.5.2 Assays for determination of IC50 
For the IC50 screening of the active extracts, assays were done using the same methodology as 
in section 2.2.7.1, with concentration range from 1-200 μg/mL of the extract (six-point 
screening), in triplicates. The assays were repeated to verify inter-day variability and 
consistency. The reference inhibitors TICL and NELF were screened in the concentration range 
1-100 μM, to determine their IC50s. The percentile of residual activity was calculated relative to 
the test control (no inhibitor), and plotted against the log-transformed concentrations of the 
herbal extract or the positive control. Non-linear regression analysis (dose-response inhibition) 
was done to obtain sigmoidal plots of enzyme kinetic data for IC50, using GraphPad Software. 
The IC50 graphs demonstrate the IC50 value (𝜇M) calculated using non-linear regression (dose-
response inhibition equations) with the actual IC50 plot curve-fit based on the concentration of 
the substrate (0-200 𝜇M and not the log(X) transformation) (Thomford et al., 2016; Awortwe et 
al., 2014). 
 
2.2.5.3 Time-dependent inhibition of CYP – Determination of TDI IC50 fold-shift 
For the TDI IC50 fold-shift assays, the procedure was similar to the IC50 screening as in section 
2.2.7.2. The plant extracts were pre-incubated with HLM and the co-factors for 30 min prior to 
addition of the substrate.  
All active extracts with concentration range from 1-200 μg/mL (six-point screening) were added 
to the enzyme/phosphate buffer reaction mixture consisting of phosphate buffer (0.2 M), final 
protein concentration of 0.5 mg/mL for EFV and 0.25 mg/mL for RIF and 90 μL of the same 
was mixed with 100 μL of reaction mix comprising of glucose 6-phosphate dehydrogenase (1 
U/mL – dissolved in 5 mM sodium citrate buffer), and cofactors (1.3 mM NADPH, 3.3 mM 
MgCl2, 1.3 mM glucose 6-phosphate) in test-tubes. The concentration of HLM was similar to 
that used in the IC50 assay. The tubes were pre-incubated at 37 °C for 30 min followed by 
addition of 10 μL of substrate reaction mixture of 15 μM EFV (CYP2B6) and 48 μM RIF, in 
phosphate buffer (0.2 M) to each tube and incubated for additional 30 min, along with the test 
control tubes (no inhibitor). The reaction was terminated using chilled ice-cold acetonitrile 
spiked with 20 μM NEO and the samples were centrifuged using 0.22 μm polypropylene 
centrifuge tube filtersat 13000 rpm for 5 min, and the supernatants were subjected to HPLC 
analysis. The percentile of residual activity was calculated relative to the test control (no 
inhibitor), and plotted against the log-transformed concentrations of the herbal extract or the 
positive control. Non-linear regression analysis was done to obtain sigmoidal plots of enzyme 
kinetic data for the fold shift in IC50 for each herbal extract. The TDI fold-shift was determined 
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for each herbal extract based on the ratio of the IC50s of the co-incubation assay IC50(-) to that 
of the pre-incubation assay IC50(+), with NADPH (equation. 2.2.4).  
 
TDIfold-shift = co-incubation assay IC50(-)/ pre-incubation assayIC50(+)  Eq. (2.2.4) 
Extracts with fold shifts ≥1.5 were classified as positive for TDI (Nomeir et al., 2004; Nebert 
and Russell, 2002). 
 
PHASE – III: CYP INDUCTION STUDY 
2.2.6 Induction assays – mRNA expression in hepatocytes 
2.2.6.1 Cytotoxicity testing 
In vitro cytotoxicity of the plant extracts were tested against HepG2 (human liver carcinoma) 
cell line. The plant extracts were taken at concentrations ranging from 1000.00-31.25 µg/mL to 
determine their percentage growth inhibition and toxic concentrations on HepG2 cell line 
(Nagarajappa et al., 2016; Denizot and Lang, 1986). 
 
2.2.6.1.1 Preparation of herb extract test solution 
For cytotoxicity studies, 100 μL of each plant extract was separately suspended and volume was 
made up with DMEM supplemented with 2% inactivated FBS to obtain a stock solution of 10% 
w
/v concentration, and filtered using 0.22 µm syringe filter. Serial two fold dilutions were 
prepared from this for carrying out the cytotoxicity studies. 
 
2.2.6.1.2 Cell line and culture medium 
HepG2 cells were cultured in DMEM supplemented with 10% inactivated FBS, penicillin (100 I 
U/mL), streptomycin (100 μg/mL) and amphotericin B (5 μg/mL) in a humidified atmosphere of 
5% CO2 at 37 °C until confluent. The cells were dissociated with trypsin phosphate versene 
glucose solution (0.2% trypsin, 0.02% EDTA, 0.05% glucose in PBS). The stock cultures were 
grown in 25 cm
2
 culture flasks and all experiments were carried out in 96-well microtiter plates 
(Freimoser et al., 1999). 
 
2.2.6.1.3 Cytotoxicity testing and determination of CTC50 
Cytotoxicity of the plant extracts was assessed based on the method described in a previous 
study on Coleus forskohlii (Nagarajappa et al., 2016). The HepG2 monolayer cell culture was 
trypsinized and the cell count was adjusted to 100,000 cells/mL using DMEM containing 10% 
FBS. To each well of the 96-well microtitre plate, 0.1 mL of the diluted cell suspension was 
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
50 
 
added. After 24 h, when a partial monolayer was formed, the supernatant was flicked off, the 
monolayer washed once with the medium and 100 μL of different test concentrations of the 
herbal extracts were added on to the partial monolayer in the microplates. The plates were then 
incubated at 37 °C for 72 h in 5% CO2 atmosphere, and microscopic examination was carried 
out; observations were noted every 24 h. After 72 h, the extract solutions in the wells were 
discarded and 50 μL of tetrazolium dye (MTT) in PBS was added to each well. The plates were 
gently shaken and incubated for 3 h at 37 °C in 5% CO2 atmosphere. The supernatant was 
removed and 100 μL of iso-propanol was added and the plates were gently shaken to solubilize 
the formazan crystals formed. Finally, the absorbance was measured using a microplate reader 
at a wavelength of 540 nm. The percentage growth inhibition was calculated using the standard 
formula: 
%growth inhibition = (Control absorbance–test absorbance)/Control absorbance×100  Eq. (2.2.4) 
 
From the dose-response curves for each extract against the cell lines, the concentration of the 
test extract needed to inhibit cell growth by 50% (CTC50) was generated (Nagarajappa et al., 
2016). 
 
2.2.6.2 Plant sample analysis - extraction and purification of total mRNA 
2.2.6.2.1 Extraction and purification of total mRNA 
The mRNA expression levels of CYP3A4 and CYP2B6 were carried out using semi-
quantitative RT-PCR. Briefly, the HepG2 cells were cultured in 60 mm petridishes and 
maintained in DMEM medium for 48 h. The DMEM medium was supplemented with FBS and 
amphotericin. Each plant extract (CTC50 concentration) was added to a petridish comprising of 
the cells and incubated for 24 h. Total cellular RNA was isolated from the untreated (control) 
and treated cells using Tri-Xtract™ according to the protocol described by the manufacturer (G-
Biosciences Ltd). The mRNA pellet was dissolved in nuclease-free water. Purity of RNA was 
estimated using the 260/280 absorbance ratio, and samples were frozen at -80 °C for further 
analysis.  
 
2.2.6.2.2 RT-PCR Procedure 
cDNA was synthesized from the total isolated RNA from the treated HepG2 cells, by reverse 
transcriptase kit according to the manufacturer‟s instructions (Thermo Scientific). The reaction 
mixture consisted of 1x cDNA synthesis buffer, dithiothreitol (0.5 M), RiboLock RNAse 
inhibitor (20 U), deoxynucleotide mix (1.6 mM), oligo dT (100 ng), reverse transcriptase (25 
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U), and total RNA. Primers for CYP3A4 and CYP2B6 were selected as per a method developed 
previously for studying the modulation of CYPs (Park et al., 2009). 50 μL of the reaction 
mixture was subjected to PCR for amplification of hepatic cells. cDNAs using specifically 
designed primers (procured from Eurofins, India) were used and as an internal control, the 
house keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was co-amplified 
with each reaction. Dexamethasone (10 μM) and rifampicin (50 μM) were used as positive 
controls for CYP2B6 and CYP3A4, respectively (Nagarajappa et al., 2016). 
 
2.2.6.2.3 Amplification conditions for pro-apoptotic gene 
CYP3A4: Polymerase chain reaction conditions were set for initial denaturation at 95 °C for 5 
min followed by 35 cycles of denaturation at 95 °C for 30 seconds, annealing of primers at 62 
°C for 30 seconds and extension at 72 °C for 45 seconds. This was followed by final extension 
at 72 °C for 10 min.  
For the first strand synthesis, oligo dT primer was used and for second strand synthesis, 5‟ 
ATTCAGCAAGAAGAACAAGGACA 3‟ and 5‟ TGGTGTTCTCAGGCACAGAT 3‟ were 
used as the forward and reverse primers, respectively (Product size: 314 bp). 
 
CYP2B6: Polymerase chain reaction conditions were set for initial denaturation at 94 °C for 5 
min followed by 35 cycles of denaturation at 94 °C for 15 seconds, annealing of primers at 62 
°C for 30 seconds and extension at 72 °C for 45 seconds. This was followed by final extension 
at 72 °C for 10 min.  
For the first strand synthesis, oligo dT primer was used and for second strand synthesis, 5‟ 
ATGGGGCACTGAAAAAGACTGA 3‟ and 5‟ AGAGGCGGGGACACTGAATGAC 3‟ were 
used as the forward and reverse primers, respectively (Product size: 283 bp). 
 
2.2.6.2.4 Analysis of amplified sequences 
The amplified samples were analysed through 1.8% agarose gel electrophoresis. The gel was 
scanned with UV illumination using digital imaging, and relative sample expression levels were 
calculated using Syngene inGenius documentation system and GeneTools analysis software. 
 
2.2.6.2.5 Statistical analysis 
Experimental data were expressed as the mean ± standard deviation or standard error of mean. 
The results were subjected to one-way analysis of variance, followed by Dunnett's multiple 
comparison tests, by fixing the significance level at p < 0.05, p < 0.01 and p < 0.001 
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(Nagarajappa et al., 2016). The statistical analyses were performed using GraphPad Prism 
Version 5.0. 
 
PHASE – IV: PHYTOCHEMICAL FINGERPRINTING 
2.2.7 Preparation of extracts 
About 8-10 mg of each extract was weighed in an Eppendorf tube and 1 mL of 50% methanol in 
water containing 2% formic acid was added, followed by dissolution in an ultrasonic bath (0.5 
Hz, Integral Systems, RSA) for 20 min at room temperature. The extracts were centrifuged 
(Hermle Z160m, 3000 g for 5 min) and transferred to vials. 
 
2.2.8 Preparation of standards 
The stock solutions of the reference standards quercetin and gallic acid were prepared in 1000 
mg/L concentrations in 50 mL volumetric flasks using 50% methanol in water containing 2% 
formic acid; 4 mL of DMSO was used to dissolve quercetin completely before the solution was 
made up to 50 mL in the volumetric flask. Using both stock solutions a cocktail was prepared in 
the concentration of 200 mg/L of each standard, to enable isomers and compounds with similar 
elemental formulas to be differentiated. 
 
2.2.9 LC-MS analysis conditions: Phytochemical fingerprinting 
Phytochemical fingerprinting of the extracts was done using high-resolution UPLC-MS 
analysis. A Waters Synapt G2 Quadrupole time-of-flight (QTOF) mass spectrometer (MS) 
connected to a Waters Acquity ultra-performance liquid chromatograph (UPLC) (Waters, 
Milford, MA, USA) was used for the same. Electrospray ionization was used in both negative 
and positive modes with a cone voltage of 15 V, desolvation temperature of 275 °C, desolvation 
gas at 650 L/h. The MS settings were optimized for best resolution and sensitivity (Stander et 
al., 2017). Data were acquired by scanning all extracts, from 150 to 1500 m/z in resolution mode 
as well as in MS
E
 mode. In MS
E
 mode two channels of MS data were acquired, one at a low 
collision energy (4 V) and the second using collision energy ramp (40−100 V) to obtain 
fragmentation data as well. The UPLC-MS was calibrated with sodium formate and leucine 
enkaphalin was used as reference mass (lock mass) for accuracy in the mass determination. A 
Waters HSS T3, 2.1 × 100 mm, 1.7 μm column was used for the separation. 2 μL of each 
extract was injected, and a mobile phase comprising of 0.1% formic acid (solvent A) and 
acetonitrile containing 0.1% formic acid as solvent B, was used. A gradient run was used with a 
flow rate of 0.3 mL min
−1
, starting with 100% solvent A for 1 min, which was changed to 28% 
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B over 22 min in a linear way. The gradient solvent composition was then changed to 40% B 
over 50 seconds followed by a wash step with 100% solvent B for 1.5 min, and finally re-
equilibration (to initial conditions) for 4 min. The column temperature was maintained at 55 °C. 
The PDA wavelength range was set between 230 and 600 nm. 
 
The reference standards quercetin and gallic acid along with the plant extracts were analysed as 
per the specific LC-MS/ PDA parameters/ conditions as outlined below in Table 4. 
 
Table [4] LC-MS/PDA parameters of the phyto-profiling method. 
Column Waters HSS T3, 2.1 × 100 mm, 1.7 μm 
Phytocompound Flavonoids Phenols 
Reference Standard  Quercetin 
(Ramos et al., 2017) 
 Gallic Acid 
 (Vallverdú-Queralt et al., 2015) 
Structure 
 
 
Flow rate  0.3 mL min
−1
 
Run Time  29 min for negative mode run, 15 min for positive mode run. 
Injection  2 μL 
Mobile Phase 
 
 0.1% Formic Acid in Water  : 0.1% Formic Acid in Acetonitrile 
 Gradient run 
Column Temperature  55 ºC 
PDA Wavelength  230 – 600 nm 
 
The methods were tested for accuracy and linearity. A linear response was obtained for 
quercetin for the positive mode runs, in the range of 200.000-6.250 mg/L (R
2
 = 0.9900) (Fig. 
13). This concentration range was selected to identify and compare the peak-retention factors 
and m/z of the herbal extract with the reference standard, along with reasonable approximations 
of the relative amounts of the identified peaks from the herbal extracts using the standard 
calibration curve of quercetin. For all the negative scans, both quercetin and gallic acid were 
used as reference standards to relatively quantify the peaks for major compounds with each 
extract. The calibration curve showed a slight bend (non-linearity) at higher concentrations (200 
mg/L) of both standards in the negative mode. A quadratic linear curve fitting model was used 
for quercetin (R
2
 = 0.9879) for relative quantification of the unknown phytocompounds, based 
on the area peak area (response) for the concentration range used (200.000-6.250 mg/L) 
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whereas a linear fit model was used for gallic acid (R
2
 = 0.9680) since the peak area (response) 
was less for low concentrations. 
 
Fig. 13–Concentration range linearity for quercetin in positive mode scan, B &C –regression line-fit concentration 
range linearity for gallic acid & quercetin in negative mode scans, respectively (LC-MS). 
 
Tentative identification of the possible phytocompounds was derived based on: 
 Accurate masses 
 m/z transitions (MS/MS fragments) 
 UV maxima 
 Relative retention times and comparison with literature review on matching compounds 
 Online mass spectral repositories: 
 Metlin Scripps (https://metlin.scripps.edu/) 
 NIST Standard Reference Data online Webbook library 
(http://webbook.nist.gov/chemistry/mw-ser.html) 
 MassBank online Spectral Database (https://massbank.eu/MassBank/) 
 Pubchem chemistry database (https://pubchem.ncbi.nlm.nih.gov). 
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Chapter 3 
RESULTS 
 
3.1 Solvent extraction yield of herbs 
The calculated yields (per 4 g of dried herb) of the solvent extracts of the investigated herbs are 
shown in table 5. Highest yields were observed in the aqueous solvent extractions. Astragalus 
membranaceus had relatively high yields per solvent extracts, and had highest yield among all 
ethanol extracts. Inula helenium had the highest yield among the aqueous extracts, while 
Glycyrrhiza glabra had the highest yield among all the methanol extracts, with 27.36%.  
Althaea officinalis had the highest yield among all ethyl acetate extracts with 14.37%. 
 
Table [5] Extraction yield of herbs.  
Herb Yield (±mg, % W/W) 
Aqueous Extract 
(A1) 
Methanol Extract 
(M2) 
Ethanol Extract 
(E3) 
Ethyl acetate Extract 
(EtA4) 
Withania somnifera 
(Ws) 
±
443 mg, 11.08% 
±
489 mg, 12.22% 
±
237 mg, 5.92% 
±
30 mg, 0.75% 
Glycyrrhiza glabra 
(Gg) 
±
364 mg, 9.10% 
±
1094 mg, 27.36% 
±
430 mg, 10.75% 
±
47 mg, 1.18% 
Astragalus 
membranaceus (Am) 
±
1147 mg, 28.69% 
±
803 mg, 20.09% 
±
473 mg, 11.82% 
±
195 mg, 4.88% 
Inula helenium 
(Ih) 
±
2198 mg, 54.95% 
±
18 mg, 0.44% 
±
295 mg, 7.37% 
±
262 mg, 6.54% 
Althaea officinalis 
(Ao) 
±
1167 mg, 29.16% 
±
731 mg, 18.29% 
±
426 mg, 10.66% 
±
575 mg, 14.37% 
Ocimum basilicum 
(Ob) 
±
1343 mg, 33.57% 
±
378 mg, 9.44% 
±
118 mg, 2.94% 
±
193 mg, 4.83% 
±mg - approximate, considering the residual amount of extract retained in the glass tubes after scraping.
 
 
3.2 Biochemical analysis of herbs 
Based on the color intensity and amount of precipitate formed, the biochemical tests confirmed 
the presence of phytoconstituents such as alkaloids, glycosides, terpenoids, phenols, coumarins 
and flavonoids within most extracts (Table 6). The following observations were noted: 
 All investigated phytocompounds, except steroids could be detected in Glycyrrhiza glabra 
extracts, coumarins being most prominent. 
 Coumarins, alkaloids and flavonoids were present in all the extracts of Inula helenium.  
 Astragalus membranaceus extracts contained all phytocompounds except steroids and 
tannins. The intensity of precipitate formation for flavonoids was high in the aqueous, 
methanolic and ethanolic extracts. 
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Table [6]            Biochemical Phyto-profiling.                                                    Legend Present,  ++ Intensity,  --- Absent 
Sl 
# 
Phyto 
Constituent 
Test Result (positive) 
 
Extract 
Inference 
Ws Gg Am Ih Ao Ob 
1 
a. 
 
 
 
 
 
b. 
 
 
 
 
Alkaloids 
Harborne 
Test 
Yellow coloration 
in extract 
indicates the 
presence of 
alkaloids.  
A1  +++ 
++
+ 
+++ 
++
+ 
++ 
M2 +++ +++ + +++ + +++ 
E3 +++ +++ 
++
+ 
+++ + ++ 
EtA4 + +++ + +++ + ++ 
Wager‟s 
Test 
Reddish-brown 
color formation 
indicates positive. 
A1 +++ ---  +++ --- +++ 
M2 +++ +++ 
++
+ 
+++ 
++
+ 
+++ 
E3 +++ +++ 
++
+ 
+++ 
++
+ 
+++ 
EtA4 +++ +++ 
++
+ 
++ ++ + 
2 Saponins 
Emulsion 
test 
Formation of 
emulsion, which 
remains 
consistent. 
A1 +++ +++ + +++ --- +++ 
M2 --- +++ 
++
+ 
+ --- +++ 
E3 --- --- --- --- --- +++ 
EtA4 --- --- + --- --- ++ 
3 Phenols 
Ferric 
Chloride 
Test 
Greenish colour 
was observed in 
extract. 
A1 --- +++  ---  +++ 
M2 --- +++ 
++
+ 
--- + +++ 
E3 --- +++  --- ---  
EtA4 --- +  --- ---  
4 Tannins 
Harborne 
Test 
Blue-black color 
formation 
indicates presence 
of Tannin. 
A1 --- +++ --- --- 
++
+ 
+++ 
M2 --- +++ --- --- + +++ 
E3 --- +++ --- --- --- + 
EtA4 --- + --- --- ---  
5 Glycosides 
Keller-
Kiliani 
Test 
Brown ring colour 
formation tests 
positive. 
A1 + +++  +++   
M2 +++ +++ 
++
+ 
+++ 
++
+ 
+++ 
E3 ++ +++ 
++
+ 
+++ 
++
+ 
+++ 
EtA4 ++ ++ 
++
+ 
+ ++  
6 Terpenoids 
Salkowski 
Test 
A reddish brown 
colouration if 
observed indicates 
positive. 
A1 ++ +++  +++ + +++ 
M2 +++ +++ ++ +++ ++ +++ 
E3 +++ +++ ++ +++ ++ +++ 
EtA4 + ++  + ++ + 
7 
  
Flavonoids 
Vanillin 
Test 
  
A reddish brown 
coloured 
precipitate is 
formed. 
  
A1 --- + 
++
+ 
+ --- --- 
M2 +++ ++ 
++
+ 
+++ 
++
+ 
+++ 
E3 ++ ++ 
++
+ 
++ 
++
+ 
+++ 
EtA4 + ++ + + ++ + 
8 Steroids 
Lieberman
n-Burchard 
Test 
Dark bluish 
precipitate 
indicates the 
presence. 
A1  --- --- --- --- --- 
M2  --- --- + --- --- 
E3  --- ---  ---  
EtA4 --- --- --- --- ---  
9 Coumarins 
Sodium 
Hydroxide 
Test 
Formation of 
yellow colour 
indicates 
presence. 
A1 + +++ 
++
+ 
+++ +++  
M2 +++ +++ 
++
+ 
+++ +++ --- 
E3 ++ +++ ++ +++ + --- 
EtA4 + +++ + +++   
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 In the extracts of Withania somnifera mostly glycosides, alkaloids and phytosteroids were 
observed. 
 Tests on the extracts of Ocimum basilicum showed positive for all compounds, coumarins 
and phytosteroids being present in trace amounts.  
 The extracts of Althaea officinalis prominently had only alkaloids, glycosides and 
flavonoids. 
 
According to this qualitative analysis G.glabra, O.basilicum, I.helenium and A.membranaceus 
contained most of the relevant groups of phytocompounds. W.somnifera and A.officinalis had 
least saponins, tannins and phenols.  
 
3.3 Inhibition assays 
3.3.1 HLM assay validation 
Satisfactory separations of all three analytes EFV, E8H and NEO, per assay were not achieved 
when using an isocratic method, especially due to interference from co-factors and secondary 
metabolites in the HLM assays; hence, gradient elution was selected (Varghese et al., 2014). 
Method optimization was done by modifying the run conditions such as change in column 
length (100 mm, 150 mm and 250 mm), inner diameter (2.6 mm and 4.6 mm), particle size (3.5 
μm and 5 μm), and change in the elution to gradient. 
 
1. HPLC–EFV methods: Satisfactory separations were achieved on the C-18 column (150 x 
4.6 mm, 2.6 μm), by gradient elution using mobile phase comprising of water (A): acetonitrile 
(B) at a flow of 0.7 mL min
−1
. Comparative analysis was done using a biphenyl column of the 
same dimension and 5μmparticle size (Restek Corp., USA) (Fig. 15). However compared to the 
separation achieved in the biphenyl column (Fig. 15), the HPLC retention times were consistent 
at ±7.57 min, ±8.15 min, and ±8.77 min for EFV, E8H and NEO, respectively for the C-18 
column with a shorter run time (Fig. 14). 
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Fig.14 HPLC chromatographic separation of E8H, EFV and NEO using the C-18 column at 200 𝜇M concentrations 
of all the drugs. 
 
 
Fig.15 HPLC chromatographic separation of E8H, EFV and NEO using the biphenyl column at 4 mM 
concentrations of all the drugs. 
 
A linear response was obtained in the concentration range 0 – 200 𝜇M for both EFV and E8H 
(R
2
 = 0.9930). LLOD and LLOQ were calculated at 7.57 𝜇M and 22.95 𝜇M for EFV and 7.99 
𝜇M and 24.24 𝜇M for E8H, respectively (Table 13). 
 
The HPLC method was also validated using in vitro human liver microsomal incubation assay. 
For all four incubation times (15, 30, 45 and 60 min), the metabolite E8H was detected using 
this method at consistent retention times along with EFV and NEO, and the peak area of NEO 
was relatively constant. Linearity was established for the 15-60 min incubation range based on 
the ratio of the metabolite to the internal standard, with R
2 
= 0.9934 (Fig. 17a, Table 7). 
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2. HPLC–RIF method: A linear response was obtained in the concentration range 0 – 200 𝜇M 
for both RIF and 25ODESRIF (R
2
 = 0.9950). LLOD and LLOQ were calculated at 5.86 𝜇M and 
17.75 𝜇M for RIF and 7.78 𝜇M and 23.57 𝜇M for 25ODESRIF, respectively (Fig. 17b, Table 7). 
The results of the system suitability tests assure the adequacy of the proposed HPLC method for 
routine analysis of RIF and 25ODESRIF alone or in combination (Fig. 16. 1). 
 
In the in vitro human liver microsomal incubation assays, for all four incubation times (15, 30, 
45 and 60 min, in duplicates) the metabolite 25ODESRIF was detected using this method at 
consistent retention times along with RIF and NEO, and the peak area of NEO was relatively 
constant (Fig. 16. 2). Linearity was established for the 15-60 min incubation range based on the 
ratio of the metabolite to the internal standard, with R
2
 = 0.9901 (Fig. 17. a-b, Table 7). 
 
Fig.16 1.HPLC chromatographic separation of RIF, 25ODESRIF and NEO using the C-18 Luna column at 100 𝜇M 
concentrations of the drug and its metabolite, 20 𝜇M internal standard, 2. HPLC chromatographic separation of 
RIF, 25ODESRIF and NEO using the C-18 Luna column, for the in vitro HLM-RIF incubation sample (75 𝜇M 
RIF) 
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Table [7] HPLC analysis retention time for both methods. 
Column 
Phenomenex-Evo C-18 100A Column 
(150 x 4.6 mm, 2.6 μm) 
Phenomenex Luna C-18  Column  (150 x 4.6 
mm, 5 μm) 
Drug EFV E8H NEO RIF 25ODESRIF NEO 
Retention Time (min) 7.57 8.15 8.77 7.70  8.25 10.70 
LLOD (𝜇M) 7.57 7.99  -  5.86  7.78  - 
LLOQ (𝜇M) 22.95 24.24  -  17.75  23.57  - 
Linear Correlation 
Coefficient (R2) 
 0.9906  0.9948  -  0.9932  0.9976  - 
Overall Run Time (min) 10.5  11.5 
HLM Time-variant assay  
Linear Correlation 
Coefficient (R2)15-60 min 
 0.9934  0.9901 
 
 
Fig.17a Standard calibration curves, regression statistics for EFV and E8H; HLM time variant incubation assay 
linearity showing the ratio of E8H to NEO, for the specific time of incubation (15, 30, 45 and 60 min).  
 
 
Fig.17b Standard calibration curves, regression statistics for RIF and 25ODESRIF; HLM time variant incubation 
assay linearity showing the ratio of 25ODESRIF to NEO, for the specific time of incubation (15, 30, 45 and 60 
min). 
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3.3.2 Kinetic analyses of EFV, RIF and their metabolites 
The kinetics for the formation of E8H from EFV, and 25ODESRIF from RIF were determined 
in several HLM incubations for concentrations in the range 0 – 150 𝜇M. Representative 
Michaelis-Menten kinetic plots from all assays are depicted in Fig.18, and the kinetic 
parameters are summarized in Table 8. 
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Fig.18 Kinetic analyses of EFV and RIF by human liver microsomes, and formation of E8H versus EFV and 
25ODESRIF versus RIF. 
 
Table [8] Kinetics of efavirenz and rifampicin metabolism. 
 HLMs Enzyme SUBSTRATE Km Vmax CLint (Vmax/ Km) 
H0610, H0620, H0630, 
H0640 
(Pooled HLM – Mixed, 
Xenotech) 
2B6 EFV 15.08 0.3576 0.0240 
B-esterases RIF 48.23 1.2330 0.0260 
Vmax, pmol/min/mg protein or pmol/min/pmol P450; Km, 𝜇M; CLint, 𝜇l/min/mg protein or 𝜇l/min/pmol P450. 
 
Efavirenz with its binding affinity to CYP2B6 had Km and Vmax values of 15.08 𝜇M and 0.3576 
pmol/min/mg protein. The intrinsic clearance CLint was calculated as Vmax/ Km and observed to 
be 0.0240 𝜇l/min/mg protein for EFV. 
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For rifampicin, the analysed Km and Vmax values were 48.23 𝜇M and 1.2330 pmol/min/mg 
protein, and CLint was calculated as 0.0260 𝜇l/min/mg protein. 
 
3.3.3 Two-point screening of herbs 
The potential of the selected herbal extracts to inhibit the enzyme activity of CYP2B6 and the 
metabolism pathway of rifampicin was investigated. All herbal extracts were screened at two 
concentrations (20 μg/mL and 200 μg/mL) and the observed remaining activity was expressed 
as percentages of the negative control (no inhibitor). For both enzymes, less than 1% solvent 
was used for the total incubation, as per the assay standard guidelines. For the solvent controls 
(solvent concentration > 1%) ethanol reduced CYP2B6 activity by 20% (illustrated in fig. 21) 
and methanol inhibited rifampicin metabolism by 20% (illustrated in fig. 24), while ethyl 
acetate had no effect on both CYP2B6 and rifampicin metabolism. All solvent controls with 
concentration < 1% had no inhibitory effect on the enzyme activity. 
 
CYP2B6: For the aqueous extracts screened with EFV as substrate (against CYP2B6) Ocimum 
basilicum (ObA1) and Inula helenium (IhA1) showed most inhibitory effect. ObA1 reduced 
CYP2B6 activity by less than 50%, while IhA1 reduced the activity by around 50%. 
Glycyrrhiza glabra (GgA1) extract showed a major increase in the rate of metabolism by more 
than 200% at 200 𝜇g/mL concentration (Fig. 19). 
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Fig.19 2-Point screening of all aqueous extracts against CYP2B6 (Code name for each herb can be referred to 
table 2). 
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For the methanolic extracts screened against CYP2B6, most of the extracts had an inhibitory 
effect. Inula helenium (IhM2) showed the largest inhibitory effect reducing the CYP2B6 
activity to around 30% and ObM2 reduced activity by less than 50%, while Withania somnifera 
(WsM2) reduced the activity to 60%. Glycyrrhiza glabra (GgM2) extract showed a major 
increase in the metabolism by more than 200% similar to its aqueous extract (Fig. 20). 
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Fig.20 2-Point screening of all methanolic extracts against CYP2B6 (Code name for each herb can be referred 
to table 2). 
 
Amongst the ethanolic extracts, except for Glycyrrhiza glabra (GgE3) all the other extracts 
inhibited CYP2B6 activity; Inula helenium (IhE3) reduced the activity to around 30% and 
Astragalus membranaceus (AmE3) reduced the activity by 50% (Fig. 21). 
 
GgE3 enhanced the rate of EFV metabolism, increasing the activity by 200%. This mechanism 
of CYP2B6 activation was similar to the trend observed for the aqueous and methanolic extracts 
of G.glabra. 
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Fig.21 2-Point screening of all ethanolic extracts against CYP2B6 (Code name for each herb can be referred 
to table 2). 
 
Amongst the ethyl acetate extracts, except for W.somnifera (WsEtA4) and A.membranaceus 
(AmEtA4), none of the extracts showed strong inhibition of CYP2B6 (Fig. 22). WsEtA4 
reduced the activity to less than 60% and AmEtA4 reduced the activity to 47%. IhEtA4 
inhibited CYP2B6 to a much lesser extent. 
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Fig.22 2-Point screening of all ethyl acetate extracts against RIF metabolism pathway (Code name for each 
herb can be referred to table 2). 
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Rifampicin metabolism: For the aqueous extracts screened against rifampicin metabolism in 
HLMs, most of the extracts increased formation of 25ODESRIF. Only IhA1 showed some 
inhibitory effect. ObA1 increased the percentage of remaining activity by almost 175%, while 
AmA1 induced by around 150% (Fig. 23).  
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Fig.23 2-Point screening of all aqueous extracts against RIF metabolism pathway (Code name for each herb 
can be referred to table 2). 
 
For the methanolic extracts, onlyObM2and IhM2 showed any inhibitory effect on the 
metabolism pathway, reducing the enzyme activity to less than 40% and 50% respectively. 
AmM2 extract showed increase in the formation of the metabolite similar to its aqueous extract. 
At a high concentration, the percentage activity increased by 150% for AmM2 (Fig. 24).  
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Fig.24 2-Point screening of all methanolic extracts against RIF metabolism pathway (Code name for each 
herb can be referred to table 2). 
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Similarly all ethanolic extracts enhanced the rate of formation of 25ODESRIF, except IhE3 
andObE3 which reduced the activity to less than 40%. AmE3 showed the highest increase in the 
enzyme activity (Fig. 25). 
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Fig.25 2-Point screening of all ethanolic extracts against RIF metabolism pathway (Code name for each herb 
can be referred to table 2). 
 
For the ethyl acetate extracts (Fig. 26), only I.helenium (IhEtA4) reduced the metabolism of 
rifampicin to 35% at 200 𝜇g/mL concentration. GgEtA4 showed modest increase in the 
metabolism rate at 200 𝜇g/mL concentration. 
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Fig.26 2-Point screening of all ethyl acetate extracts against RIF metabolism pathway (Code name for each 
herb can be referred to table 2). 
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From all extracts screened, WsM2, WsEtA4, AmE3, AmEtA4, ObA1, ObM2, IhA1, IhM2 and 
IhE3 were selected as potential inhibitors of CYP2B6, and further screened for IC50 
determination with TICL as the positive control. Extracts ObM2, ObE3, IhA1, IhM2, IhE3 and 
IhEtA4 were chosen as potential inhibitors of rifampicin metabolism for IC50 screening. All 
extracts of Inula helenium showed good inhibitory effect on both CYP2B6 and rifampicin 
metabolism.  
 
3.3.4 IC50 determination of selected extracts 
For CYP2B6 screening of the extracts, all IC50 values were in the range of 36-122 𝜇g/mL for a 
concentration screening range between 1 and 200 𝜇g/mL, which indicated that none of the 
extracts were potent inhibitors of CYP2B6 in that concentration range. ObM2 inhibited 
CYP2B6 with an IC50 value 36.07 𝜇g/mL, while AmE3 had an IC50 value 53.37 𝜇g/mL. IhA1 
had an IC50 value 122.00 𝜇g/mL. However at a higher concentration of 200 𝜇g/mL the activity 
was less than 20% (Table 9). 
Comparatively the positive control TICL had an IC50 value of 54.88 𝜇M (14.47 𝜇g/mL) when 
tested in a concentration range of 0-100 𝜇M (Fig. 27) (Table 10). 
 
Both ethyl acetate extracts that were screened against CYP2B6 showed clear inhibition. For 
Withania, WsEtA4 showed more inhibition of CYP2B6 with an IC50 value 57.96 𝜇g/mL 
compared to its methanolic extract (IC50 79.16 𝜇g/mL). Similar for Astragalus, the ethyl acetate 
extract inhibited CYP2B6 with an IC50 value 29.70 𝜇g/mL and the ethanolic extract had an IC50 
value 53.37 𝜇g/mL. 
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AmE3 TDI IC50 (EFV - CYP2B6)
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Fig.27 Statistical plots of herbal extract concentration (with IC50s) of A: WsM2 (79.16 𝜇g/mL), B: WsEtA4 
(57.96 𝜇g/mL), C: AmE3 (53.37 𝜇g/mL), D: AmEtA4 (29.70 𝜇g/mL), E: ObA1 (54.96 𝜇g/mL), F: ObM2 
(36.07 𝜇g/mL), G: IhA1 (122 𝜇g/mL), H: IhM2 (63 𝜇g/mL), I: IhE3 (89.43 𝜇g/mL) and positive control J: 
TICL (14.47 𝜇g/mL, 54.88 𝜇M) against percentage remaining activity of CYP2B6 with EFV as the substrate. 
The IC50 is calculated as log(X) against Y. The plot demonstrates the IC50 (𝜇M) calculated using non-linear 
regression (dose-response inhibition) 
v
/s the actual IC50 plot curve-fit (Code name for each herb can be referred 
to table 2). 
 
For the screening of extracts against rifampicin metabolism, all IC50 values were in the range of 
8-108 𝜇g/mL for a screening range between 1 and 200 𝜇g/mL, indicating the potent inhibition 
effect of these extracts on the activity of the enzymes (Fig. 28) (Table 9). ObE3 inhibited the 
formation of 25ODESRIF, with the lowest IC50value 8.94 𝜇g/mL, while ObM2 had an IC50 
value 31.00 𝜇g/mL. IhE3 had an IC50 value 18.58 𝜇g/mL (Fig. 28, E), while IhA1 and IhEtA4 
inhibited rifampicin metabolism with values 108.00 𝜇g/mL and 62.10 𝜇g/mL, respectively (Fig. 
28, C and F). 
 
Comparatively it was observed that higher concentrations of NELF inhibited rifampicin 
metabolism in HLM and had an IC50 value of 9.59 𝜇M (5.44 𝜇g/mL) within a concentration 
range of 1-100 𝜇M (Fig. 28, G) (Table 10). 
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NELF IC50 (RIF)
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Fig.28 Statistical plots of herbal extract concentration (with IC50s) of A: ObM2 (31.00 𝜇g/mL), B: OBE3 
(8.94 𝜇g/mL), C: IhA1 (108.00 𝜇g/mL), D: IhM2 (42.79 𝜇g/mL), E: IhE3 (18.58 𝜇g/mL), F: IhEtA4 (62.10 
𝜇g/mL) and positive control G: NELF (5.44 𝜇g/mL, 9.59 𝜇M) against percentage remaining activity of 
rifampicin metabolism. The IC50 is calculated as log(X) against Y. The plot demonstrates the IC50 (𝜇M) 
calculated using non-linear regression (dose-response inhibition) 
v
/s the actual IC50 plot curve-fit (Code name 
for each herb can be referred to table 2). 
 
Table [9]             IC50 values of herbal extracts. 
Extract Extract code CYP/Metabolism 
pathway 
Determined IC50 values 
(𝜇g/mL) 
Withania somnifera 
WsM1 CYP2B6 79.16 
WsEtA4 CYP2B6 57.96  
Astragalus membranaceus AmE3 CYP2B6 53.37 
AmEtA4 CYP2B6 29.70  
Inula helenium 
IhA1 CYP2B6 122.00 
IhM2 CYP2B6 63.00 
IhE3 CYP2B6 89.43 
IhA1 RIF metabolism 108.00 
IhM2 RIF metabolism 42.79 
IhE3 RIF metabolism 18.58 
IhEtA4 RIF metabolism 62.10 
Ocimum basilicum 
ObA1 CYP2B6 54.96 
ObM2 CYP2B6 36.07 
ObM2 RIF metabolism 31.00 
ObE3 RIF metabolism 8.94 
 
Table [10] IC50 values of positive controls. 
Positive Control CYP/Metabolism pathway Determined IC50 values (𝜇g/mL) 
Ticlopidine (TICL) CYP2B6 14.47 (54.88 𝜇M) 
Nelfinavir (NELF) RIF metabolism 5.44 (9.59 𝜇M) 
 
3.3.5 TDI IC50 fold shift determination of selected extracts 
For TDI screening of the extracts, many of the extracts showed clear TDI of CYP2B6 activity 
(Fig. 29a, b). The aqueous, methanolic and ethyl acetate extracts of Inula helenium showed 
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clear TDI of CYP2B6 with values 40.37, 33.00 and 66.48 𝜇g/mL when compared to their 
normal IC50s which did not involve preincubation with NADPH (Table. 11). Both the Ocimum 
basilicum extracts also showed TDI of CYP2B6 and ObM2 had a shift of IC50 from 36.07 
𝜇g/mL to 4.93 𝜇g/mL. The ethyl acetate extracts WsEtA4 and AmEtA4 showed no TDI. 
Compared to the IC50 for the assays with no pre-incubation of NADPH, both extracts had higher 
TDI IC50 values of 94.87 𝜇g/mL and 101.00 𝜇g/mL, respectively (Fig. 29a, B & D). 
The positive control TICL showed TDI where the IC50 shifted to 36.51 𝜇M (9.63 𝜇g/mL) (Fig. 
29a, J). 
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Fig.29a Statistical TDI plots of herbal extract concentration (with TDI IC50s) of A: WsM2 (98.93 𝜇g/mL), B: 
WsEtA4 (94.87 𝜇g/mL), C: AmE3 (113.20 𝜇g/mL), D: AmEtA4 (101.00 𝜇g/mL), E: ObA1 (33.35 𝜇g/mL), F: 
ObM2 (4.93 𝜇g/mL), G: IhA1 (40.37 𝜇g/mL), H: IhM2 (33.00 𝜇g/mL), I: IhE3 (66.48 𝜇g/mL) and positive 
control J: TICL (9.63 𝜇g/mL, 36.51 𝜇M) against percentage remaining activity of CYP2B6 with EFV as the 
substrate. The IC50 is calculated as log(X) against Y. The plot demonstrates the IC50 (𝜇M) calculated using 
non-linear regression (dose-response inhibition) 
v
/s the actual IC50 plot curve-fit. 
 
For the TDI screening of the extracts against rifampicin metabolism pathway, none of the 
extracts showed a trend for inhibiting the activity, on preincubation with NADPH, except for 
IhM2 where the IC50 shifted from 42.79 to 23.11 𝜇g/mL (Table. 11). Some of the extracts even 
had an IC50 shift of > 100 𝜇g/mL on preincubation with NADPH (Fig. 29b). 
 
The ethyl acetate extract IhEtA4, showed an IC50 value 62.10 𝜇g/mL in the assay without 
pre-incubation of NADPH. For the TDI assay, the IC50 shift observed for the extract was > 
100 𝜇g/mL (Fig. 29b, F). 
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Fig.29b Statistical TDI plots of herbal extract concentration (with TDI IC50s) of A: ObM2 (>100 𝜇g/mL), B: 
OBE3 (75.76 𝜇g/mL), C: IhA1 (>150 𝜇g/mL), D: IhM2 (23.11 𝜇g/mL), E: IhE3 (>100 𝜇g/mL), F: IhEtA4 
(62.10 𝜇g/mL) against percentage remaining activity of rifampicin metabolism. The IC50 is calculated as 
log(X) against Y. The plot demonstrates the IC50 (𝜇M) calculated using non-linear regression (dose-response 
inhibition) 
v
/s the actual IC50 plot curve-fit. 
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NELF showed clear TDI of the metabolism, where the IC50 value shifted from 9.59 𝜇M 
(5.44 𝜇g/mL) to 6.39 𝜇M (3.63 𝜇g/mL) (fig 29c). 
 
NELF TDI IC50 (RIF - CYP3A4)
0 20 40 60 80 100
40
60
80
100
120
IC50 =  3.63 g/mL, 6.39 M
(pre-incubation with NADPH)
IC50 = 5.44 g/mL, 9.59 M
(No pre-incubation)
Concentration M
R
e
m
a
in
in
g
 A
c
ti
v
it
y
 (
%
)
 
                                               G 
Fig.29c Statistical TDI plot of the positive control G: NELF (TDI IC50= 3.63 𝜇g/mL, 6.39 𝜇M) against 
percentage remaining activity of rifampicin metabolism. The IC50 is calculated as log(X) against Y. The plot 
demonstrates the IC50 (𝜇M) calculated using non-linear regression (dose-response inhibition) 
v
/s the actual IC50 
plot curve-fit. 
 
Table [11] TDI IC50Shift-fold values of herbal extracts and positive controls. 
Extract Extract code 
CYP/ Metabolism 
pathway 
Determined IC50 
values 
IC50(-)(𝜇g/mL) 
TDI IC50 values 
IC50(+) (𝜇g/mL) 
TDI fold-shift 
IC50(-)/IC50(+) 
Withania somnifera 
 
WsM1 CYP2B6 79.16 98.93 <1.5 
WsEtA4 CYP2B6 57.96 94.87  < 1.5 
Astragalus membranaceus 
 
AmE3 CYP2B6 53.37 113.20 < 1.5 
AmEtA4 CYP2B6 29.70  101.00 < 1.5 
Inula helenium 
IhA1 CYP2B6 122.00 40.37 > 1.5 
IhM2 CYP2B6 63.00 33.00 > 1.5 
IhE3 CYP2B6 89.43 66.48 <1.5 
IhA1 RIF metabolism 108.00 > 150 <1.5 
IhM2 RIF metabolism 42.79 23.11 >1.5 
IhE3 RIF metabolism 18.58 > 100 <1.5 
IhEtA4 RIF metabolism 62.10 > 100 <1.5 
Ocimum basilicum 
ObA1 CYP2B6 54.96 33.35  >1.5 
ObM2 CYP2B6 36.07 4.93 >1.5 
ObM2 RIF metabolism 31.00 > 100 <1.5 
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ObE3 RIF metabolism 8.94 75.76 <1.5 
Ticlopidine TICL CYP2B6 14.47 (54.88 𝜇M) 9.63 (36.51 𝜇M) >1.5 
Nelfinavir NELF RIF metabolism 5.44 (9.59 𝜇M) 3.63 (6.39 𝜇M) >1.5 
 
 
Fig.30 Determination of TDI based on IC50 shift-fold. Bars represent the ratio of IC50 values for the co-
incubation(-) to the preincubation (+) assays with NADPH, for the herbal extracts. TICL and NELF were 
positive controls for CYP2B6 and RIF metabolism pathway, respectively. 
 
For the TDI determination, the IC50 shift-fold was calculated as the ratio of the co-incubation 
IC50(-) to the pre-incubation IC50(+) with NADPH (Fig. 30). IhA1, IhM2, ObA1 and ObM2 
showed positive TDI for CYP2B6. IhA1 showed 3-fold increase in the IC50 against CYP2B6 
and IhM2 had 2-fold shift, for rifampicin metabolism.ObM2 exhibited strong TDI on CYP2B6 
with 7.4-fold increase in the IC50. 
Both positive controls TICL and NELF showed clear TDI with the IC50 shift-fold >1.5. 
 
3.4 Phytochemical fingerprinting – Extracts inhibiting CYP activity 
3.4.1 LC-MS/ PDA analysis 
Gallic acid and quercetin were used as reference standards for relative quantification of the 
identified acid compounds and non-acid compounds, respectively. Majority of the acid 
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compounds were detected in negative scan mode and hence, gallic acid calibration was 
determined in negative scan mode (table 12, fig. 31). 
 
The linearity characteristics of the LC-MS method for both standards are shown in Table 8. 
Table [12]             LC-MS analysis characteristics. 
Reference Standard Quercetin Gallic Acid 
Retention time (min) 24.21 6.73 
[M-H]
 –
 169.1001 301.1211 
Linearity range (mg/L) 200.000 – 6.250 200.000 – 6.250 
Linear Correlation 
Coefficient (R
2
) 
 -
ve
 scan mode  0.9442 
-
ve
scan mode 0.9700 
 +
ve
 scan mode  0.9900 
UV range Between 230 and 600 nm 
 
 
Fig.31 Gallic acid and quercetin scans on LC-MS at 200.000, 100.000 and 50.000 mg/L injections. 
 
All negative scans were performed for 29 min, while positive scans were performed for 15 min. 
The major peaks and their masses were used in the tentative identification of the 
phytocompounds based on database search, m/z transitions and the retention time match from 
literature. 
 
For the negative mode extract scans, the following main findings were observed (for details, see 
table 13): 
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
78 
 
1. Ocimum basilicum (aqueous, methanol and ethanol) extracts (fig. 32 shows the 
chromatogram of the aqueous extract):  
 The most prominent peak in all extracts of O.basilicum was the polyphenol - rosmarinic 
acid (fig. 33 a) with a retention time of 21.65 min at m/z 359 at a PDA detection 
wavelength 329nm. 
 Another prominent peak observed in all three extracts was the flavone salvigenin (5-
Hydroxy-6,7,4'-trimethoxyflavone), at retention time 24.36 min at m/z 327 with product 
ions at m/z 116.9, 205, 215, 277 and 311 (fig. 33 b). 
 Acids such as tartaric, isocitric, caftaric and chicoric acids were prominently observed 
in the aqueous extract at m/z 149, 191, 311 and 473, at UV wavelengths 230 nm for the 
first two and 328-329 nm for the latter two compounds (fig. 33 c, d, e). 
 The flavanoid rutin was another major peak observed only in the methanolic extract at 
m/z 609 with products ions at m/z 151, 255, 271, 300 and 301 (fig. 33 f). 
 Apigenin-7-O-glucoside was observed in the ethanolic extract with a retention time 
14.76 min and m/z 431. 
 Other compounds detected in the extracts included 12-hydroxyjasmonic acid (225 m/z), 
medioresinol (387 m/z), trans-Ocimene oxide (137 m/z) and eucommiol (187 m/z). 
 
 
  Fig. 32 LC-MS chromatogram of O.basilicum (aq. extract) in negative mode scan for 29 min. 
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Fig. 33 Structures of some of the main compounds identified from crude herbal extracts of O.basilicum: (A) 
Rosmarinic acid; (B) Salvigenin; (C) Tartaric acid; (D) Isocitric acid; (E) Caftaric acid; (F) Rutin 
 
 
2. Inula helenium (aqueous, methanol, ethanol and ethyl acetate) extracts (fig. 34 shows the 
ethanol extract chromatogram):  
 The most prominent peak in all organic solvent extracts of I.helenium was identified as 
the sesquiterpenoid tanacetol A (2-acetoxy-11-hydroxy-1(10),4(15)-germacradien-5-
one) (fig.35 a) with a retention time of 24.77 min at m/z 293 at a UV detection 
wavelength 275 nm, and product ions at m/z 87, 116 and 231. 
 Macrophyllilactone B, which was previously reported in I.helenium extracts, was 
observed in all three organic solvent extracts at retention time 26.3 min at m/z 265 with 
product ions at m/z 112.98, 183 and 248.95 (fig. 35 b). 
 The aqueous extract had a major peak identified as a dihexose sugar, at 1.79 min and 
m/z 341. 
 Three quinic acid derivatives – chlorogenic acid, cryptochlorogenic acid and 5-
caffeoylquinic acid were observed in the aqueous extract (fig. 35 c, d, e) at m/z 353 and 
distinguished based on the product ions as in table 11. 
 Compounds such as isocitric acid and fukugetin were identified in the aqueous extract 
at m/z 191 and 555, respectively. 
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 The polyphenol epigallocatechin gallate was present in all the extracts but most 
prominent in the methanolic extract at m/z 457 and product ions at m/z 112, 191, 209 
and 371, at retention time 19.57 min. 
 Chlorogenic acid derivative (quinic acid isomer) was observed in the methanol and 
ethanol extracts at m/z 191, retention 12.71 min and daughter ions m/z 85, 135, 161, 179 
(Zhang et al., 2016), while the known compound 5alpha-epoxyalantolactone was 
noticed only in the aqueous extract at m/z 247 and product ions m/z 115.92, 197, 221 
and 233. 
 
 
   Fig. 34 LC-MS chromatogram of I.helenium (ethanol extract) in negative mode scan for 29 min. 
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Fig. 35 Structures of some of the main compounds identified from crude herbal extracts of I.helenium: (A) 
Tanacetol A; (B) Macrophyllilactone B; (C) Chlorogenic acid (D) Cryptochlorogenic acid; (E) 5-
caffeoylquinic acid and; (F) Epigallocatechin gallate 
 
3. Withania somnifera (methanol and ethyl acetate) extracts (fig. 36 shows the chromatogram 
of the ethyl acetate extract):  
 The most prominent peaks in the methanol extract of W.somnifera were observed at 
retention times 24.36 and 24.12 min at m/z 811 and 827 respectively, at a UV detection 
wavelength 230 nm. The product ions for the main peak were m/z 179, 329, 503, 765 
and the same for the second major peak were m/z 179, 312, 503, 653 and 781. These 
compounds did not match any of the previously identified compounds, but the 
molecular formula and the corresponding masses indicated that they could probably be 
withanoside derivatives or withanolide complexes. 
 
 
  Fig. 36 LC-MS chromatogram of W.somnifera (ethyl acetate extract) in negative mode scan for 29 min. 
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 Salvigenin was observed in the methanol extract (fig. 37 b) at 24.57 min, while the 
alkaloid isopelletierine (1-pyridin-2-ylpropan-2-one) was observed at 2.11 min (fig. 37 
c) with m/z 133 and product ions m/z 43, 71 and 93. 
 The known compounds withaperuvin I and withaferin derivative, were observed in the 
ethyl acetate extract at 230 nm, with retention times 24.28 and 23.10 min, respectively, 
while the steroidal lactone dihydrowithaferin A (472 m/z) was observed in the aqueous 
extract at 13.09 min at 280 nm (fig. 37 d).  
 Other peaks identified included the fatty acid trihydroxy octadecenoic acid (m/z 329) 
and eucommiol (187 m/z) at retention times 24.43 and 21.12 min (fig. 37 e) 
respectively. 
 
 
 
Fig. 37 Structures of some of the main compounds identified from crude herbal extracts of W.somnifera: (A) 
Withaperuvin I; (B) Salvigenin; (C) Isopelletierine; (D) Dihydrowithaferin A; (E) Eucommiol. 
 
 
4. Astragalus membranaceus (methanol, ethanol and ethyl acetate) extracts (fig. 38 illustrates 
the chromatogram of the methanol extract):  
 Prominent peaks in all the extracts of A.membranaceus were identified as the 
isoflavonoids calycosin (7,3'-dihydroxy-4'-methoxyisoflavone) and formononetin (7-
hydroxy-4'-methoxyisoflavone) and observed at retention times 24.22 and 24.57 min 
with m/z 283 and 267, respectively, at a UV detection wavelength 230 nm (fig. 39 a, b). 
The product ions for calycosin were m/z 136, 196, 211, 240, 269 and the same for 
formononetin were m/z 115, 117, 196, 207 and 236. 
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 A dihexose sugar (341 m/z) was observed in the methanol and ethanol extracts at 1.79 
min, with product ions identified at m/z 89, 101, 119, 161 and 179. 
 The fatty acid trihydroxy octadecenoic acid (329 m/z) was observed at 24.43 min in all 
extracts, with product ions m/z 116.92, 171, 211and 258 (fig. 39 d). 
 Other minor peaks included the compounds trifolirhizin (491 m/z) and eucommiol (187 
m/z). 
 
   Fig. 38 LC-MS chromatogram of A.membranaceus (methanol extract) in negative mode scan for 29 min. 
 
 
 
Fig. 39 Structures of some of the main compounds identified from crude herbal extracts of A.membranaceus: 
(A) Calycosin; (B) Formononetin; (C) Example of a dihexose sugar structure; (D) Trihydroxy octadecenoic 
acid; (E) Trifolirhizin. 
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Table [13]   Compounds detected in O.basilicum, I.helenium, W.somnifera and A.membranaceus extracts in negative 
scan mode in LC-MS/ PDA. 
 
SL 
NO. 
RT 
(MIN) 
M-H [M-H] – MS/MSC TENTATIVE ID
#
 COMPOUND NATURE 
ObA1  
1 21.65 359.0736 C18H15O8 
161, 133, 135, 179, 
197 
Rosmarinic acid Phenolic acid 
2 1.75 149.0076 C4H5O6 113, 130.997, 141 Tartaric acid Organic acid 
3 3.86 191.0175 C6H7O7 111, 129, 173 Isocitric acid Citric acid 
4 24.36 327.2150 C18H15O6 
116.9, 205, 215, 277, 
311 
Salvigenin (5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavones 
5 10.59 311.0392 C13H11O9 135, 149, 179, 311 
Caftaric acid  
(Caffeoyl-tartaric acid) 
Non-flavanoid phenolic 
8 16.22 225.1110 C12H17O4 
112, 135, 161, 195, 
203, 216 
12-hydroxyjasmonic acid Carboxylic acid  
6 18.23 473.0708  C22H17O12 
135, 149, 179, 293, 
311 
Chicoric acid  
(dicaffeoyl-tartaric acid) 
Hydroxycinnamic acid 
7 23.38 717.1448 C36H29O16  243, 343, 519 Unknown  – 
ObM2 
1 21.61 359.0761 C18H15O8 
161, 133, 135, 179, 
197 
Rosmarinic acid Phenolic acid 
2 1.79 341.1076 C12H21O11 89, 173 Dihexose Sugar 
3 24.36 327.2150 C18H15O6 
116.9, 205, 215, 277, 
311 
Salvigenin  
(5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavones 
4 18.09 609.1499 C27H29O16 
151, 255, 271, 300, 
301 
Rutin 
(Quercetin-hexoside-
rhamnoside) 
Flavonoid 
5 14.45 387.1648 C21H23O7 59, 119, 207, 300 Medioresinol Furanoid lignin 
6 18.74 463.0882 C21H19O12 89, 151, 255, 271, 300 
Isoquercetin (Quercetin-
hexoside) 
Flavonoid 
7 23.38 717.1450 C36H29O16 243, 343, 519 Unknown  – 
8 20.99 137.1212 C9H13O 93, 121 trans-Ocimene oxide Monoterpenes 
ObE3 
1 21.6 359.0758 C18H15O8 
161, 133, 135, 179, 
197 
Rosmarinic acid Phenolic acid 
2 9.35 153.4201 C10H17O 79, 93, 121, 136 
Linalool  
(2,6-Dimethyl-2,7-octadien-6-
ol; allo-Ocimenol) 
Terpene alcohol  
3 24.36 327.2150 C18H15O6 
116.9, 205, 215, 277, 
311 
Salvigenin  
(5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavone 
4 14.76 431.1907 C21H19O10 
153, 205, 269, 354, 
385 
Apigenin-7-O-glucoside Flavonoid glycoside 
5 13.82 179.0330 C9H7O4 135 Caffeic acid Hydroxycinnamic acid 
6 24.43 329.2310 C18H33O5 171, 211 Trihydroxy octadecenoic acid  Fatty acid 
7 21.15 187.0958 C9H15O4 125, 141, 169 Eucommiol Cyclopentene dimethanol 
8 16.19 225.1113 C12H17O4 
112, 135, 161, 195, 
203, 216 
12-hydroxyjasmonic acid Carboxylic acid  
9 18.71 463.0874 C21H19O12 89, 151, 255, 271, 300 
Isoquercetin  
(Quercetin-hexoside) 
Flavonoid 
 IhA1 
1 1.79 341.1082 C12H21O11 89, 179, 267 Dihexose Sugar 
2 1.71 317.0541 C18H23O5 80, 96, 164, 225 
10-isobutyryloxy-8,9-
epoxythymol isobutyrate 
Isobutyrate 
3 3.88 191.0173 C6H7O7 111, 129, 173 Isocitric acid Citric acid 
4 26.30 555.2842 C27H37O10 
112.98, 180.97, 248, 
316, 384.9 
(E)-Fukugetin Flavonoid 
5 1.33 173.1028 C9H17O3 131 Unknown  – 
6 10.50 353.0718 C16H17O9 179, 191 
Chlorogenic Acid  
(3-Caffeoylquinic acid) 
Polyphenols/flavonoids 
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7 13.12 353.0862 C16H17O9 173, 179, 191 
Cryptochlorogenic Acid  
(4-Caffeoylquinic acid) 
Polyphenols/flavonoids 
8 12.72 353.0858 C16H17O9 191 5-Caffeoylquinic acid Polyphenols/flavonoids 
9 5.90 827.2750 C41H47O18 89, 179, 341, 503, 665 Unknown  – 
10 19.59 457.2078 C30H40O4 112, 191, 209, 371 Epigallocatechin gallate Polyphenols/flavonoids 
11 24.53 233.1176 C14H17O3, C10H17O6 116, 161, 213 Unknown – 
12 24.87 247.1327 C15H19O3  115.92, 197, 221, 233 5alpha-Epoxyalantolactone Lactone  
IhM2 
1 24.77 293.1378 C17H25O4 87, 116, 231 
Tanacetol A 
(2-Acetoxy-11-hydroxy-
1(10),4(15)-germacradien-5-
one) 
Germacrane 
sesquiterpenoids 
2 24.44 329.2317 C18H33O5 116, 171, 239 Trihydroxy octadecenoic acid  Fatty acid 
3 22.95 239.1279 C13H19O4 161, 177 Unknown  – 
4 19.56 457.2078 C22H17O11 112, 191, 209, 371 Epigallocatechin Gallate Polyphenols/flavonoids 
5 24.22 693.4105 C45H57O6 114, 201, 346 Unknown  – 
6 26.30 265.1459 C15H22O4 112, 180 Macrophyllilactone B Lactone 
7 21.09 187.0958 C9H15O4 113, 123, 143, 170 Unknown  – 
8 12.71 191.0552 C7H11O6 85, 135, 161, 179 Chlorogenic acid derivative Polyphenols 
 IhE3 
1 24.77 293.1382 C17H25O4 87, 116, 231 
Tanacetol A  
(2-Acetoxy-11-hydroxy-
1(10),4(15)-germacradien-5-
one) 
Germacrane 
sesquiterpenoids 
2 26.30 265.1458 C15H22O4 112.98, 183, 248.95 Macrophyllilactone B Lactone 
3 22.95 239.1271 C13H19O4 97, 161, 177 Unknown  – 
4 24.45 329.2312 C18H33O5 59, 116, 171, 187, 239 Trihydroxy octadecenoic acid  Fatty acid 
5 21.11 187.0959 C9H15O4 113, 123, 143, 170 Unknown  – 
6 19.57 457.2078  C22H17O11 112, 191, 209, 371 Epigallocatechin Gallate Polyphenols/flavonoids 
7 21.43 225.1149 C11H13O5 125, 163, 169 
Trimethoxybenzoic acid 
methyl ester 
Acid ester 
8 12.71 191.0535 C7H11O6 85, 135, 161, 179 Chlorogenic acid derivative Polyphenols 
IhEtA4 
1 24.77 293.1382 C17H25O4 87,116, 231 
Tanacetol A  
(2-Acetoxy-11-hydroxy-
1(10),4(15)-germacradien-5-
one) 
Germacrane 
sesquiterpenoids 
2 26.30 265.1459 C15H22O4 112.98, 183, 248.95 Macrophyllilactone B Lactone 
3 22.96 239.1271 C13H19O4 97,161, 177 Unknown  – 
4 24.43 329.2318 C18H33O5 59, 116,171,187, 239 Trihydroxy octadecenoic acid  Fatty acid 
5 21.13 187.0959 C9H15O4 113, 123, 143, 170 Unknown  – 
6 19.58 457.2078  C22H17O11 112, 191, 209, 371 Epigallocatechin Gallate Polyphenols/flavonoids 
7 21.45 225.1149 C11H13O5 125,163,169 
Trimethoxy benzoic acid 
methyl ester 
Acid ester 
8 20.06 239.1273 C13H19O4 125,161,177,193 Unknown  – 
 WsM2 
1 24.36 811.4113 C51H89O7 179, 329, 503, 765 Unknown  – 
2 24.12 827.4061 C41H63O17, C48H59O12 
179, 312, 503, 653, 
781 
Unknown  – 
3 24.57 327.2144 C18H15O6 
116.9, 205, 215, 277, 
311 
Salvigenin  
(5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavone 
4 1.81 341.1064 C12H21O11 89, 179, 267 Dihexose Sugar 
5 21.68 
1093.566
5 
C56H81O25 341, 763, 932 Pentagycoside complex
?
 Glycoside 
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6 2.11 133.0129 C8H7NO 43, 71, 93 
Isopelletierine  
(1-Pyridin-2-ylpropan-2-one) 
Alkaloid 
7 13.09 472.0012 C28H39O6 186, 308, 350 
Withaferin A, dihydro-  
(2,3-Dihydrowithaferin-A) 
Steroidal Lactone 
WsEtA4 
1 24.28 533.2756 C29H41O9 89, 179, 327 Withaperuvin I Withanolide 
2 24.36 811.4103 C51H89O7 179, 329, 503, 765 Unknown  – 
3 24.43 329.2314 C18H33O5 116.92, 171 Trihydroxy octadecenoic acid  Fatty acid 
4 23.19 567.2249 C34H50NO6 96, 179, 341, 503 
Withaferin derivative 
(Withaferin deriv GG-AM-4) 
Steroidal Lactone 
5 21.12 187.0954 C9H15O4 125, 141, 169 Eucommiol Cyclopentene dimethanol 
 AmM2 
1 1.79 341.1072 C12H21O11 89, 101, 119, 161, 179 Dihexose Sugar 
2 24.43 329.2312 C18H33O5 116.92, 171, 211, 258 Trihydroxy octadecenoic acid  Fatty acid 
3 24.23 283.0591 C16H11O5 
136, 196, 211, 240, 
269 
Calycosin  
(7,3'-dihydroxy-4'- 
methoxyisoflavone) 
Isoflavone 
4 24.57 267.0653 C16H11O4 115,117,196, 207, 236 
Formononetin  
(7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
5 23.23 567.2245 C28H39O10S 96,179, 341, 503 Unknown  – 
6 18.03 491.1185 C22H22O10 233, 255, 268 
Trifolirhizin 
( (-)-Maackiain-3-Oglucoside) 
Flavonoid 
7 6.52 383.1220 C14H23O12 156, 323 Unknown  – 
8 21.16 187.0963 C9H15O4 125, 141, 169 Eucommiol Cyclopentene dimethanol 
AmE3 
1 24.22 283.0591 C16H11O5 
136, 196, 211, 240, 
269 
Calycosin  
(7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
2 24.57 267.0653 C16H11O4 
115, 117, 196, 207, 
236 
Formononetin  
(7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
3 1.80 341.1072 C12H21O11 89, 101, 119, 161, 179 Dihexose Sugar 
4 24.43 329.2322 C18H33O5 116.92, 171, 211, 258 Trihydroxy octadecenoic acid  Fatty acid 
5 18.02 491.1198 C22H22O10 233, 255, 268 
Trifolirhizin 
( (-)-Maackiain-3-Oglucoside) 
Flavonoid 
6 23.01 475.1220 C23H23O11 267, 343 Unknown  – 
7 21.12 187.0936 C9H15O4 125, 141, 169 Eucommiol Cyclopentene dimethanol 
AmEtA4 
1 24.22 283.0591 C16H11O5 
136, 196, 211, 240, 
269 
Calycosin  
(7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
2 24.57 267.0367 C16H11O4 
115, 117, 196, 207, 
236 
Formononetin  
(7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
3 24.43 329.2317 C18H33O5 116.92, 171, 211, 258 Trihydroxy octadecenoic acid  Fatty acid 
4 24.83 311.2206 C18H31O4 117, 183, 223 Unknown  – 
5 24.89 913.4787 C46H73O18 311, 402, 708 Unknown  – 
#
REFERENCES – Stander et al., 2017; Said et al., 2017; Chen et al., 2017; Chang et al., 2016; Chen et al., 2016; Zhang et al., 2016; Liu et al., 2016; 
Simirgiotis et al., 2015; Du et al., 2014; Kuo et al., 2014; Zhang et al., 2013; Mena et al., 2012; Wang et al., 2012; Čejchanová, 2011; Hossain et al., 
2010. 
https://www.ncbi.nlm.nih.gov/pccompound; https://massbank.eu/MassBank/; https://metlin.scripps.edu/; https://webbook.nist.gov/chemistry/mw-ser/ 
 
For the positive mode extract scans, the following observations were noted (details summarized 
in table 14): 
1. Ocimum basilicum (aqueous, methanol and ethanol) extracts (fig. 40 shows the 
chromatogram of the ethanol extract):  
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 The most prominent peak in the methanol and ethanolic extracts of O.basilicum was 
salvigenin (5-Hydroxy-6,7,4'-trimethoxyflavone) with a retention time of 7.32 min at 
m/z 329 at a PDA detection wavelength 230 nm. 
 Pyridine carboxylic acid esters (fig. 41 b) were identified in all extracts at m/z 398 and 
product ions at m/z 149, 240 and 266. 
 Other compounds include the flavone eupatorin (3',5-dihydroxy-4',6,7-
trimethoxyflavone, 345 m/z) (fig. 41 a) and the aromatic lactone furan-2(3H)-one 
complex (311 m/z) at retention times 6.42 and 6.91 min, respectively. 
 
   Fig. 40 LC-MS chromatogram of O.basilicum (ethanol extract) in positive mode scan for 15 min. 
 
Fig. 41 Structures of some of the main compounds identified from crude herbal extracts of O.basilicum 
(positive mode): (A) Eupatorin; (B) Pyridine carboxylic acid ester. 
 
2. Inula helenium (aqueous, methanol, ethanol and ethyl acetate) extracts:  
 The most prominent peak observed in all the organic solvent extracts of I.helenium was 
the known sesquiterpene lactone helenin (isoalantolactone) with a retention time of 8.33 
min at m/z 465 at a PDA detection wavelength 230 nm (fig. 42 a). The product ions 
were noted at m/z 105, 151, 187, 215 and 233. 
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 Other compounds included pyridine carboxylic acid ester at m/z 398 and apigenin at m/z 
271. 
 Major peaks in the methanolic extract detected at 4.78 and 4.9 min (m/z 348 and 304), 
and the ethyl acetate extract at 6.12 and 8.21 min (m/z 271 and 465) could not be 
identified. 
 
Fig. 42 Structures of some of the main compounds identified from crude herbal extracts of I.helenium (positive 
mode): (A) Helenin (isoalantolactone); (B) Apigenin. 
 
3. Withania somnifera (methanol and ethyl acetate) extracts:  
 The major withanolides were observed in all extracts of W.somnifera in the positive 
mode scan. Withanolide A and withanolide B (fig. 43 a, b) were identified with 
retention times 5.54 and 7.53 min at m/z 471 and 455 respectively, at a PDA detection 
wavelength 230 nm. The product ions were noted as m/z 125, 246, 276, 299 and m/z 
401, 419, 437 respectively. 
 Withaferin A was identified at retention time 5.92 min and m/z 471 (fig. 43 c) and 
product ions at m/z 263, 265, 283, 353, 417 and 435. 
 Other known compounds observed were vicosalactone B (489 m/z), withanamide D/E 
(783 m/z) and withasomidienone (439 m/z). 
 
Fig. 43 Structures of some of the main compounds identified from crude herbal extracts of W.somnifera 
(positive mode): (A) Withanolide A; (B) Withanolide B; (C) Withaferin A. 
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4. Astragalus membranaceus (methanol, ethanol and ethyl acetate) extracts:  
 The major known compounds within A.membranaceus were observed in the positive 
mode scan. Astragaloside IV and astragaloside I (fig. 44 a, b) were identified with 
retention times 5.61 and 6.87 min at m/z 785 and 869 respectively, at a PDA detection 
wavelength 230 nm. The product ions were noted as m/z 269, 437, 587 and m/z 143, 
297, 437, 455, 653, 671, respectively. 
 Other major compounds observed included formononetin (269 m/z), calycosin (285 
m/z), acetylastragaloside I (911 m/z), astragaloside II (827 m/z) and ononin (431 m/z) at 
230nm. 
 The benzopyran derivative 3',4',7-trimethoxyflavan and the carboxylic acid 4,10-
dihydroxy-3,9-dimethoxypterocarpan, was observed in the ethyl acetate extract at 
retention times 9.35 min and 7.03 min respectively. 
 
 
Fig. 44 Structures of some of the main compounds identified from crude herbal extracts of A.membranaceus 
(positive mode): (A) Astragaloside IV; (B) Astragaloside I. 
 
Table [14]   Secondary metabolites/compounds detected in O.basilicum, I.helenium, W.somnifera and 
A.membranaceus extracts in positive scan mode in LC-MS/ PDA. 
SL 
NO. 
RT 
(MIN) 
M+H [M+H]+ MS/MSC TENTATIVE ID
#
 TYPE OF COMPOUND  
ObA1 
1 10.63 398.2331 C24H32NO4 149, 240, 266 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
2 7.74 304.3008 C21H38N 91, 212 Pyridine/ Amine complex Secondary Metabolites 
3 12.28 411.2662 C30H35O 175, 283, 355 Unknown  – 
4 6.91 311.2210 C18H31O4 96, 149, 219, 275 Furan-2(3H)-one complex Aromatic lactone 
5 9.06 399.2498 C25H35O4, C18H39O9 221, 324 Unknown  – 
ObM2 
1 7.32 329.1014 C18H17O6 133, 268 
Salvigenin (5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavones 
2 10.63 398.2324 C24H32NO4 149, 240, 266 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
3 7.74 304.2997 C21H38N 91, 212 Pyridine/ Amine complex Secondary Metabolites 
4 6.42 345.0979 C18H17O7 182, 240, 312, 315 
Eupatorin (3',5-Dihydroxy-
4',6,7-trimethoxyflavone) 
Flavones 
ObE3 
1 7.32 329.1023 C18H17O6 133, 268 
Salvigenin (5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavones 
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2 6.42 345.0959 C18H17O7 182, 240, 312, 315 
Eupatorin (3',5-Dihydroxy-
4',6,7-trimethoxyflavone) 
Flavones 
3 7.16 445.2117 C21H33O10, C32H29O2 
105, 194 224, 385, 
407 
Unknown  – 
4 10.63 398.2336 C24H32NO4 149, 240, 266 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
 IhA1 
1 10.62 398.3220 C24H32NO4 149, 240, 266 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
2 12.28 411.2646 C30H35O, C19H39O9 175, 231, 283, 355 Unknown  – 
IhM2 
1 4.78 348.2174 C20H28O5 128, 302, 304 Unknown  – 
2 4.90 304.2271 C18H13N3O2 84, 128 Unknown  – 
3 8.34 465.3008 C30H41O4 105, 233, 383 Helenin : Isoalantolactone Sesquiterpene lactones 
IhE3 
1 8.33 465.3002 C30H41O4 
105, 151, 187, 215, 
233 
Helenin : Isoalantolactone Sesquiterpene lactones 
2 6.12 271.1299 C15H11O5 
105, 121, 131, 182, 
231, 240 
Apigenin Flavone 
3 8.20 465.2986 C30H41O4 314, 443 Unknown  – 
4 10.62 398.2334 C24H32NO4 149, 240, 266 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
 IhEtA4 
1 8.34 465.3006 C30H41O4 
105, 151, 187, 215, 
233 
Helenin : Isoalantolactone Sesquiterpene lactones 
2 6.12 271.1334 C17H19O3 185, 231 Unknown  – 
3 8.21 465.2995 C30H41O4 314, 443 Unknown  – 
4 9.36 301.1416 C18H21O4, C11H25O9 149, 231 Unknown  – 
 WsM2 
1 5.54 471.2741 C28H39O6 125, 246, 276, 299 Withanolide A Secondary metabolite 
2 5.92 471.2727 C28H39O6 
263, 265, 283, 353, 
417, 435 
Withaferin A Steroidal Lactone 
3 5.69 503.3006 C29H43O7 331, 407, 425, 443 2,25-Diepoxywithaferin A Steroidal Lactone 
4 7.54 455.2797 C28H39O5 401, 419, 437 Withanolide B Secondary metabolite 
5 4.71 489.2848 C28H41O7 281, 299, 317 Vicosalactone B Lactone 
6 4.38 783.4157 C40H67N2O13 441, 459, 621 Withanamide D/E Secondary metabolite 
7 3.79 754.3456  C38H62N2O13 574, 593, 630, 736 Withanamide B/C isomer Secondary metabolite 
WsEtA4 
1 5.54 471.2744 C28H39O6 125, 246, 276, 299 Withanolide A Secondary metabolite 
2 5.92 471.2742 C28H39O6 
263, 265, 283, 353, 
417, 435 
Withaferin A Steroidal Lactone 
3 7.53 455.2791 C28H39O5 401, 419, 437 Withanolide B Secondary metabolite 
4 5.70 503.3001 C29H43O7 331, 407, 425, 443 2,25-Diepoxywithaferin A Steroidal Lactone 
5 4.71 489.285 C28H41O7 317, 459 Vicosalactone B Lactone 
6 7.22 439.2825 C28H39O4 187, 367, 383, 427 Withasomidienone Secondary metabolite 
 AmM2 
1 5.61 785.4658 C41H68O14 269, 437, 587 Astragaloside IV Triterpene glycoside 
2 5.65 269.0811 C16H13O4 71, 190, 197, 253 
Formononetin (7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
3 4.44 285.0765 C16H13O5 137, 241, 270 
Calycosin (7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
4 10.63 398.2325 C24H32NO4 149, 240, 266, 296 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
5 3.05 447.1285 C22H23O10 285, 365, 429 
Calycosin 7-O-beta-D-
glucoside 
Isoflavone glucoside 
6 6.87 869.9849 C45H73O16 
143, 297, 437, 455, 
653, 671 
Astragaloside I Triterpene glycoside 
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7 3.91 489.1394 C24H25O11, C17H29O16 149, 270, 285 Unknown  – 
8 4.09 431.1328 C22H23O9 268.2 Ononin Isoflavone glycoside 
AmE3 
1 5.65 269.0803 C16H13O4 71, 190, 197, 253 
Formononetin (7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
2 5.60 785.4661 C41H68O14 269, 437, 587 Astragaloside IV Triterpene glycoside 
3 4.43 285.0757 C16H13O5 137, 241, 270 
Calycosin (7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
4 6.88 869.9915 C45H73O16 
143, 297, 437, 455, 
653, 671 
Astragaloside I Triterpene glycoside 
5 9.34 301.1404 C18H21O4, C11H25O9 121, 149, 150 Unknown  – 
6 8.17 911.4993 C47H75O17 437, 695, 753 Acetylastragaloside I Triterpene glycoside 
7 10.62 398.2334 C24H32NO4 149, 240, 266, 296 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
8 6.04 827.9796 C43H71O15 629, 707 809 Astragaloside II Triterpene glycoside 
9 3.91 489.1394 C24H25O11, C17H29O16 149, 270, 285 Unknown  – 
10 4.09 431.1331 C22H23O9 268.2 Ononin Isoflavone glycoside 
AmEtA4 
1 5.65 269.0810 C16H13O4 71, 190, 197, 253 
Formononetin (7-Hydroxy-4'-
methoxyisoflavone) 
Isoflavone 
2 4.43 285.0764 C16H13O5 137, 241, 270 
Calycosin (7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
3 6.68 869.9904 C45H73O16 
143, 297, 437, 455, 
653, 671 
Astragaloside I Triterpene glycoside 
4 9.35 301.1416 C17H17O5 121, 149, 150 
9,10-Dimethoxy-6a,11a-
dihydro-6H-[1]benzofuro[3,2-
c]chromen-3-ol 
Benzopyran derivative 
5 10.62 398.2323 C24H32NO4 149, 240, 266, 296 
2,6-Pyridinedicarboxylic acid, 
nonyl phenethyl ester 
Carboxylic acid 
6 7.03 316.9838 C17H17O6 149, 280, 298 
4,10-Dihydroxy-3,9-
dimethoxypterocarpan 
Flavonoid 
7 3.91 489.1419 C24H25O11, C17H29O16 149, 270, 285 Unknown  – 
8 4.09 431.1339 C22H23O9 268.2 Ononin Isoflavone glycoside 
#
REFERENCES – Liu et al., 2018; Chang et al., 2016; Liu et al., 2016; Du et al., 2014; Wang et al., 2012; Bolleddula et al., 2012; Čejchanová, 2011; 
Hossain et al., 2010; Ye et al., 2005. 
https://www.ncbi.nlm.nih.gov/pccompound; https://massbank.eu/MassBank/; https://metlin.scripps.edu/; https://webbook.nist.gov/chemistry/mw-ser/ 
 
The major identified compounds for the twelve active extracts showing inhibition, were 
quantified (in mg/L equivalent units of gallic acid/ quercetin) relative to the linear calibration 
curve of the reference standards - gallic acid for all the acid compounds and quercetin for the 
non-acid compounds (table 15). 
 
Table [15]   Relative quantification of the identified phytocompounds detected in O.basilicum, I.helenium, 
W.somnifera and A.membranaceus extracts in positive scan mode in LC-MS/ PDA. 
 
# SLNO COMPOUND NAME SAMPLE NAME AREA RT(MIN) 
CONC. UNITS
 *
  
(MG/L EQUIVALENTS OF 
GALLIC ACID/ QUERCETIN) 
Compound 1 Rosmarinic acid                                                                                                                                                                          ** 
1  ObA1 1699.1760 21.61 2298.037 
2  ObM2 1423.3300 21.61 1923.756 
3  ObE3 585.0240 21.61 786.304 
Compound 2  Tartaric acid 
1  ObA1 593.9001 1.76 798.347 
2  ObM2 33.9320 1.76 38.556 
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3  ObE3 45.3010 1.76 53.982 
Compound 3   Isocitric acid 
1  ObA1 742.4790 3.88 999.946 
2  IhA1 742.2550 3.88 999.642 
3  WsM2 34.6080 3.89 39.474 
4  AmM2 94.1240 3.88 120.228 
Compound 4   Caftaric acid 
1  ObA1 407.1970 10.60 545.019 
Compound 5  Chicoric acid 
1  ObA1 371.2370 18.23 496.228 
2  ObM2 22.3180 18.26 22.798 
Compound 6 Salvigenin (5-Hydroxy-6,7,4'-trimethoxyflavone)                                                                                                                 *** 
1  ObA1 430.9610 24.36 73.634 
2  ObM2 213.4770 24.36 24.150 
3  ObE3 670.6350 24.36 128.167 
4  IhM2 90.6170 24.37 0.020 
5  IhE3 85.7520 24.36 0.015 
6  IhEtA4 103.6490 24.36 0.035 
7  AmM2 169.7220 24.36 14.194 
8  AmE3 225.7240 24.36 26.936 
9  AmEtA4 266.1060 24.36 36.124 
Compound 7   Rutin (Quercetin-Hexoside-rhamnoside) 
1  ObA1 80.0950 18.07 0.010 
2  ObM2 144.1280 18.09 8.371 
3  ObE3 146.4550 18.07 8.900 
Compound 8 Isoquercetin (Quercetin-Hexoside) 
1  ObM2 108.5580 18.73 0.277 
2  ObE3 156.3420 18.72 11.150 
Compound 9   Linalool (2,6-Dimethyl-2,7-octadien-6-ol) 
1  ObE3 133.6801 9.35 5.993 
Compound 10 12-hydroxyjasmonic acid 
1  ObA1 262.7230 16.21 348.991 
2  ObE3 255.5850 16.19 339.305 
Compound 11   Caffeic acid 
1  ObM2 29.9890 13.83 33.206 
2  ObE3 433.6770 13.80 580.949 
3  IhM2 69.7520 13.79 87.159 
4  IhE3 29.0440 13.78 31.924 
5  IhEtA4 47.1690 13.78 56.517 
Compound 12 5-Caffeoylquinic acid 
1  IhA1 249.3501 12.72 330.846 
2  IhM2 138.6160 12.70 180.596 
3  IhE3 148.7140 12.69 194.298 
4  IhEtA4 61.1370 12.69 75.469 
5  WsM2 30.0660 12.73 33.311 
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Compound 13   3-Caffeoylquinic acid 
1  IhA1 27.0460 10.50 29.213 
2  IhM2 5.6830 10.47 0.227 
Compound 14  4-Caffeoylquinic acid 
1  IhA1 43.5890 13.12 51.659 
Compound 15  (E)-Fukugetin 
1  ObE3 45.8240 26.32 0.005 
2  IhA1 80.2310 26.31 0.010 
3  IhM2 41.0590 26.32 0.005 
Compound 16 Medioresinol 
1  ObM2 114.7220 14.45 6.020 
2  ObE3 69.9301 14.44 0.005 
Compound 17 Apigenin-7-O-glucoside 
1  ObM2 75.4170 14.77 0.010 
2  ObE3 404.7730 14.75 67.675 
3  WsM2 54.0010 14.77 0.005 
4  WsEtA4 43.6480 14.75 0.004 
Compound 18 Epigallocatechin Gallate 
1  IhA1 124.1370 19.58 3.822 
2  IhM2 862.2060 19.56 171.755 
3  IhE3 282.0750 19.56 39.758 
4  IhEtA4 203.1610 19.58 21.802 
Compound 19   Chlorogenic acid derivative(quinic acid isomer) 
1  IhA1 258.4760 12.72 343.228 
2  IhM2 151.3150 12.71 197.827 
3  IhE3 158.6690 12.7 207.805 
4  IhEtA4 71.3690 12.7 89.353 
Compound 20 5alpha-Epoxyalantolactone 
1  IhA1 38.9350 24.87 0.003 
2  IhE3 36.9050 24.86 0.003 
Compound 21 Tanacetol A (2-Acetoxy-11-hydroxy-1(10),4(15)-germacradien-5-one) 
1  IhA1 261.0970 24.79 34.985 
2  IhM2 1732.9920 24.77 369.886 
3  IhE3 1067.0550 24.77 218.365 
4  IhEtA4 958.1890 24.77 193.594 
Compound 22 Macrophyllilactone B 
1  IhM2 850.4980 26.27 169.091 
2  IhE3 1328.5220 26.27 277.856 
3  IhEtA4 1476.2560 26.28 311.470 
Compound 23 Trihydroxy octadecenoic acid 
1  ObA1 127.4110 24.44 165.393 
2  ObM2 100.3910 24.44 128.731 
3  ObE3 396.4770 24.44 530.474 
4  IhA1 121.5620 24.44 157.457 
5  IhM2 776.1910 24.44 1045.688 
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6  IhE3 357.1530 24.44 477.118 
7  IhEtA4 369.2920 24.44 493.588 
8  WsM2 737.4840 24.44 993.168 
9  WsEtA4 887.2440 24.44 1196.370 
10  AmM2 565.2730 24.44 759.505 
11  AmE3 929.1930 24.44 1253.288 
12  AmEtA4 857.0140 24.43 1155.352 
Compound 24 Isopelletierine (1-Pyridin-2-ylpropan-2-one) 
1  IhA1 344.2740 2.14 53.910 
2  WsM2 936.7730 2.14 188.721 
3  AmM2 187.9380 2.16 18.339 
4  AmE3 55.1380 2.15 0.005 
Compound 25 2,3-Dihydrowithaferin-A 
1  WsM2 172.1430 13.09 14.745 
Compound 26 Withaperuvin I 
1  WsM2 719.6570 24.29 139.321 
2  WsEtA4 1141.7950 24.29 235.370 
Compound 27 Calycosin (7,3'-dihydroxy-4'-methoxyisoflavone) 
1 
-
 ve
 scan mode 
AmM2 474.4250 24.22 83.523 
2 AmE3 1356.2370 24.22 284.162 
3 AmEtA4 1106.9550 24.22 227.443 
1 
+
ve
 scan mode 
AmM2 450.4570 4.44 230.881 
2 AmE3 1335.9570 4.44 684.621 
3 AmEtA4 969.9740 4.44 497.087 
Compound 28   Formononetin (7-Hydroxy-4'-methoxyisoflavone) 
1 
-
 ve
 scan mode 
AmM2 358.6960 24.57 57.191 
2 AmE3 962.8320 24.57 194.651 
3 AmEtA4 889.0850 24.57 177.871 
4 
+
ve
 scan mode 
AmM2 429.2270 5.65 220.003 
5 AmE3 1402.4480 5.65 718.691 
6 AmEtA4 1218.4690 5.65 624.419 
Compound 29   Eucommiol 
1  ObA1 138.4490 21.16 7.078 
2  ObE3 354.5340 21.15 56.244 
3  IhM2 402.1650 21.12 67.082 
4  IhE3 299.7260 21.12 43.774 
5  IhEtA4 399.0440 21.13 66.372 
6  WsM2 210.6120 21.14 23.498 
7  WsEtA4 321.8020 21.12 48.797 
8  AmM2 98.4510 21.15 0.019 
9  AmE3 140.9520 21.12 7.648 
Compound 30   Dihexose 
1  ObM2 279.5990 1.8 39.194 
2  IhA1 695.6030 1.8 133.848 
3  IhM2 164.2950 1.79 12.959 
4  IhE3 110.4890 1.79 0.717 
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5  WsM2 1317.3660 1.81 275.318 
6  WsEtA4 209.1890 1.8 23.174 
7  AmM2 1659.8130 1.8 353.235 
8  AmE3 1459.8480 1.81 307.737 
9  AmEtA4 211.0201 1.79 23.590 
Compound 31   Withaferin deriv GG-AM-4 
1  WsM2 11.2940 23.07 < 0.001 
Compound 32 Eupatorin (3',5-Dihydroxy-4',6,7-trimethoxyflavone) 
1  ObA1 44.5180 6.42 22.874 
2  ObM2 217.4830 6.42 111.503 
3  ObE3 1305.0280 6.42 668.772 
Compound 33  Salvigenin (5-Hydroxy-6,7,4'-trimethoxyflavone) 
1  ObA1 75.5380 7.33 38.769 
2  ObM2 655.0720 7.32 335.728 
3  ObE3 3619.8580 7.32 1854.916 
Compound 34   Helenin : Isoalantolactone 
1  IhM2 2463.0110 8.34 1262.135 
2  IhE3 2223.4920 8.34 1139.403 
3  IhEtA4 2581.1450 8.34 1322.668 
Compound 35   Apigenin 
1  IhA1 60.5130 6.13 31.070 
2  IhM2 977.9820 6.13 501.190 
3  IhE3 886.9750 6.13 454.558 
4  IhEtA4 1041.6290 6.13 533.804  
Compound 36 Withanolide A 
1  WsM2 3435.2220 5.54 1760.306 
2  WsEtA4 3914.2630 5.54 2005.772 
Compound 37   Withaferin A 
1  WsM2 1453.5440 5.92 744.873 
2  WsEtA4 2181.1220 5.92 1117.692 
Compound 38 2,25-Diepoxywithaferin A 
1  WsM2 1285.5780 5.7 658.806 
2  WsEtA4 1439.2740 5.7 737.561 
Compound 39   Withanolide B 
1  WsM2 1249.7840 7.53 640.465 
  WsEtA4 1790.1690 7.53 917.364 
Compound 40 Vicosalactone B 
1  WsM2 846.4430 4.71 433.788 
2  WsEtA4 1197.2560 4.7 613.549 
Compound 41 Withanamide D/E 
1  WsM2 680.3950 4.38 348.704 
2  WsEtA4 307.8630 4.38 157.814 
Compound 42 Withasomidienone 
1  WsM2 60.0101 7.22 30.812 
2  WsEtA4 137.7530 7.22 70.648 
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Compound 43   Astragaloside IV 
1  AmM2 15.7301 5.60 8.122 
2  AmE3 49.5440 5.60 25.449 
3  AmEtA4 17.7540 5.60 9.159 
Compound 44 Astragaloside I 
1  AmM2 194.4810 6.88 99.716 
2  AmE3 923.8080 6.88 473.431 
3  AmEtA4 718.0280 6.88 367.987 
Compound 45 Ononin 
1  AmM2 138.3420 4.09 70.950 
2  AmE3 292.6760 4.09 150.032 
3  AmEtA4 142.2420 4.09 72.948 
Compound 46 Astragaloside II 
1  AmM2 77.5830 6.05 39.816 
2  AmE3 391.8720 6.05 200.861 
3  AmEtA4 240.5150 6.05 123.305 
*
 The relatively quantified concentrations are reasonable approximations of the relative amounts of the identified compounds present in each extract 
(Bhandari and Rajbhandari, 2015; Punyasiri et al., 2015), ** All the acid compounds are relatively quantified equivalent to the linear curve of gallic 
acid, *** All the non- acid compounds are relatively quantified equivalent to the linear curve of quercetin. 
 
As per the data in table 15, the concentration of salvigenin was found to be highest in ObE3 
(1854.916 mg/L), along with the fatty acid trihydroxy octadecenoic acid (530.474 mg/L), 
eupatorin (668.772 mg/L) and caffeic acid (580.949 mg/L). Rosmarinic acid was predominant 
in ObA1 (2298.037 mg/L), along with tartaric acid (798.347 mg/L), isocitric (999.946 mg/L), 
caftaric (545.019 mg/L) and chicoric acids (496.228 mg/L). 
 
Caffeoylquinic acid derivatives were most prominently present in IhA1 (330.846 mg/L). 
Epigallocatechin gallate was mostly present in IhM2 along with tanacetol A (369.886 mg/L). 
Macrophyllilactone B and helenin (isoalantolactone) was mostly present in IhEtA4 extract 
(311.470 mg/L and 1322.668 mg/L respectively). 
 
High concentration of trihydroxy octadecenoic acid was noted in WsEtA4 (1196.370 mg/L), 
along with withaperuvin I (235.370 mg/L), withanolide A (2005.772 mg/L), withaferin A 
(1117.692 mg/L), diepoxywithaferin A (737.561 mg/L), withanolide B (917.364 mg/L) and 
vicosalactone B (613.549 mg/L). 
 
Amongst all extracts, dihexose sugar and trihydroxy octadecenoic acid was most present in 
Astragalus extracts. Calycosin and formononetin was present most in AmE3 (684.621 mg/L and 
718.691 mg/L respectively). Highest concentrations of astragaloside I and II were noted in 
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AmE3 (473.431 mg/L and 200.861 mg/L respectively). Isocitric acid was only found in AmM2 
(120.228 mg/L). 
 
3.5  Induction assays 
3.5.1 Screening of herbal extracts – determination of CTC50 
In the MTT assays, all plant extracts were screened and tested for their in vitro cytotoxicity 
effect against HepG2 cells, by exposing the cells to different concentrations of each extract. 
Based on the assays the calculated CTC50 for all the extracts were in the range of 38-796 𝜇g/mL 
for a screening concentration range between 31.25 and 1000.00 𝜇g/mL, indicating stronger 
inhibition of HepG2 cell growth by various extracts at higher concentrations (Fig. 45, table 16). 
 
 
A      B 
 
C      D 
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E      F 
Fig. 45 Cytotoxicity % level graphs of all extracts on HepG2 cells A: W.somnifera B: G.glabra C: 
A.membranaceus D: I.helenium E: A.officinalis F: O.basilicum; the various test concentrations of each extract is 
plotted against the percentage of inhibition (dose-response) caused in the activity of the HepG2 cells. 
 
Table [16].Concentration of each extract that causes 50% cytotoxicity in HepG2 cells (CTC50). CTC50 calculated as 
the mean ± SD of cytotoxicity % values on HepG2 cells at concentration range 1000.00-31.25 µg/mL for each 
extract. 
Sample Name Concentration(µg/ml) Cytotoxicity (%) CTC50 (µg/ml)
 #
 
WsA1 
1000 
500 
250 
125 
62.5 
89.56±0.28 
75.36±0.54 
62.02±0.30 
52.06±0.47 
41.25±0.31 
113.18±1.97 
WsM2 
1000 
500 
250 
125 
62.5 
74.97±0.54 
72.14±0.56 
66.16±0.44 
48.46±0.25 
39.85±0.31 
67.13±0.83 
WsE3 
1000 
500 
250 
125 
62.5 
70.21±0.54 
67.01±0.56 
61.09±0.44 
41.72±1.56 
31.05±0.04 
72.13±1.93 
WsEtA4 
1000 
500 
250 
125 
62.5 
73.43±0.57 
61.92±0.54 
40.53±0.87 
25.77±0.54 
7.85±0.45 
90.07±2.03 
GgA1 
1000 
500 
250 
125 
62.5 
75.10±0.45 
71.30±0.22 
47.30±0.43 
16.60±1.09 
11.70±0.97 
278.1±4.15 
GgM2 
1000 
500 
250 
125 
62.5 
76.96±0.45 
75.45±0.66 
58.60±0.33 
11.66±0.65 
2.38±0.78 
227.09±0.87 
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GgE3 
1000 
500 
250 
125 
62.5 
75.16±0.22 
73.58±0.33 
62.42±1.51 
40.75±0.76 
31.53±1.42 
178.47±4.18 
GgEtA4 
1000 
500 
250 
125 
62.5 
73.43±0.57 
61.92±0.54 
40.53±0.87 
25.77±0.54 
7.85±0.45 
360.57±4.18 
AmA1 
1000 
500 
250 
125 
62.5 
77.80±0.34 
64.03±0.34 
45.04±0.26 
28.80±1.05 
6.60±0.98 
315.34±3.72 
AmM2 
1000 
500 
250 
125 
62.5 
61.30±0.19 
33.50±0.19 
27.40±0.11 
15.70±0.24 
11.40±0.57 
796.80±3.11 
AmE3 
1000 
500 
250 
125 
62.5 
60.30±1.34 
31.50±0.34 
25.40±2.26 
13.70±1.05 
10.40±0.71 
757.31±1.02 
AmEtA4 
1000 
500 
250 
125 
62.5 
61.45±0.49 
47.52±0.89 
29.31±3.11 
18.01±0.24 
12.01±0.17 
802.21±4.71 
IhA1 
1000 
500 
250 
125 
62.5 
70.91±0.38 
56.95±0.30 
38.33±0.23 
28.61±0.20 
19.75±2.75 
406.70±1.41 
IhM2 
1000 
500 
250 
125 
62.5 
31.25 
99.91±3.96 
86.05±0.56 
80.92±0.72 
70.15±0.33 
67.92±0.97 
44.61±0.31 
38.48±0.31 
IhE3 
1000 
500 
250 
125 
62.5 
31.25 
99.87±1.99 
89.46±0.41 
78.01±0.54 
64.07±0.41 
57.95±0.37 
40.83±0.30 
47.99±0.37 
IhEtA4 
1000 
500 
250 
125 
62.5 
31.25 
92.01±1.07 
85.46±1.41 
72.01±2.59 
60.07±0.41 
51.95±1.37 
33.83±0.09 
79.54±0.21 
AoA1 
1000 
500 
250 
125 
62.5 
63.05±0.55 
38.15±0.26 
27.94±0.60 
12.85±0.78 
4.70±0.81 
737.96±3.11 
 
  
Stellenbosch University                                                                           http://scholar.sun.ac.za 
 
 
100 
 
AoM2 
1000 
500 
250 
125 
62.5 
83.42±0.36 
79.92±0.36 
45.73±0.70 
28.86±0.65 
3.04±0.26 
281.22±4.77 
AoE3 
1000 
500 
250 
125 
62.5 
84.45±0.87 
81.24±0.46 
40.56±0.60 
30.12±0.86 
5.62±1.21 
307.99±3.41 
AoEtA4 
1000 
500 
250 
125 
62.5 
83.45±1.87 
82.24±1.46 
39.56±0.20 
25.01±0.86 
5.67±2.21 
311.71±1.21 
ObA1 
1000 
500 
250 
125 
62.5 
66.95±1.35 
61.34±1.73 
53.85±0.54 
42.98±0.94 
2.23±0.33 
205.73±1.26 
ObM2 
1000 
500 
250 
125 
62.5 
72.20±1.17 
58.80±0.78 
54.50±0.72 
37.90±0.52 
14.10±1.05 
216.30±3.35 
ObE3 
1000 
500 
250 
125 
62.5 
90.75±0.15 
89.13±0.67 
75.38±0.54 
65.08±0.33 
47.75±0.31 
70.58±0.83 
ObEtA4 
1000 
500 
250 
125 
62.5 
97.43±0.15 
61.92±1.67 
40.53±2.54 
25.77±0.33 
7.86±0.31 
320.18±2.13 
# Values are represented as mean ± SD (n = 3). 
 
As shown in table 16, IhM2 showed the lowest CTC50 value of 38.48±0.31 µg/mL, compared to 
all other extracts which indicated its potent toxicity levels on the HepG2 cells at higher 
concentrations. AmM2 had the highest CTC50 value of 796.8±3.11 µg/mL, which indicated that 
it was much less cytotoxic at higher concentrations. All extracts of W.somnifera showed CTC50 
values in the range of 67-113 µg/mL, the aqueous extract having the highest value. All the 
extracts of A.membranaceus, had CTC50 values > 315 µg/mL. 
 
3.5.2 mRNA expression – using CTC50 concentration of herbal extracts 
To analyse the inducing effect of the herbal extracts on the mRNA expression of HepG2 cells, 
using RT-PCR technique, they were screened using their CTC50 concentrations (as shown in 
section 3.5.1). Relative mRNA expressions of CYP3A4 by the herbal extracts on agarose gel 
are represented in figure 46. The expression levels of CYP2B6 and CYP3A4 are depicted as 
arbitrary units normalized to (GAPDH) mRNA. 
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For the induction screening against CYP2B6, dexamethasone (DEX, 10µM) was used as the 
positive control, and showed significant fold induction (p < 0.001) compared to the cell control 
(CC).Compared to DEX, none of the extracts showed 2-fold induction (200% increase in fold-
shift) and most of them were only moderate inducers of CYP2B6 (< 50%-fold shift). ObM2 
induced CYP2B6 mRNA the most; followed by AmA1 with 36%-fold response increase 
compared to CC.  The methanolic and ethanolic extracts of O.basilicum and G.glabra 
moderately induced CYP2B6 mRNA with 38%- and 28%-fold shift and 26%- and 33%-fold 
shift respectively, compared to CC. All the extracts of W.somnifera showed least induction of 
CYP2B6 mRNA, with fold responses < 20%, compared to CC (fig 47). 
 
Fig.46 Relative (A) CYP3A4 and (B) CYP2B6 mRNA expressions by CC, RIF, DEX and the extracts on agarose 
gel. (C) GAPDH mRNA expression on agarose gel relative to CC, RIF, DEX and the extracts for normalization. 
 
 
Fig.47 Histograms of all the herbal extracts and their fold responses for CYP2B6 mRNA expression, relative to 
cell control (CC); DEX is the positive control. 
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For CYP3A4, most of the extracts showed inducing potential. The positive control rifampicin 
(RIF, 50 µM) showed significant fold induction (p < 0.001) compared to the cell control (CC). 
When compared to RIF, none of the extracts showed 2-fold induction of CYP3A4. However on 
an average scale compared to CC, most of the extracts moderately induced CYP3A4 mRNA, 
with an average fold response > 25% of the CC (fig 48). 
 
Relative to CC, the ethanolic and methanolic extracts of A.officinalis induced CYP3A4, with 
48%- and 44%-fold increases in gene expression. AoE3 induced the most with 48%-fold 
response (0.5-fold induction). The extracts of O.basilicum induced 3A4, with ObM2 showing 
22%-fold response increase and ObE3 at 44%. All the extracts of A.membranaceus showed 
good induction of CYP3A4, with an average fold response of 37% compared to CC (fig 48). 
 
For W.somnifera extracts, WsA1 induced CYP3A4 with 38%-fold shift followed by WsM2 and 
WsM3 (30%increase in the fold response). Comparatively, all extracts of G.glabra showed less 
induction with average fold response < 15%. 
 
 
Fig.48 Histograms of all the herbal extracts and their fold responses for CYP3A4 mRNA expression, relative to 
cell control (CC); DEX is the positive control. 
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The aqueous extract of A.membranaceus consistently induced both CYP2B6 and CYP3A4 
mRNA expression with 36%-fold increase in the gene expression (fig.47, 48) indicating that 
this extract is a moderate inducer of the CYPs. However none of the extracts induced both 
CYPs over 2-fold, indicating that the phytoconstituents present in these extracts are not strong 
inducers of the CYPs. The mRNA expression assays depicted that CYP3A4 was more inducible 
by the investigated herbs compared to CYP2B6. 
 
3.6 Phytochemical fingerprinting – Extracts inducing CYP activity 
3.6.1 LC-MS/ PDA analysis 
For the negative mode extract scans, the following observations were noted (table 17): 
1. Althaea officinalis (methanol and ethanol) extracts (fig. 49 shows the chromatogram of the 
ethanol extract):  
 The most prominent peak in both the extracts of A.officinalis was tentatively identified 
as quinic acid derivative [quinic acid−H−H2O]- (fig. 50 a) (Li et al., 2016; Chang et al., 
2016) with a retention time of 17.16 min at m/z 173 at a PDA detection wavelength 230 
nm and daughter ions at m/z 83, 111, 127 and 173. 
 
    Fig. 49 LC-MS chromatogram of A.officinalis (ethanol extract) in negative mode scan for time duration of 
29 min. 
 
 Another prominent peak observed in both extracts was identified as eucommiol, at 
retention time 21.09 min at m/z187 and fragment ions at m/z 125, 141, 169, and 187. 
 D-Galacturonic acid monohydrate was observed in the ethanolic extract at m/z 211 and 
retention time 12.08 min (fig. 50 b). 
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 The fatty acid trihydroxy-octadecenoic acid (329 m/z) was prominently observed in the 
ethanolic extract.  
 Other common compounds included salvigenin (327 m/z) and dihexose sugar (341 m/z). 
 
Fig.50 Structures of some of the main compounds identified from crude herbal extracts of A.officinalis: (A) 
Quinic acid derivative; (B) D-Galacturonic acid, monohydrate. 
 
2. Glycyrrhiza glabra (ethanol) extract (fig. 51 shows the chromatogram of the ethanol 
extract):  
 The most prominent peak identified as the known chalcone, licochalcone B observed at 
a retention time of 23.91 min (fig. 51 a) with m/z 285 at a PDA detection wavelength 
230 nm and fragment ions at m/z 150, 270 and 285 (table 17). 
 
Fig. 51 LC-MS chromatogram of Glycyrrhiza glabra (ethanol extract) in negative mode scan for time duration 
of 29 min. 
 
 The second most prominent peak observed was identified as a flavonone, liquiritin 
apioside at retention time 18.02 min, m/z 549 and daughter ions at m/z 255, 285 and 429 
(fig. 51 b). 
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 Other known compounds identified included liquiritigenin (255 m/z) and licuraside/ 
neolicuroside (549 m/z). 
 
 
Fig.52 Structures of some of the main compounds identified from crude herbal extracts of Glycyrrhiza glabra: 
(A) Licochalcone B; (B) Liquiritin apioside; (C) Liquiritigenin; (D) Licuraside; (E) Neolicuroside. 
 
 
3. Astragalus membranaceus (aqueous) extract:  
 The phytochemical profile of the aqueous extract was very similar to the organic 
solvent extracts of A.membranaceus. The major compounds observed included isocitric 
acid at 3.72 min (191 m/z), dihexose sugar (341 m/z) at 1.76 min, trifolirhizin (491 m/z) 
at 18.01 min, quercetin isomer (301 m/z) at 21.11 min, and calycosin (283 m/z) and 
formononetin (267 m/z) at 24.21 and 24.56 min respectively (table 17). 
 
Table [17]   Compounds detected in A.officinalis, G.glabra and A.membranaceus extracts in negative scan mode in LC-
MS/ PDA. 
 
SL 
NO. 
RT 
(MIN) 
M-H [M-H] – MS/MSC TENTATIVE ID
#
 
COMPOUND 
NATURE 
AoMeOH 
1 17.14 173.0802 C8H13O4 83, 111, 127 
Quinic Acid derivative 
[quinic acid−H−H2O]- 
Carboxylic acid 
2 21.09 187.0978 C9H15O4 125, 141, 169 Eucommiol Cylopentenoid-tetrol 
3 24.36 327.2158 C18H31O5 
116.9, 205, 215, 277, 
311, 
Salvigenin (5-Hydroxy-6,7,4'-
trimethoxyflavone) 
Flavones 
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4 1.76 683.2255 C25H13N2 377, 503 Unknown  – 
5 1.80 341.1066 C12H21O11 89, 119, 179, 341 Dihexose Sugar 
6 24.03 312.1241 C19H14N5, C18H18NO4 148, 178, 312 Unknown  – 
7 16.22 358.0936 C18H16NO7, C19H12N5O3 135,160, 178, 222, 358 Unknown  – 
 AoEtOH 
1 17.16 173.0813 C8H13O4 83, 111, 127 
Quinic Acid derivative 
[quinic acid−H−H2O]- 
Carboxylic acid 
2 21.08 187.0968 C9H15O4 125, 141, 169 Eucommiol Cylopentenoid-tetrol 
3 24.45 329.2330  C18H33O5 116.92,171, 211, 258 
Trihydroxy-octadecenoic 
acid 
Fatty acid 
4 12.08 211.0640 C6H11O8 96, 127, 162 
D-Galacturonic acid, 
monohydrate 
Sugar acid 
5 1.76 341.1066 C12H21O11 89, 119, 179 Dihexose Sugar 
6 24.36 327.2175 C18H15O6 
116.9, 205, 215, 277, 
311 
 Salvigenin (5-Hydroxy-
6,7,4'-trimethoxyflavone) 
Flavones 
7 24.04 312.1232 C18H18NO4 148, 178 Unknown  – 
 GgEtOH 
1 23.91 285.0758 C16H13O5 150, 270 Licochalcone B Chalcones 
2 18.02 549.1607 C36H29O13  255, 285, 429 Liquiritin apioside Flavonones 
3 11.75 209.0443 C10H9O5 165 Unknown  – 
4 24.09 255.0661 C15H11O4 119, 135 Liquiritigenin  Flavonones 
5 22.72 549.1612 C26H29O13 255, 429 Isoliquiritin apioside Chalcones 
6 17.67 549.1602 C26H29O13 135, 255, 297, 429 Licuraside/ Neolicuroside Chalcones 
7 21.11 301.0726 C9H17O11 151, 191, 286, Quercetin isomer Flavonoid 
8 1.77 341.1091 C12H21O11 89, 119, 179 Dihexose Sugar 
AmAq 
1 3.72 191.0189 C6H7O7 111, 129, 173 Isocitric acid Citric acid 
2 1.76 341.1091 C12H21O11 89, 119, 179 Dihexose Sugar 
3 24.21 283.0612 C16H11O5 
136, 196, 211, 240, 
269 
Calycosin (7,3'-dihydroxy-4'-
methoxyisoflavone) 
Isoflavone 
4 10.73 205.0723 C8H13O6 115,129 Unknown  – 
5 18.01 491.1184 C22H22O10  [M+FA-H] 233, 255, 268, 283 
(-)-Maackiain-3-Oglucoside 
(Trifolirhizin) 
Flavonoid 
6 21.04 187.0945 C9H15O4 125, 141, 169 Eucommiol Cylopentenoid-tetrol 
7 24.56 267.0654 C16H11O4 115,117,196, 207, 236 
Formononetin (7-Hydroxy-
4'-methoxyisoflavone) 
Isoflavone 
8 22.98 475.1259 C16H27O16 25, 267, 268 Unknown  – 
#
REFERENCES –Chen et al., 2017; Said et al., 2017; Chang et al., 2016.; Chen et al., 2016; Deters et al., 2016; Li et al., 2016; Liu et al., 2016; Soleimany 
et al., 2016; Zhang et al., 2016; Simirgiotis et al., 2015; Du et al., 2014; Kuo et al., 2014; Zhang et al., 2013; Mena et al., 2012; Wang et al., 2012; Farag et 
al., 2012; Čejchanová, 2011; Hossain et al., 2010; Li et al., 2007. 
https://www.ncbi.nlm.nih.gov/pccompound; https://massbank.eu/MassBank/; https://metlin.scripps.edu/; https://webbook.nist.gov/chemistry/mw-ser/ 
 
For the positive mode extract scans, the following observations were noted (details summarized 
in table 18): 
1. Althaea officinalis (methanol and ethanol) extracts (fig. 53 illustrates the chromatogram of 
the methanolic extract):  
 The most prominent peaks in both the extracts of A.officinalis were having m/z 398 with 
a retention times of 7.6 and 7.43 min at UV detection wavelength of 230 nm. These 
molecules resembled characteristics of the previously reported compound 
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altheahexacosanyl lactone with m/z = 391, isolated from the seeds of A.officinalis (Rani 
et al., 2010) and were tentatively identified as derivatives 1 and 2 (table 18, fig54 a). 
 Some of the other peaks in both the extracts at 5.76 min (348 m/z), 7.86 min (412 m/z) 
and 7.91 min (412 m/z) could not be identified and were derived as nitrocompounds 
([M+H]
+
 formula details in table 18). 
 The dihydrochalcone phloretin (fig. 54 b) was identified at 6.27 min retention time with 
m/z 275, and fragment ions at m/z 215 and 229. 
 
Fig. 53 LC-MS chromatogram of Althaea officinalis (methanol extract) in positive mode scan for time 
duration of 15 min. 
 
 
Fig. 54 Structures of some of the main compounds identified from crude herbal extracts of Althaea officinalis 
(positive mode): (A) Altheahexacosanyl lactone; (B) Phloretin. 
 
 
2. Glycyrrhiza glabra (ethanol) extract (fig. 55 shows the chromatogram of the ethanolic 
extract):  
 The positive scan of the ethanol extract resulted in the identification of three major 
compounds in G.glabra namely, licochalcone C (339 m/z), glabrene (323 m/z) and 
glabridin (325 m/z) at retention time points 8.42, 7.58 and 8.86 min, respectively. The 
UV detection wavelength for licochalcone B was at 354 nm (fig. 56). The daughter ions 
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for licochalcone C where identified as m/z 229 and 297, whereas the products ions for 
glabrene and glabridin were identified as m/z 267 and m/z 123, 149, 189 respectively. 
 Licoflavone B was detected at a retention time 9.8 min and m/z 391 at UV wavelength 
of 300 nm. 
 
Fig. 55 LC-MS chromatogram of Glycyrrhiza glabra (ethanol extract) in positive mode scan for time duration 
of 15 min. 
 
 
 
Fig.56 Structures of some of the main compounds identified from crude herbal extracts of Glycyrrhiza glabra 
(positive mode): (A) Licochalcone C; (B) Glabrene; (C) Glabridin. 
 
 
3. Astragalus membranaceus (aqueous) extract:  
 The prominent peaks were identified as physcion (285 m/z), physcion 8-glucoside (447 
m/z) and apigenin 7-glucuronide (269 m/z) (fig. 57). Physcion had a retention time of 
5.76 min and its product ions were identified as m/z 206, 219, 240, 268 and 270. 
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Physcion 8-glucoside eluted at 4.09 min, while apigenin 7-glucuronide eluted at 7.03 
min.  
 The bioactive saponin cycloastragenol was identified at 4.99 min, though in lesser 
concentrations, with m/z 491 and product ions m/z 270, 286 and 383.
 
 
Fig.57 Structures of some of the known and proposed compounds identified from crude herbal extracts of 
Astragalus membranaceus (positive mode): (A) Physcione; (B) Physcione 8-glucoside; (C) Apigenin 7-
glucuronide; (D) Cycloastragenol. 
 
Table [18]   Compounds detected in A.officinalis, G.glabra and A.membranaceus extracts in positive scan mode in LC-MS/ 
PDA. 
 
SL 
NO. 
RT 
(MIN) 
M+H [M+H]+ MS/MSC TENTATIVE ID
#
 
COMPOUND 
NATURE 
AoM2 
1 7.60 398.3265 C26H54O2  
118, 119, 202, 231, 
270, 321, 349 
Altheahexacosanyl lactone 
derivative 1? 
Lactone 
2 7.43 398.3266 C26H54O2 118, 136, 331 
Altheahexacosanyl lactone 
derivative 2? 
Lactone 
3 5.76 348.2172 C20H30NO4 128, 219, 302 Unknown  – 
4 7.86 412.3422 C24H46NO4 118, 301, 332 Unknown  – 
AoE3 
1 7.65 398.3267 C26H54O2 
118, 119, 202, 231, 
270, 321, 349 
Altheahexacosanyl lactone 
derivative 1? 
Lactone 
2 7.44 398.3258 C26H54O2 118, 136, 331 
Altheahexacosanyl lactone 
derivative 2? 
Lactone 
3 7.91 412.3416 C24H46NO4 118, 184, 333 Unknown  – 
4 6.27 275.0906 C15H15O5 215, 229 Phloretin Dihydrochalcone 
 GgE3 
1 8.42 339.1591 C21H23O4 229, 297 Licochalcone C Chalcone 
2 7.58 323.1274 C20H19O4 267 Glabrene Isoflavonoid 
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3 5.42 287.0912 C16H15O5 121, 240 Licochalcone B Chalcone 
4 7.02 269.0807 C16H13O4 197, 253 Unknown  – 
5 5.13 431.1343 C22H23O9 269 Unknown  – 
6 8.86 325.1439 C20H21O4 123, 149, 189 Glabridin Isoflavane 
7 9.38 391.1907  C25H25O4 333 Licoflavone B Flavones 
8 9.72 355.0125 C21H23O5 297, 338 Licochalcone D Chalcones 
AmA1 
1 5.76 285.0763 C16H13O5 
206, 219, 240, 268, 
270 
Physcion Flavonoid 
2 14.32 247.1665 C11H23N2O4, C16H23O2 124, 148, 226 Unknown  – 
3 4.09 447.1295 C22H23O10 269, 270, 285 Physcion 8-glucoside 
Anthraquinone 
glucoside 
4 7.22 192.1388 C12H18NO 91, 119, 167 Unknown  – 
5 7.03 269.0805 C16H13O4 197, 225, 237 Apigenin 7-glucuronide Flavone metabolite 
6 1.65 259.0928 C10H14N3O5, C8H18NO8 150, 196, 210 Unknown  – 
7 5.12 431.1347 C22H23O9 269, 270 Unknown  – 
8 4.99 491.1021 C30H49O5 270, 286, 383 Cycloastragenol Bioactive Saponin 
#
REFERENCES – Sendker et al., 2017; Wintola and Afolayan, 2017; Deters et al., 2016; Soleimany et al., 2016;  Liu et al., 2016; Du et al., 2014; 
Bolleddula et al., 2012; Wang et al., 2012; Farag et al., 2012; Čejchanová, 2011; Hossain et al., 2010; Rani et al., 2010; Li et al., 2007, Ye et al., 2005. 
https://www.ncbi.nlm.nih.gov/pccompound; https://massbank.eu/MassBank/; https://metlin.scripps.edu/; https://webbook.nist.gov/chemistry/mw-ser/ 
 
The major identified compounds for the three active extracts were relatively quantified (in mg/L 
equivalent units of gallic acid/ quercetin), with respect to the linear calibration curve of the 
reference standards quercetin and gallic acid (table 19). The major compounds 
altheahexacosanyl lactone derivatives 1 & 2, were relatively quantified at 3874.310 and 
1341.994 mg/L in AoM2 and 4324.664 and 1903.778 mg/L in AoE3, respectively. In GgE3 
extract, licochalcone C was the most prominent compound (2208.600 mg/L) followed by 
glabrene and licochalcone B. For AmA1, all the identified compounds were found to be < 500 
mg/L in concentration. 
 
Table [19]   Relative quantification of the major compounds identified in A.officinalis, G.glabra and 
A.membranaceus extracts in positive scan mode in LC-MS/ PDA. 
# SLNO COMPOUND NAME SAMPLE NAME AREA RT(MIN) 
CONC. UNITS
*
  
(MG/L EQUIVALENTS OF GALLIC 
ACID/ QUERCETIN) 
Compound 1 Altheahexacosanyl lactone derivative 1                                                                                                                                         *** 
1  AoM2 7560.8280 7.60 3874.310  
2  AoE3 8439.7201 7.65 4324.664 
Compound 2 Altheahexacosanyl lactone derivative 2 
1  AoM2 2618.8600 7.43 1341.994 
2  AoE3 3715.2160 7.44 1903.778 
Compound 3 Phloretin 
1  AoE3 2103.2310 6.27 1077.780 
Compound 4 Salvigenin (5-Hydroxy-6,7,4'-trimethoxyflavone) 
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1  AoM2 190.1650 24.36 18.845 
2  AoE3 154.5610 24.36 10.744 
Compound 5 Trihydroxy octadecenoic acid                                                                                                                                                           ** 
1  AoE3 189.0380 24.45 249.011 
Compound 6 Eucommiol 
1  AoM2 365.7730 21.09 58.802 
2  AoE3 321.1200 21.08 48.642 
Compound 7 Dihexose 
1  AoM2 117.9770 1.80 2.420 
2  AoE3 168.5270 1.76 13.922 
3  AmA1 131.4520 1.76 5.486 
Compound 8 Calycosin (7,3'-dihydroxy-4'-methoxyisoflavone) 
1  AmA1 105.4160 24.21 0.070 
Compound 9 Isocitric acid 
1  AmA1 174.1490 3.72 228.809 
Compound 10 Apigenin 7-glucuronide 
1  AmA1 472.3550 7.03 242.102 
Compound 11 Licochalcone C 
1  GgE3 4310.0950 8.42 2208.600 
Compound 12 Glabrene 
1  GgE3 2808.0590 7.58 1438.941 
Compound 13 Licochalcone B 
1  GgE3 2377.3450 5.42 1218.239 
Compound 14 Glabridin 
1  GgE3 1454.4840 8.86 745.355 
Compound 15 Licoflavone B 
1  GgE3 1083.8200 9.38 555.423 
Compound 16 Licochalcone D 
1  GgE3 387.8520 9.72 198.802 
Compound 17 Physcion 
1  AmA1 839.8840 5.76 430.428 
Compound 18 Physcion 8-glucoside 
1  AmA1 349.3340 4.09 179.065 
Compound 19 Cycloastragenol 
1  AmA1 168.9620 4.99 86.640 
*
 The relatively quantified concentrations are reasonable approximations of the relative amounts of the identified compounds present in each extract 
(Bhandari and Rajbhandari, 2015; Punyasiri et al., 2015), ** All the acid compounds are relatively quantified equivalent to the linear curve of gallic acid, 
*** All the non-acid compounds are relatively quantified equivalent to the linear curve of quercetin. 
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Chapter 4 
DISCUSSION 
 
1.1 Biochemical phytoprofiling 
Medicinal plants are a source of natural components for both traditional systems of medicine 
such as Ayurveda, Chinese, Unani, and homeopathy as well as modern medicine. Herbal 
medicine is gaining more popularity as tea extracts, health and fitness supplements, over-the-
counter tablets, as well as potential ingredients for the pharmaceutical industry. Most of the 
herbs are not fit for consumption in their natural state and preparations suitable for 
administration are made or advised by THPs. Most of these preparations are hot water tea 
decoctions. In certain cases, use of alcohols such as brandy is also a practice to prepare extracts. 
As described by the THPs, the herbs used in this study are incubated overnight with alcoholic 
beverages such as brandy before consumption (Thring and Weitz, 2006). Hence aqueous and 
ethanolic extractions have been selected for this study. Methanol and ethyl acetate are effective 
solvents in extracting a wide range of hydrophilic phytocompounds (Dhawan and Gupta, 2017), 
especially flavonoids and phenols (Siddhuraju and Becker, 2003). Aqueous extractions produce 
the more hydrophilic constituents for most herbs. However higher pharmacological activity is 
generally observed in methanolic, ethanolic and ethyl acetate extractions (Dhanani et al., 2017). 
In this study, except for Withania somnifera and Glycyrrhiza glabra, all other herbs gave the 
highest yield with the aqueous extraction, Inula helenium having the highest % yield of 55%, 
followed by Ocimum basilicum with 33.57%. The lowest % yield was observed in the 
methanolic extract of I.helenium (0.44%). 
 
Qualitative analysis of the herbs is an essential step as a precursor to in vitro studies and 
analytical fingerprinting of the phytoconstituents. Standard methodologies are followed to 
analyse the various classes of compounds present in each extract based on precipitate formation 
and color intensity on addition of specific chemical reagents. As per the results, the extracts of 
G.glabra, Astragalus membranaceus, I.helenium and O.basilicum had prominent 
phytocompounds such as phenols, alkaloids, tannins, terpenoids and glycosides.  
 
Saponins were observed in O.basilicum. High intensity of flavonoids, phenols, alkaloids, 
terpenoids and glycosides were observed in G.glabra, I.helenium and O.basilicum, some of 
these compounds could also attribute to their strong aromatic nature (Petkova et al., 2015; 
Loughrin and Kasperbauer, 2003). Phytochemical composition, antimicrobial and medicinal 
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properties of G.glabra, and compounds isolated from its roots such as glycyrrhizin have 
previously been reported (Karkanis et al., 2018; Thakur et al., 2016). Saponins, alkaloids, 
flavonoids as well as phenolic compounds such as liquiritigenin, liquiritin apioside, neoliquiritin 
apioside, isoliquiritin etc. have been identified (Ammar et al., 2012). Plants from the genus 
Inula being popular medicines in Africa, have been analysed for their bioactive components. 
Mono- and cyclic sesqui-terpene lactones are some of the major phytocompounds identified in 
I.helenium (Zhao et al., 2006; Seca et al., 2014) along with flavonoids (Yanitskaya et al., 2012). 
O.basilicum extracts have been analysed to determine triterpenoid saponins (Habib et al., 2016), 
alkaloids, flavonoids, saponins and anthraquinones from the methanolic extract as well as 
glycosides, tannins, terpenoids, phenols and phlobatatannins in the aqueous extract (Fakhroo 
and Sreerama, 2016). Major saponins such as astragaloside and astramembranoside were 
identified from the ethanolic extract of Astragalus roots (Ju et al., 2008). Other phytochemical 
studies investigated the flavonoid derivatives and lignans present in this herb (Bratkov et al., 
2016; Lee et al., 2008). The biochemical profile of the some of the herbs in this study showed 
the presence of more compounds such as phytosteroids in W.somnifera and O.basilicum. The 
ethyl acetate extract of O.basilicum comprised of all the phytocompounds including steroids, in 
trace amounts. The presence of more coumarins and alkaloids in the extracts of 
A.membranaceus and I.helenium compared to the other class of phytocompounds was new data. 
Previous studies have not reported comparative biochemical analysis of all extracts for each 
herb, including the ethyl acetate extract. 
 
As illustrated in the phyto-CYP interaction assessment prediction model (fig. 3), flavonoids 
have been previously reported to have inducing as well as inhibitory effects on CYPs. Common 
phytoconstituents such as rutin, isoquercitrin and quercetin have inducing effects on many 
CYPs, while dimethoxy flavanones inhibit certain CYPs. Since the intensity of flavonoids was 
high in G.glabra, I.helenium and O.basilicum, the prediction model would associate these herbs 
to have inhibitory or inducing effects on the CYPs. Saponins as well as glycosides are known to 
have moderate inhibitory effects on certain CYPs (3A4, 1A2), which could indicate that 
A.membranaceus and O.basilicum also have more inhibitory effect based on the type of extract 
used, attributing to the solvent extraction. Extracts of Althaea officinalis had mostly flavonoids 
and glycosides; some of these compounds could make them potential candidates to cause HDI. 
From the qualitative analysis, the herbs that would cause strong interactive effect with the CYPs 
based on the presence of the various classes of phytocompounds where ranked as follows: 1. 
O.basilicum, 2. G.glabra, 3. A.membranaceus, 4. I.helenium, 5. W.somnifera and A.officinalis. 
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From the biochemical analysis, the intensity of phytocompounds present in W.somnifera and 
A.officinalis was comparatively less, indicating their potential to cause moderate yet clinically 
relevant HDI. 
 
1.2 CYP inhibition 
HLM assays for in vitro inhibitory evaluation of herbs on CYP metabolism is one of the most 
convenient methodologies, recommended by FDA (FDA Clinical Pharmacology Guidelines, 
2012). Mostly the assay samples are analysed using HPLC and LC-MS techniques, for 
quantification of the metabolites, the parent drug and the internal standard. Two methods using 
different solvents were developed to separate and quantify EFV, E8H and NEO as well as RIF, 
25ODESRIF and NEO. The assay yielded well-resolved peaks for all the analytes with good 
accuracy, precision and recovery, within a short run time. As per literature, biphenyl columns 
are preferable for the analysis of cyclic compounds (Powell and D'Arcy, 2013); hence a 
comparative study was done to analyse EFV and its metabolite using a biphenyl column as well 
as a C-18 column. Good separation of analytes was obtained on both columns, however shorter 
run time was observed in the C-18 column. For RIF, a column with comparatively larger 
diameter was preferred and the C-18 Luna column gave good separation. 
 
The HLM assay samples were analysed using the same methods as the standards, and a gradient 
elution gave better results, and negated the interference of other metabolites or co-factors from 
the assay. For the HLM and time variant assays, consistent results were observed for both EFV 
and RIF. Based on the rate of metabolite formed, as well as the time of incubation, 0.5 mg/mL 
and 0.25 mg/mL protein concentrations were selected for EFV and RIF assays, respectively. 
EFV has a higher binding affinity to CYP2B6 with reported Km values ranging from 13-20 𝜇M 
(Ward et al., 2003; Ogburn et al., 2010) compared to other substrates such as bupropion (Xu and 
Desta, 2013). Other reported Km values of EFV include 3.2-8.8 𝜇M (in CYP2B6.1/2B6.6 
isoenzymes; Xu et al., 2012) and 14.3-15.9 𝜇M (in CYP2B6/2B6.4 isoenzymes; Bumpus et al., 
2006). The Km value expressed for EFV-HLM in this study (15.08 𝜇M) was in agreement with 
the latter values reported in literature. 
 
Previously reported values of RIF Km in transporters SLCO1B1 (OATP1B1, OATP-C, OATP2, 
LST-1) in HeLa-OATP1B1, OATP1B1-expressing oocytes, and SLCO1B3 (OATP1B3, 
OATP8) in OATP1B3-expressing oocytes are 1.5 𝜇M, 13 𝜇M and 2.3 𝜇M (Tirona et al., 2003; 
Vavricka et al., 2002) respectively. High rifampicin hydrolase activity was observed in 
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recombinant human arylacetamide deacetylase (AADAC) and human liver and jejunum 
microsomes with Km values 0.2 mM, 0.4 mM and 0.3 mM, respectively (Kobayashi et al., 
2012). In a study on Staphylococcus aureus, based on the accumulation of 
14
C-Rifampicin, the 
Km value expressed was 0.06 𝜇M (Williams and Piddock, 1998). 
 
The in vitro data showed that 25ODESRIF is the primary metabolite, which concurs with 
previous studies (Seng et al., 2015; Panchagnula et al., 1999). However since RIF is 
conventionally used as an inducer of CYP3A4 with other drugs, no substantial in vitro data is 
available on the kinetics of RIF (Km and Vmax) based on the formation of 25ODESRIF using 
HLMs. 
 
In the two-point screening assays all herbs were screened for inhibitory activity against 
CYP2B6 and the metabolism pathway of RIF, since the THP advises using combination of 
these herbs in scenarios of HIV patients with TB. The results showed that except for ObA1 
(affected only RIF metabolism), all extracts of Ocimum basilicum and Inula helenium inhibited 
CYP2B6-mediated metabolism of EFV and formation of 25ODESRIF from RIF. Among the 
other herb extracts including ObA1 there was an increase in the rate of formation of 
25ODESRIF at both concentrations (20, 200 𝜇g/mL). For the extracts of I.helenium, the activity 
was concentration-dependent against CYP2B6; IhA1, IhM2 and IhEtA4 inhibited CYP2B6 at 
higher concentration (200 𝜇g/mL). IhM2 reduced the activity to 30% at 200 𝜇g/mL, whereas 
IhE3 reduced the activity to 35% at both 20 and 200 𝜇g/mL showing that the ethanolic extract 
inhibitory effect was not concentration-dependent and was the most potent amongst all the Inula 
extracts. IhE3 has a similar inhibitory effect on rifampicin metabolism also. AmE3 was the only 
other extract that showed concentration-independent inhibitory effect on CYP2B6. This proved 
that different solvent extractions had different effects on the activity of the CYPs because the 
polar/non-polar nature of the solvents whereby different phytoconstituents get extracted in each 
solvent. ObM2, ObE3, IhM2 and IhE3 strongly inhibited CYP2B6 activity. The ethyl extracts 
of A.membranaceus and W.somnifera also inhibited CYP2B6.  
 
The in vitro activation of CYP-mediated metabolism of certain substrates has been analysed and 
reported previously (Tracy, 2006; Hutzler et al., 2003; Atkins et al., 2001; Korzekwa et al., 
1998); however the relevance of such CYP modulations in vivo is still uncertain. CYP 
activation is not associated with the increase in mRNA expression and protein levels as in 
induction, but only an enhancement in the enzyme activity. This enzyme modulation is 
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measured by the amount of metabolite formed by the CYP from its relevant substrate. In this 
study the aqueous, methanolic and ethanolic extracts of Glycyrrhiza glabra activated CYP2B6 
metabolism of efavirenz, increasing the remaining activity by 200% at a higher concentration 
(200 𝜇g/mL). The aqueous extract of W.somnifera increased CYP2B6 metabolism by 195% at a 
concentration of 20 𝜇g/mL. Similarly, an increase in the metabolism of rifampicin was noticed 
for many extracts such as ObA1 (170% at 20 𝜇g/mL), AmA1 (143% at 200 𝜇g/mL), GgA1 
(136% at 200 𝜇g/mL), AmM2 (146% at 200 𝜇g/mL), AmE3 (122% at 200 𝜇g/mL) and AoE3 
AmM2 (118% at 200 𝜇g/mL). A possible reason explaining this mechanism of CYP activation 
would be the presence of multiple binding sites at the active site of the enzyme (Tracy, 2006; 
Atkins et al., 2001; Korzekwa et al., 1998). The activation of CYP2B6 and the enzymes 
involved in rifampicin metabolism could be due to the ability of the phytoconstituents present in 
these extracts, to bind to the active site of these enzymes thereby inducing conformational 
changes, thereby increasing the activity. CYP3A4 activation with similar speculations was 
reported previously, where an increase in the metabolism of dextrorphan and the formation of 3-
methoxymorphinan was observed in microsomes treated with Ferula asafetida extracts (Al-
Jenoobi et al., 2014). Furthermore, such CYP modulations are concentration-dependant. 
 
In the IC50 screening, AmEtA4 exhibited strong inhibition of CYP2B6 (29.70 𝜇g/mL) followed 
by ObM2 (36.07 𝜇g/mL), and IhM2 (42.79 𝜇g/mL), while all other extracts had IC50values > 50 
𝜇g/mL. The positive control TICL inhibited CYP2B6 with an IC50 value 14.47 𝜇g/mL (54.88 
𝜇M). In the case of rifampicin, ObE3 was a potent inhibitor of its metabolism with an IC50 value 
of 8.94 𝜇g/mL, followed by IhE3 (18.58 𝜇g/mL) and ObM2 (31 𝜇g/mL). The ethanolic and 
methanolic extracts of I.helenium showed more inhibition in the metabolism of EFV and RIF 
compared to its aqueous extract. Comparatively NELF inhibited RIF biotransformation to 
25ODESRIF, with an IC50 value of 5.44 𝜇g/mL (9.59 𝜇M). NELF was used as an inhibitor 
control for RIF pathway based on the assumption that certain CYP inhibitors could also inhibit 
esterases (Polsky-Fisher et al., 2006). The IC50 curves for some of the extracts also showed that 
a proportion of enzyme activity was not inhibited by increased concentrations of the extract. For 
example, in the 2-point screening against CYP2B6, IhM2 reduced the activity to 30% at 200 
𝜇g/mL. However in the IC50 curve, the enzyme activity was reduced to less than 50% at a 
concentration of 100 𝜇g/mL, beyond which the rate of inhibition was less. This indicates that 
the 2-point screening data is only a relative measure of the inhibitory effect of an extract at two 
different concentrations (ten-fold difference as in this case) and does not always correlate with 
the observed IC50 data. Similarly, ObE3 and IhE3 showed most activity for a concentration 
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range from 0-100 𝜇g/mL. At higher concentrations (>100 𝜇g/mL) the IC50 curve did not show a 
drop in the % of remaining activity. In contrast the IC50 curve for IhA1 showed weaker 
inhibition till the concentration range from 0-125 𝜇g/mL (IC50122 𝜇g/mL); between 150 and 
200 𝜇g/mL concentrations of this extract, the inhibition curve dipped further reducing the 
remaining activity to 20%. 
 
Some of the previously reported IC50 values of ticlopidine are 0.32 𝜇M (buproprion CYP2B6; 
Turpeinen, 2004), 2.1 𝜇M (2C19, Chang et al., 2009); 163 𝜇M (TDI for NADPH in HLM; 
Cerep app. notes, 2010), 12.4-50 𝜇M (for various CYPS; Hagihara et al., 2008). Comparatively, 
the IC50 value obtained in this study for ticlopidine (54.88 𝜇M) was within the range reported 
earlier of 12.4-55 𝜇M (Choi et al., 2011; Hagihara et al., 2008). In the literature, IC50 values for 
nelfinavir have been reported as 1.90 𝜇M (on CYP3A4 isoform; Granfors et al., 2006), 11-60 
𝜇M (on UGTs), 8.4 𝜇M, 2.7 𝜇M (UGT1A1, HLM) (Zhang et al., 2005) and 2.7 𝜇M, 5.1 𝜇M (in 
cell culture assays; Mahdi et al., 2015).The IC50 value of nelfinavir in this study (9.59 𝜇M) was 
slightly higher than previously reported for an HLM assay (2.7 𝜇M); however the assay 
conditions and substrates were different; in the latter bilirubin was the substrate and nelfinavir 
was used as an inhibitor of bilirubin glucuronidation. As per the FDA guidelines (Clinical 
Pharmacology, 2012) there are no selective in vitro inhibitors available for CYP2B6-mediated 
metabolism; phencyclidine, thiotepa and ticlopidine have been used as time-dependent 
inhibitors. 
 
TDI is an MBI process where the potency of the inhibitor increases upon prolonged exposure to 
the enzyme during the pre-incubation period, and the potential formation of metabolites that 
possess stronger inhibitory activity than the parent molecule to inactivate the enzyme through 
irreversible binding. The inactivated enzyme has to be replaced by newly synthesized protein to 
restore activity (de novo synthesis) (Meibohm and Zhou, 2013). Since most of the herbal 
medications are consumed on a daily basis, the inhibition observed could increase over time. 
Hence all extracts showing inhibition were screened for TDI IC50 shift-fold, on preincubation 
with NADPH, and it was observed that some of the extracts that were not potent inhibitors of 
CYP2B6 and CYP3A4, had a TDI effect on their activity thereby lowering the IC50 value. TDI 
results in a prolonged interaction with the metabolism of the involved drugs, such as efavirenz 
in this case. Similar studies have shown that other drugs such as isoniazid have strong TDI 
effect on the metabolism of efavirenz by CYP2B6 (Court at.al, 2014). 
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Almost all extracts of I.helenium had a lower TDI IC50 value on both CYP2B6 and esterase-
mediated metabolism of RIF, except for IhA1, IhE3 and IhEtA4 (only showed TDI on 
25ODESRIF formation). IhM2 showed most TDI effect on both the enzymes (33 𝜇g/mL and 
23.11 𝜇g/mL respectively). ObA1 and ObM2 had strong TDI effect on CYP2B6. ObM2 had the 
highest TDI shift-fold (> 7). Comparatively both positive controls showed TDI too, the shift-
fold observed was >1.5. A possible reason for the TDI effect of most of the herbal extracts 
could be attributed to the rate of formation of reactive secondary metabolites on preincubation. 
Extracts such as WsM2, AmE3, ObM2, IhE3 (CYP2B6) and IhM2, IhE3 (RIF-esterases) 
showed more TDI at lower concentrations on pre-incubation with NADPH, which could be due 
to the formation of more reactive metabolites at higher concentration, that could have resulted 
in the uncoupling of the „active‟ inhibitory phytoconstituent from the binding site of the 
enzyme, thereby reducing its TDI (Fowler and Zhang, 2008). At lower concentrations, there 
might be less secondary metabolites to interfere with the binding of the active constituent to the 
enzyme thereby showing more TDI. 
 
IhA1, IhM2 (CYP2B6) and IhM2 (RIF-esterases) showed more TDI at higher concentrations on 
preincubation with NADPH which could indicate the possibility of MBI. TICL and NELF also 
inhibited more at higher concentrations indicating their MBI of both the CYPs. 
 
1.2.1 Phytochemical analysis of extracts causing inhibition 
The use of pure compounds of particular phytochemical groups, as standard reference markers 
based on their important properties, is the “gold standard” for analytical fingerprinting (Zöllner 
and Schwarz 2013). The LC-MS/ PDA analysis used quercetin and gallic acid as reference 
markers. In other instances where pure reference standards for the various phytocompounds 
were not available, tentative identifications were made for the compounds present in each 
extract on the basis of their accurate mass, elemental composition and the corresponding MS 
fragmentation spectra from the literature, and the UV maxima. 
 
The LC-MS/PDA analysis approach outlined the following principles for identification/relative 
quantification of a phytocompound: 1. Accurate masses of the major peaks from the 
chromatograms, and their product ion transitions (MS/MS fragments) 2. Relative retention 
times and UV maxima 3. Comparison of the masses and their transitions to known compound 
matches in spectral database repositories and literature, and 4. Based on specific methods and 
conditions, each reference standard gave an optimum peak resolution at a specific retention time 
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for the positive and negative scan modes, and this was used to set up a calibration curve for 
relative quantification of the identified phytoconstituent in the herbal extract. 
 
For all the extracts that showed inhibitory activity on CYP2B6 and RIF metabolism in HLMs, 
the LC-MS analysis both in positive and negative scan modes mainly helped in identifying the 
polyphenols and flavonoids in these extracts, and relatively quantifying the major compounds 
using the calibration curves set up for the reference standards gallic acid and quercetin. For 
O.basilicum the major polyphenol identified was rosmarinic acid, which is a potential inducer 
of certain CYPs. This aromatic compound is a major constituent in the fragrant essential oil 
from basil. The other major compounds included salvigenin, tartaric, isocitric, caftaric and 
chicoric acids and the flavonoid rutin, apigenin-7-O-glucoside along with eupatorin. These 
compounds had shown varying levels of inhibition on the CYPs and could have contributed to 
the activity shown by basil extracts in HLM on CYP2B6 and RIF metabolism. In previous 
studies, salvigenin was reported to have a moderate inhibiting effect on the activity of CYP3A 
enzymes (Quintieri et al., 2007). The caftaric and chicoric acid present in Echinacea, is known 
to interfere with CYP activity, especially inhibiting CYP3A4 (Cichello et al., 2016; Bossaer and 
Odle, 2012). Rutin had previously been reported to inhibit CYP3A4 in human hepatoma cells 
(Karakurt, 2016). Apigenin derivatives have also shown an inhibitory effect on CYP3A4 
activity (Tang et al., 2017, Basheer and Kerem, 2015). Rosmarinic acid induced the in vitro 
activity of CYP1A, 2B, and 3A in rat HepG2/C3A and MH1C1 cells (Cho and Yoon, 2015) and 
jasmonic acid strongly induced CYP mRNA in biotransformation of (--)-isopiperitenone (Son et 
al., 1998). Highest concentrations (mg/L equivalents of quercetin/ gallic acid) of salvigenin, 
eupatorin, and caffeic acids were observed in the ethanolic extract; hence it caused strong 
inhibition of both the RIF metabolism pathway, compared to the aqueous and methanolic 
extracts. Eupatorin has previously been reported to inhibit CYP1A2 with IC50 value of 50.8 μM 
(Pan et al. 2014), and strongly inhibit the in vitro proliferation of MDA-MB-468 human breast 
cancer cells that express CYP1A1 (Androutsopoulos et al., 2008). Furan-2(3H)-one compound, 
a moderate inhibitor of CYP1A2 (Martikainen, 2012), was observed in the aqueous extract. The 
methanolic extract had much more phytocompounds including rutin and medioresinol, which 
could explain its inhibitory effect on both CYP2B6 and RIF metabolism. This matched the HDI 
data (section 1.7.6) on the inhibitory characteristics of basil with other CYPs. 
The fingerprint results indicated the presence of compounds that have mostly inhibitory effect 
on CYP activity. Compounds such as salvigenin, tartaric, isocitric, caftaric and chicoric acids, 
apigenin-7-O-glucoside, eupatorin, furan-2(3H)-one and rutin are capable of inhibiting CYP-
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mediated metabolism (Ashour et al., 2017; Pan et al. 2014; Martikainen, 2012; Mandery et al., 
2010; Androutsopoulos et al., 2008; Quintieri et al., 2007; Budzinski et al., 2000), which could 
explain the inhibitory effects of basil extracts on CYP2B6 and RIF metabolism. 
 
For the extracts of I.helenium, the phytochemical profile comprised more of germacrane 
sesquiterpenoids and lactones, along with quinic acid. Tanacetol A was the major compound 
detected, along with macrophyllilactone B. Germacrane sesquiterpenoids of the similar category 
have shown inhibitory potential on CYP2B6 and CYP3A4 activities in vitro, with IC50 values 
below 10 μM (Pimkaew et al., 2013), which could explain as to how Inula extracts are the 
strong inhibitors of both CYP2B6 and RIF metabolism. The positive scan showed the presence 
of isoalantolactone (helenin) which has good inhibitory potential on CYPs such as CYP2C19 
(IC50 38μM, Kong et al., 2014). Epigallocatechin gallate was mostly present in IhM2 along with 
the sesquiterpene alcohol - tanacetol A (Špičáková et al., 2017), which could explain as to why 
this extract inhibits both metabolism pathways. Epigallocatechin gallate has previously been 
isolated from green tea extracts and identified as an inhibitor of CYP2B6, CYP2C8, CYP2C19, 
CYP2D6 and CYP3A (Misaka et al., 2013) and CYP2A6, CYP2C19 and CYP2E1 (Muto et al., 
2001). Other compounds identified in the aqueous extract included chlorogenic acid, 
cryptochlorogenic acid and 5-caffeoylquinic acid. Chlorogenic acid compounds have previously 
been reported to inhibit CYP2C8, CYP2C9, CYP2B6, CYP2C19, CYP1A2 and CYP3A4 in 
HLMs (Kang et al., 2016). The synergistic effect of all these compounds or the influence of one 
single compound could be responsible for the inhibitory effect of Inula extracts. Alantolactones 
and isoalantolactones from Inula showed strong inhibitory effects on CYP3A4 and CYP2C19 
activity (Qin et al., 2015, Kong et al., 2015). Apigenin detected in the ethanolic extract, has 
previously been reported to have a strong CYP inhibitory effect, comparable to that of known 
inhibitors such as ketoconazole (Steuck et al., 2016). 
 
Based on these results, there is substantial phytochemical evidence of the presence of 
compounds in the Inula extracts which may have an inhibitory effect on CYP2B6 or on RIF 
metabolism. Phytocompounds such as tanacetol A, chlorogenic acid, cryptochlorogenic acid, 5-
caffeoylquinic acid, epigallocatechin gallate, helenin (isoalantolactone) and apigenin could be 
involved in the inhibition shown in HLMs (section 3.3.4). Furthermore, pure alantolactones 
isolated from Inula have been shown to inhibit the activity of CYP3A4 and CYP2C19, as 
discussed in the literature review. 
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W.somnifera was ranked last in the list of herbs as per their biochemical profiles (section 1.1) to 
have potential in causing HDI as per the phyto-CYP assessment model; however the methanol 
and ethyl acetate extracts inhibited CYP2B6 metabolism in HLMs, when compared to the other 
herbs that were ranked higher for having more potential of causing inhibition. The ethyl acetate 
extract contained higher concentrations of withaperuvin, withanolides, eucommiol and 
vicosalactone B. Isopelletierine was found only in the methanol extract, along with trace 
amounts of withaferin derivative. Herbal constituents from these chemical classes including 
isopelletierine have previously been reported to affect CYP1A2 and CYP3A4 (Hidaka et al., 
2005; Yu et al., 2014) activity. These compounds could have been responsible for the 
significant inhibitory activity shown by Withania extracts on CYP2B6 in this study. In previous 
studies, the principal phytoconstituents from Withania (Withaferin-A, Withanolide-A and 
Withanoside-IV) and crude methanolic extracts did not having any significant inhibitory effect 
on the activity of CYPs such as CYP3A4, CYP1A and CYP2D6 in both rat and human liver 
microsomes (Savai et al., 2015; Savai et al., 2014; Savai et al., 2013). In this scenario, a 
possible explanation would be that the previous studies did not explore the effect of Withania 
on CYP2B6, even though this herb is used by THPs for HIV/AIDS and many other diseases. 
Compounds such as withaferin A, salvigenin and isopelletierine detected in the phytochemical 
screening extracts could be involved in the inhibitory effect on CYP2B6, alone or in 
combination with some or all withanolides or withanosides. 
 
The previous studies on the activity of W.somnifera extracts used the roots available in India 
(Savai et al., 2015; Savai et al., 2014; Savai et al., 2013). In all the studies, no significant 
inhibition on the CYPs was observed for Withania. In this study, the extracts from the roots of 
W.somnifera obtained from South Africa showed significant inhibition of CYP2B6. This could 
be attributed to the fact that the phytochemical composition of any herb depends on the type of 
plant, its family characteristics, the geographical conditions and pedodiversity of its place of 
origin (Gambetta et al., 2017; Machado et al., 2016; Pirbalouti and Mohammadi, 2013). For 
example, evidence-based studies previously reported the compound withaferin A in Withania 
somnifera (L.) Dunal, being present in most of the Indian chemotypes, but absent in other non-
Indian varieties except two chemotypes, one from South Africa and the other from Israel (Kaul 
et al., 2009). 
 
A.membranaceus inhibited CYP2B6 metabolism, and like Withania the ethyl acetate extract 
was more potent than the ethanolic extract, whereas the methanolic extract showed no inhibition 
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at all. Calycosin (7,3'-dihydroxy-4'-methoxyisoflavone) and formononetin (7-hydroxy-4'-
methoxyisoflavone) were prominent in all extracts. Herbal formulations containing these 
isoflavonoids significantly increased the mRNA expression of hepatic CYP1A2 and CYP2B1/2 
in female rats (Jin et al., 2017). Furthermore, formononetin moderately inhibited CYPs such as 
CYP3A4 and CYP2C9 (Kopečná-Zapletalová et al., 2016). Astragaloside I, II, IV and ononin 
were detected in the methanolic and ethanolic extracts (using the positive mode scan). 
Astragaloside IV inhibited the activity of CYP3A4 and CYP2C9 in rat liver microsomes (Wei et 
al., 2014; Shan et al., 2012). Ononin was one of the compounds isolated from the extracts of 
plants used in TCM that inhibited CYP3A4 activity (Ashour et al., 2017). Benzopyran 
derivatives (3',4',7-trimethoxyflavan) and salvigenin were observed in the ethyl acetate extract, 
which could have contributed to its inhibitory effect on CYPs.  
The inhibitory effect of Astragalus extracts on CYP2B6 could be due to presence of the various 
astragalosides as well as other flavonoids such as calycosin, formononetin and ononin. 
Literature review on Astragalus describes the inhibitory effect of the pure astragalosides 
isolated from the roots of this herb (astragaloside IV, cycloastragenol) and not all its crude 
extract forms (aqueous, methanolic, ethanolic and ethyl acetate). 
 
A.membranaceus, G.glabra and W.somnifera are few herbs from which many pure molecules 
have been isolated and identified. The predictions of possible compounds and a literature review 
of their previous reported interactions with CYPs formed the basis for this analysis, to link the 
fingerprint of each extract to the inhibition/ induction assays as a potential inhibitor or inducer 
of CYP2B6 and RIF metabolism pathway. As per literature review, some of the pure molecules 
from these herbs such as astragaloside, cycloastragenol and glycyrrhizin are inhibitors of the 
CYPs (Qin et al., 2015; Kong et al., 2014; Wei et al., 2014; Shan et al., 2012; Zhao et al., 2012; 
Kent et al., 2002). This study has provided substantial data on the potential of the crude extracts 
(comprising of several active compounds) of these herbs to interact with the CYPs. 
 
1.3 CYP induction 
Understanding the induction of CYPs is critical especially in scenarios where herbal medicines 
are used, as a basis for proper clinical studies on their effects on CYP-mediated metabolism. 
Compared to the other CYPs, CYP3A4 is more efficiently induced (Dogra et al., 1998; Denison 
and Whitlock, 1995; Waxman and Azaroff, 1992) and was chosen for the mRNA expression 
study along with CYP2B6. Using this methodology, the major emphasis was on determining the 
cytotoxicity concentrations (CTC50) of each herbal extract by screening various concentrations 
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(1000.00-31.25 µg/mL) and analysing the CYP2B6/CYP3A4 mRNA expression in HepG2 cell 
lines using this concentration. Based on this data, the fold responses for both the CYPs were 
calculated and compared to the (negative) cell control and a positive control.  
 
For almost all extracts, the aqueous and ethyl acetate extracts had higher CTC50 values than the 
ethanolic and methanolic extracts indicating a higher potency of the phytoconstituents present in 
these solvent extracts. 
 
For CYP2B6, the methanolic extract of O.basilicum and the aqueous extract of 
A.membranaceus caused moderate induction compared to the cell control (no inducer). The 
ethanolic extract of basil showed moderate induction which could be attributed to the presence 
of rosmarinic acid both extracts, at varying levels. The ethanolic extract of G.glabra showed 
moderate induction of CYP2B6 which could be due to the presence of compounds such as 
glycyrrhizin, or the synergistic effect of the licochalcones and licosaponins. However, none of 
the extracts showed 0.5-fold shift (50% increase) in the levels of gene expression when 
compared to the positive control, dexamethasone. The total amount of hepatic CYP3A is 33% 
compared to only 0.2% for total CYP2B6 (Michaels and Wang, 2014). Previous evaluations on 
CYP2B6 inductions and DDI predictions have shown that the magnitude of CYP3A4 induction 
both in vitro and in vivo was found to be higher than CYP2B6 (Fahmi et al., 2016). 
 
All extracts screened for CYP3A4 induction, except for a few ethyl acetate extracts, showed 
moderate induction of mRNA expression in HepG2 cells. The methanolic and ethanolic extracts 
of A.officinalis showed most activity with 48%-fold-response shift. This was different from the 
phyto-CYP prediction model ranking based on the biochemical tests, where Althaea extracts 
showed lesser intensity of phytocompounds. The Althaea extracts showed no inhibitory effect 
on CYP2B6 and RIF metabolism, indicating that the principle constituent has more of an 
inducing effect on the CYPs. The methanolic extract of basil and the ethanolic extract of 
G.glabra induced CYP2B6 moderately with an increase in fold-response by 38 and 33%, 
respectively. 
The aqueous extract of Astragalus (at CTC50 concentration 315 µg/mL) induced both the CYPs 
equally with a 36%-fold response increase compared to the cell control (no inducer). This was 
slightly different from all other aqueous extracts screened, where the relative induction levels 
were comparatively less. This could be attributed to the fact that the principle constituent in 
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Astragalus causing induction is extracted most in the aqueous solvent and has a stronger 
inducing effect on both CYP2B6 and CYP3A4. 
 
An in vivo pharmacokinetic study of co-administered methanolic extract of Withania somnifera 
and phenacetin in male wistar rats, revealed that the crude extract induced CYP1A and lead to 
an approximate 1.5-fold (31%) decrease in AUC 0-24h (p < 0.05) (Savai et al., 2014). In this 
study, the methanolic extracts of Withania showed moderate induction of both CYP2B6 (16%-
fold) and CYP3A4 (31%-fold). 
 
In this study, all the extracts of A.membranaceus moderately induced CYP3A4. Previous 
studies reported on the inhibitory effect of its pure molecules (astragalosides and 
cycloastragenol) on CYP3A4-mediated metabolism, and not on its inducing potential. 
Cycloastragenol and astragaloside IV were analysed and reported previously as potential 
inhibitors of CYP3A4, and CYP2C9 (Wei et al., 2014; Shan et al., 2012). In this study, the 
crude extract of A.membranaceus was screened against both CYPs using HepG2 cells for 
mRNA expression; hence it could be that the synergistic effects of various molecules, or some 
other unidentified phytoconstituent might be making it a potential inducer of CYP3A4. Another 
possibility is the presence of glycosides in the extracts as shown in the LC-MS analysis in 
section 3.6.1, and the synergistic effects of these glycosides could be the reason for the relevant 
induction observed. 
Similarly, O.basilicum has been reported as an inhibitor of CYP3A4 (Nguyen et al., 2014). In 
this study the extracts of O.basilicum inhibited CYP3A4, and the ethanolic extract moderately 
induced CYP3A4 mRNA in HepG2 cells.  
In most of the induction studies reported on CYPs, using in vitro model (hepatocytes) or animal 
model (rats), the herbal extract is administered for 2-8 days or prolonged time frame up to 4 
weeks (Cho and Yoon, 2015; Komoroski et al., 2004) before analysing the CYP protein 
expression. In this study, the HepG2 cells were incubated with the herbal extracts for a shorter 
time period of 24 h, for optimum CYP-mRNA expression (Nagarajappa et al., 2016; Brimer, 
2011; Jia and Liu, 2009). 
 
1.3.1 Phytochemical analysis of extracts causing inhibition 
A.officinalis extracts were found to have moderate induction potential on CYP3A4. This could 
be attributed to the high mucilage and fatty acid content within althaea roots, especially acids 
such as trihydroxy-octadecenoic acid. Increased levels of fatty acids are known to induce 
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hepatic CYP3A4 activity, as reported in an in vitro study in HepG2 cell and Fa2N-4 cell lines 
(Hu et al., 2014). The other prominent compounds included altheahexacosanyl lactone 
derivatives (n-hexacos-2-enyl-1,5-olide) and phloretin, which could have probably caused the 
observed induction of CYP3A4 mRNA in HepG2 cells. Polyphenolic apple juice extract 
consisting of phloretin showed moderate inducing effect on CYP1A1 (Pohl et al., 2006). 
The inducing effect shown by the methanolic and ethanolic extracts of althaea could be 
attributed to the presence of compounds such as altheahexacosanyl lactones and phloretin, along 
with the natural fatty acids present in the mucilage extracted from this herb (Hu et al., 2014). 
Few of the other known compounds such as 2B-hydroxycalamene (altheacalamene), 5,6-
dihydroxycoumarin-5-dodecanoate-6B-D-glucopyranoside (altheacoumarin glucoside) and B–
sitosterol were not detected in the LC-MS scans, however the inducing effect could be the 
synergistic effect of all these compounds. Isolation, characterization and purification of these 
molecules and separate analysis on HepG2 cells, is warranted. 
 
O.basilicum extracts had rosmarinic acid, along with 12-hydroxyjasmonic acid and fukugetin, 
which could have added to their inducing capabilities on CYP3A4 mRNA expression (Cho and 
Yoon, 2015). 
 
The bioactive saponin cycloastragenol was analysed in rat hepatic microsome enzymes to 
induce CYP2E1. Rats treated with cycloastragenol for 7 days to induce hepatic microsomal 
enzyme, significantly activated CYP2E1, inhibited CYP3A4 and caused no major effect on 
CYP2D6, CYP1A2 and CYP2C9 activity (Wei et al., 2014). This compound was detected in the 
aqueous extract of Astragalus and could have been the inducer of CYP2B6, or it could have 
also been the synergistic effect of all the astragalosides and cycloastragenol along with other 
molecules like physcion. 
Astragalus injections and astragalus granules significantly increased the CYP3A1 mRNA 
expression on the HLMs in rats; along with inducing CYP3A4 reporter gene luciferase activity 
in the reporter gene study conducted in human intestinal LS174T cells (Zhang et al., 2013). The 
results of this study matched the inducing potential previously reported for astragalus on the 
CYPs, though comparatively being moderate inducer of CYP2B6 and CYP3A4 in HepG2 cells. 
 
The ethanolic extract G.glabra induced CYP3A4 which could be the combined effect of the 
licochalcones and glycyrrhizin. As reported previously, CYP3A4 was mostly inhibited by the 
pure molecules isolated from some of these herbs (Wei et al., 2014; Shan et al., 2012; Zhao et 
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al., 2012; Kent et al., 2002), except for glycyrrhizin (from liquorice) which induced CYP3A4 
(Tu et al., 2010).In a study previously reported in mice and rats, multiple oral doses of 
liquorice extract during 4 or 10 days induced the mRNA and protein expression of 
CYP3A and activity of CYP1A2, CYP2B1 and CYP3A (Cho and Yoon, 2015) indicating 
the similarity in activity of this extract, causing moderate induction on CYP3A4 mRNA 
expression in HepG2 cell lines in this study. Liquorice extracts including glycyrrhizin have 
been reported to significantly induce hepatic CYP3A- and, to a lesser extent, CYP2B1- and 
CYP1A2-dependent microsomal monooxygenase activities, as well as 6beta- (CYP3A), 2alpha, 
6alpha- (CYP2A1, CYP2B1) and 7alpha-, 16alpha- (CYP2B9) activities in male and female 
mice (Paolini et al., 1998). The observed induction could be the effect of glycyrrhizin, because 
most of the licochalcones extracted from liquorice previously, have been associated with 
inhibitory effects on the CYPs (Li et al., 2017). 
 
The inhibitory/ inducing activity observed for the extracts, could be due to the presence of other 
unidentified molecules or the synergistic effect of the identified compounds together. It cannot 
be substantiated if a single molecule alone might cause interactions with CYP2B6 and RIF 
metabolism, or other unidentified phytoconstituents are involved. For e.g., for basil, the 
methanolic and ethanolic extracts inhibited CYP2B6 and rifampicin metabolism in HLM, and 
the same extracts induced CYP2B6 and CYP3A4 mRNA expression in HepG2 cells. The 
inhibitory effect could be due to the presence of caftaric, chlorogenic and chicoric acids 
(Cichello et al., 2016; Bossaer and Odle, 2012), or rutin alone (Karakurt, 2016), or a 
combination of all these molecules along with other unidentified molecules present in the 
extracts. Similarly, the inducing effect could be attributed to the presence of rosmarinic acid 
alone in the extracts (Cho and Yoon, 2015), or other compounds such as jasmonic acid (Son et 
al., 1998), or even a combination of both and other unidentified molecules. Previous studies 
have reported cases of a plant extract having stronger inhibition potential than its single isolated 
bioactive molecule, where it was explained as the synergistic effect of other active molecules 
(Kar et al., 2015; Harwansh et al., 2014). 
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Chapter 5 
CONCLUSIONS, STUDY LIMITATIONS 
AND RECOMMENDATIONS 
 
1.1 Conclusions 
The primary objective of this research study was to investigate the possible inhibitory and 
inducing effects of Withania somnifera, Glycyrrhiza glabra, Astragalus membranaceus, Inula 
helenium, Althaea officinalis and Ocimum basilicum on CYP2B6, esterase-mediated 
metabolism of rifampicin, and CYP3A4. This was achieved in four phases of research: [1] 
biochemical phytoprofiling of all the extracts to assess their HDI potential, [2]investigating the 
inhibitory effect of each extract on CYP2B6 and rifampicin metabolism pathway, using human 
liver microsomes, and ranking the extracts for potential HDI based on IC50s, as well as TDI 
shift-foldIC50s, [3] investigating the potential of the herbal extracts to induce CYP2B6 and 
CYP3A4 mRNA expression in HepG2 cell lines using RT-PCR technique based on the CTC50 
concentrations determined for each extract, and [4] a complete phytochemical analysis of the 
active herbal extracts using LC-MS/PDA, to understand the constituents present and their 
potential to interfere with the CYP activity. 
 
Based on the findings of the study, the following conclusions can be drawn. 
1.1.1 Biochemical phytoprofiling: 
Bioactive compounds present in the herbs were analysed, for their properties to interfere 
with CYP activity. These included alkaloids, flavonoids, phenols, coumarins, saponins, 
glycosides, sterols, tannins and terpenoids. Based on the biochemical profiling each herb 
was ranked for its potential to cause HDI.  
In this study, the qualitative screening ranked Ocimum basilicum to be most active, and 
Withania somnifera and Althaea officinalis to have lesser potential to cause HDI. 
 
1.1.2 HLM Assays, kinetics of efavirenz/ rifampicin and CYP-herb inhibition data: 
Based on the solvent extraction each extract from the same herb showed variable 
activity on the enzyme activity. Though rifampicin is used as an inducer, in this study it 
was specifically used as a substrate. Using HLM assays and the optimal parameters (Km, 
protein concentration), the herbal extracts were screened for activity. As per the study, 
extracts prepared from hot tea decoctions as practised by the THPs, had less inhibitory 
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activity on the CYPs compared to the methanolic, ethanolic and ethyl acetate extracts. 
All the extracts of O.basilicum showed strong inhibitory potential as well as TDI, which 
may be attributed to the fact that for this herb the dried leaves, inflorescence and seeds 
were used compared to the root extracts of all the other herbs; hence more 
phytoconstituents such as flavonoids and other secondary metabolites may be present in 
the essential oil of these extracts (Idris et al., 2017; Mulata et al., 2015; Ugochukwu et 
al., 2013; Fathiazad et al., 2012).The aqueous and methanolic extracts of O.basilicum 
showed reversible and TDI of CYP2B6, while the methanolic and ethanolic extracts 
inhibited the formation of 25-O-desacetyl rifampicin. Previous studies reported the 
inhibitory effect of its ethanolic extract on CYPs such as CYP3A4. However no data is 
available on its effect on in vitro rifampicin metabolism. The ethyl acetate and ethanolic 
extracts of A.membranaceus, and ethanolic extract of I.helenium showed strong 
inhibition of CYP2B6 and rifampicin metabolism, respectively. O.basilicum, 
A.membranaceus and I.helenium have high risk to cause HDI in patients on other 
medications metabolized by CYP2B6 as well as the biotransformation of rifampicin, 
which might have toxic effects. 
 
The THPs use alcoholic beverages such as brandy for reconstitution of the herbs. Ethyl 
acetate extractions are used for specific compounds such as TA-65 or secondary 
metabolites from A.membranaceus (Ghasemian-Yadegari et al., 2017). All extracts of 
I.helenium inhibited the investigated enzymes, which could be due to the presence of 
inulin, alantolactone and isoalantolactone. Only the ethyl acetate and methanolic extracts 
of Withania somnifera inhibited CYP2B6. Rifampicin being the first-line agent in the 
treatment of drug-susceptible TB could undergo incomplete metabolism due to the 
inhibition caused by some of the herbs, which might result in toxic effects. Thus 
I.helenium should be used with caution, if co-administered with rifampicin. 
 
O.basilicum showed strong TDI on CYP2B6. Previous in vitro studies has shown that 
NADPH is not a requirement for deacetylation of rifampicin, and that the addition of 
NADPH to microsomes increased the formation of 25-O-ascetyl rifampicin, which was 
then attributed to the possible involvement of NADPH-dependent enzymes such as 
CYPs (Jamis-Dow et al., 1997; Parkinson et al., 1996). In the HLM assays performed in 
this study NADPH was used in both co-incubation and pre-incubation assays with herbs. 
It was noticed that both nelfinavir and O.basilicum caused strong TDI of the formation 
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of 25-O-desacetyl rifampicin when pre-incubated with NADPH. This suggests that there 
could be other enzymes involved in the biotransformation of rifampicin, since 
exogenous supply of NADPH was not mandatory in the deacetylation of this drug.  
 
Caution must be exercised in patients concurrently taking such medications, especially 
rifampicin. This finding is particularly relevant for basil, considering the fact that it is 
commonly used as a culinary spice, herbal tea, as well as an essential oil. At low 
concentrations basil extracts could inhibit CYP2B6 and rifampicin metabolism in vitro 
in HLM; if the same or putative concentration levels are reached in the GIT, it could 
cause adverse HDI in patients consuming basil. 
 
1.1.3 mRNA expression assays using RT-PCR for induction analysis: 
All extracts screened in this study, showed moderate induction of CYP3A4, while only 
few extracts induced CYP2B6. The main conclusion of this part of the study was that 
CYP3A4 was more inducible compared to CYP2B6, which could be attributed to the 
lesser amount of total CYP2B6 content in the cells as mentioned earlier. This matched 
previous HDI studies on CYP3A4 (Cho and Yoon, 2015; Hellum et al., 2007; Kent et 
al., 2002). All extracts of A.membranaceus showed moderate induction of CYP3A4 
which was in contrast to previous reports of its inhibition of CYP3A4. In the inhibition 
assays the ethanolic and methanolic extracts of O.basilicum inhibited RIF metabolism 
and CYP2B6 activity in the HLMs, but in the induction assays the methanolic extract 
induced CYP2B6 mRNA expression, while the ethanolic extract induced CYP3A4. This 
could be attributed to the various phytoconstituents in basil such as rosmarinic acid, 
rutin and salvigenin, and the two different cell systems (HLM and HepG2), where 
incubation time points and activity assessment metrics (drug-metabolite levels and 
mRNA expression) are also different.  
 
The ethanolic and methanolic extracts of A.officinalis showed the highest levels of 
induction (0.48, 0.44-fold responses), among all the extracts screened on CYP3A4. 
Previously, no published data was available on the screening of althaea against 
CYP3A4 and CYP2B6, for induction studies. 
 
The aqueous extract of A.membranaceus showed moderate and equal induction of 
CYP3A4 and CYP2B6. Caution must be exercised in patients concurrently taking 
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conventional medications, when using A.membranaceus because of its inducing 
potential on CYP2B6 and CYP3A4, though at moderate levels. A.officinalis root extracts 
are used in preparing the marshmallow confectionaries, and this could also be a factor in 
its inducing effect on CYP3A4.All the extracts above showed moderate induction of the 
CYPs (when compared to the positive control). 
 
1.1.4 Phytochemical fingerprinting: 
The LC-MS/PDA methodology detailed the fingerprinting further into the peaks masses 
and their transition product ions combined with the UV maxima, to identify a list of 
possible compounds present in each herb. It was observed that extracts prepared using 
methanol, ethanol and ethyl acetate had higher quantities of phytochemicals compared to 
the aqueous extracts, though the % yield was higher for the aqueous extracts. The 
relative quantification of the tentatively identified compounds helped predict the varying 
levels of activities of the different solvent extracts for each herb on HLMs and HepG2 
cells, based on literature review. Prominent and previously unreported phytocompounds 
were identified in the negative mode LC-MS full scan analyses. These compounds were 
used to link the activity of the extract to the inhibition/ induction assays and the phyto-
CYP prediction model (Fig. 3); the assumption was that herbs such as Ocimum 
basilicum, Astragalus membranaceus, and Inula helenium would inhibit CYP2B6, and 
possibly the esterase-mediated metabolism pathway of rifampicin. Phenolic compounds, 
terpenes and lactones were the most observed compounds in the herbs showing activity. 
 
1.1.5 Impact: 
The THPs involved in this study, were very keen on the outcomes of the research, in 
understanding the potential of the herbs in causing relevant HDI with ARVs and TB 
drugs, whereby they could also ensure safer use of such herbs and educate their 
customers of the potential interactions, when co-administered with conventional drugs. 
The involvement of THPs in such studies is of critical importance in bridging the gap in 
contemporary health research, especially in African countries. 
 
1.1.6 Overview: 
As per the biochemical analysis, it was predicted that herbs such as O.basilicum, 
A.membranaceus and I.helenium had the potential to inhibit CYP2B6 and possibly affect 
esterase-mediated metabolism of rifampicin. Different solvent extracts for the same herb 
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had different phytochemical compositions which attributed to the fact that some of them 
may induce CYPs such as CYP3A4. However the inhibition and induction studies 
showed that each extract had its own potential to interact with the CYPs. The same herb 
showed inhibition effect on the CYP2B6 and rifampicin pathway, as well as induction of 
CYP3A4 based on the type of solvent extract used, and this was attributed to the various 
phytocompounds identified in each solvent extract of the same herb using LC-MS 
fingerprinting. These results link the HDI potential of the herb to its fingerprint, to 
further investigate, isolate and evaluate the potential of various phytoconstituents to 
cause both induction and inhibition based on the solvent extraction. 
 
Figure 58 provides an overview of the work carried out in this research study. The study 
has clearly demonstrated the connection and overlap between the various in vitro models 
used. This study design offers a comprehensive model to investigate the HDI potential 
of herbal medicine, from various aspects.  
 
Fig.58 Summary of this research study design and the in vitro methods used. 
 
1.2 Limitations of the study 
The herbs selected in this study were provided in dried packaged forms by a natural product 
supplier company. All herbs were from various regions of Africa including South Africa. 
However there are possibilities that a different batch of these herbals product could be from a 
different region and hence based on the climatic and environmental conditions, the 
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phytoconstituents present might vary. It is therefore possible that the same herb from a different 
region might not show the same CYP interaction as observed in this research study. 
 
All assays were done using the crude extracts. The LC-MS/PDA analysis only provides a 
potential list of possible phytoconstituents in the extract but not exact molecule responsible for 
the inhibitory/ inducing effect on the CYPs. Bio-assay guided fractionations are required, and 
these sub-fractions should be further screened to understand if the interaction is caused by a 
single fraction or a synergistic effect of two or more fractions. Further analysis of these 
fractions to isolate the pure molecule is warranted. 
 
For all the HLM assays, the standard deviation (standard error of the mean) for the data points 
for few extracts show high variance. This could be attributed to external factors, which might 
have interfered with the assays. All assays including duplicates were done in different test 
tubes; pipetting the assay termination solvent (acetonitrile) from one tube to another might have 
had time variance of few seconds or it could have also been due to the loss of metabolite due to 
degradation, during the prolonged HPLC runs. 
 
All extractions performed in this study follow a pattern of extraction conditions such as 
temperature, solvent and duration. These factors would ultimately determine the amount of 
phytoconstituents present in the extract. Roto-evaporation and freeze-drying can have an effect 
on the extract composition, compared to traditional (non-standardized) methodologies followed 
by the herbal practitioners. Hence the levels of interactions seen in vitro might not be the same 
in vivo in human subjects. 
 
The rifampicin metabolism pathway putforth in this study needs to be analysed and evaluated 
further, to understand the levels to which B-esterases are involved in this pathway and also 
investigate any potential involvement of CYPs in this pathway. Currently there is very little 
information available on this metabolic pathway, in order to fully appreciate the relevance of 
the findings in this study. 
 
HLMs and HepG2 cells were used as part of in vitro model in this study and in all these assays 
the herbal extracts were in direct contact with the enzymes as well as the substrates, and the cell 
lines. However in an in vivo system, there are many other factors involved such as redistribution 
through the tissues, concentration differential between tissues, presence of natural barriers such 
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as varying capillary bed permeability, the epithelial membrane barrier, apical membrane barrier 
in passive transcellular transport etc. as well as plasma protein binding, sub-epithelial blood 
flow and intestinal pH (El-Kattan and Varma, 2012; Gavhane and Yadav, 2012). The amount of 
phytoconstituents that enter the GIT, is dependent on various factors such as intestinal fluid 
composition, GIT transit time, disease state and dosage form (Fasinu et al., 2014). 
 
The phytochemical analysis using LC-MS, for relative quantification of the tentatively 
identified compounds uses two standard calibrators, quercetin and gallic acid. The standard 
curves for both reference compounds are in the range of 6.25-200 mg/L; however there are 
identified compounds within the plant extracts that have values above the range of the curves 
(upto values of around 4000 mg/L). These values are relative quantifications based on 
extrapolations of the standard curves and could have a certain degree of inaccuracy. The acidic 
compounds were identified relative to gallic acid and the other compounds relative to quercetin. 
The various classes of compounds detected are likely to ionize in the MS to vastly different 
degrees, when compared to the standard calibrators. Fold-variations can thus occur in the 
observed peak area of a compound, when compared to an equivalent amount of gallic acid or 
quercetin. The matrix effects in the plant extracts can reduce the peak areas significantly and 
there is no internal standard used in this analysis to measure the impact of such effects on the 
peak area of a compound. This can also affect the quantification data for the identified 
compounds. The concentrations represented in this study for the identified compounds are 
reasonable approximations of the relative amounts, in comparison to the standard calibrators, 
and are not absolute quantifications (Al Feteisi et al., 2015). 
 
1.3 Recommendations 
It is critical to understand HDI especially when CAM is increasingly being included within 
mainstream integrative healthcare services (Singer and Adams, 2014). In many countries such 
as USA, India, China, Australia, as well as few of the European countries, CAM has already 
been incorporated into clinical care, especially in scenarios of therapeutic alliance of CAM with 
biomedicine, as well as psychological therapies. Traditional systems of medicine being part of a 
country‟s heritage, identity and culture always gain more popularity especially among the rural 
areas. Hence the risk of potential HDI always surface in such cases where herbal medicines are 
used in combination with conventional drugs. This is where in vitro liver-based models for 
screening such herbal medicines become the best standard for drug interaction studies. However 
with the increase in consumption of herbal medicines in the form of supplements and tea 
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extracts, especially among the HIV/TB patients, in vivo studies in healthy human subjects are 
recommended as the next step in understanding HDI of the herbs used as part of this research 
study. Randomized placebo controlled trial studies would be beneficial to evaluate the safety of 
consuming such herbal medications, since clinical studies are definitive and considered the 
"gold standard". Previously such studies have been done for few herbs such as Lessertia 
frutescens in 2015, in South Africa, where the possibility of interaction between isoniazid 
preventive therapy and L.frutescens was identified (Wilson et al., 2015). With trial results 
available in electronic databases, data extraction and pharmacokinetic/ pharmacodynamics 
modelling for in vivo predictions would be helpful. Alternatively, new in vitro strategies using 
„Whole Cell‟ approach where certified human hepatocytes in sandwich-culture provide a fully 
integrated hepatic cell system with the drug clearance pathways of metabolism and transport, as 
well as the key regulatory pathways (CAR/PXR) (Jackson et al., 2017). Such systems help in 
the quantitative assessment of HDI potential of herbal medications. In vitro testing on the CYP 
isoenzymes and transporters as well as clinical trial studies on human subjects will determine if 
these herbal extracts have additional effects on the CYP-mediated metabolism and the 
pharmacokinetics of the drugs. The effects of prolonged intake of such herbal medications on 
the induction of the CYPs should also be investigated. The findings of this study will help to 
guide planning and designing of clinical trials. The data collected from these trials would help 
establish the existence of clinically significant HDI in patients, as well as patient counselling by 
clinicians on the adverse effects of such interactions. Case reports on adverse drug events on 
these herbs as well as clinical data would also be helpful to connect them to all the relevant in 
vitro findings on these herbs and entries in the FDA Med Watch system, which would ensure 
post marketing safety assessment of such herbal products (Hussain, 2011). 
 
Furthermore, a critical step forward would be the fractionation, isolation and identification of 
the active phytoconstituents in these herbal extracts. Bioassay-guided fractionation and 
structural elucidation of the pure molecules based on NMR spectroscopic analysis would also 
be beneficial, in drug discovery. These studies would help better in understanding the active 
„ingredients‟ in the herbs as well as their safety or potential toxicity. 
 
The THP involved in this study and I had the opportunity to attend two conferences organized 
by the Department of Science and Technology and the National Research Foundation of South 
Africa on indigenous knowledge systems to present my work, along with the views of the THP 
on how HDI information is very important for evaluating the safety of herbs. The involvement 
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of THPs in HDI studies is very important; especially to select and identify the herbs, share their 
knowledge on THMs and methods of treatment, as well as viewpoints on the research outputs. 
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Appendix 1.1:  Simultaneous HPLC Determination of Efavirenz, 8-Hydroxy Efavirenz, 
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